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La thérapie photodynamique (PDT) cutanée est utilisée pour traiter les kératoses actiniques, 
la maladie de Bowen et les carcinomes basocellulaires. Malgré des résultats prometteurs, 
elle manque d'efficacité pour les lésions profondes et l'amélioration des photosensibilisateurs 
est d'actualité. 
Nous avons étudié les propriétés photophysiques et photosensibilisatrices de porphyrines 
tricationiques substituées. Elles sont fluorescentes et leur état excité triplet a une grande 
durée de vie et un rendement quantique élevé à l'exception du conjugué poly-S-lysine. 
L'oxygène singulet est formé quantitativement depuis ce triplet. 
L’étude chez des kératinocytes cutanés humains hyperproliférants de l'incorporation et de la 
photocytotoxicité montrent que 3 d'entre eux soutiennent favorablement la comparaison avec 
la protoporphyrine IX induite par l'acide δ-aminolévulinique (traitement actuel en PDT 
cutanée). Ils se localisent dans des vésicules d'endo- et pinocytose mais pas dans le noyau 
ni les mitochondries. La structure de leur chaîne substituée conditionne l'incorporation, la 
localisation et donc la phototoxicité. 
Les mécanismes de mort cellulaire étudiés avec le dérivé le plus efficace montrent l'absence 
de fixation de l'annexine V, d'activation des caspases, de condensation de la chromatine et 
donc d'apoptose. L'apparition de vésicules LC3-positives dans ces cellules transfectées par 
GFP-LC3 et la dégradation de p62 démontrent l’implication de l’autophagie dans la 
photocytotoxicité avec une régulation négative par JNK. 
En conclusion, ce sont des photosensibilisateurs intéressants nécessitant des études 
complémentaires dans des modèles cellulaires et animaux.  
 
Mots-clés: thérapie photodynamique; porphyrines tricationiques; fluorescence; état excité 
triplet; oxygène singulet; incorporation cellulaire; localisation intracellulaire; photocytotoxicité; 







La thérapie photodynamique (PDT) utilise la combinaison d'un médicament 
photosensibilisant et de la lumière visible pour causer des dommages sélectifs au tissu 
tumoral cible. La nature locale plutôt que systémique des effets de la thérapie 
photodynamique doit être soulignée. Elle contribue à la fois aux limites et aux possibilités de 
la PDT dans un traitement efficace contre le cancer. Une limitation de la PDT est qu'elle ne 
peut être envisagée pour des tumeurs avancées et disséminées, car l'irradiation du corps 
entier avec des doses appropriées n'est pas possible. Néanmoins, la PDT peut être une 
thérapie sélective et curative appropriée, avec des avantages potentiels par rapport à 
d'autres propositions thérapeutiques pour des tumeurs précoces et/ou localisées ou encore 
certains troubles infectieux. Pour des cancers avancés, la PDT peut améliorer la qualité de 
vie et prolonger la survie. 
En dermatologie, l'administration intraveineuse de Photofrin®, premier médicament 
"PDT" approuvé par la FDA en 1993, a montré son efficacité dans le traitement de diverses 
lésions cutanées, mais l'administration systémique de ce médicament n'est pas justifiée pour 
le traitement à grande échelle de pathologies localisées. En outre, la complexité et la 
variabilité du mélange de plus de 60 composés ayant des propriétés et activités différentes 
constituant le Photofrin®, sa lente élimination de l'organisme ajoutées à la photosensibilité 
cutanée résiduelle, due à la faible sélectivité pour les tissus tumoraux ont limité son 
utilisation en Dermatologie. La PDT utilisant l'acide aminolévulinique (ALA) ou son ester 
méthylique (MAL) comme pro-drogues a partiellement résolu ces problèmes en raison de sa 
commodité et de sa simplicité d'utilisation. L'ALA ou le MAL permettent la synthèse 
endogène localisée de la protoporphyrine IX (PPIX) comme photosensibilisant et ne sont 
donc pas associés à d'importants effets toxiques systémiques, à savoir la photosensibilité 
cutanée résiduelle. Bien qu'étant approuvés pour le traitement des cancers non-mélaniques 
de la peau, comme la maladie de Bowen (BD) et le carcinome basocellulaire superficiel 
(SBCC), et pour les lésions cutanées pré-néoplasiques, telles que la kératose actinique (AK), 
ALA et MAL présentent quelques limitations cliniques. Ils présentent en effet une pénétration 
cutanée limitée, et comme le Photofrin ®, la protoporphyrine IX induite possède des 
coefficients d'extinction molaire modestes dans le domaine visible rouge où est réalisée 
l'irradiation car correspondant à la fenêtre thérapeutique optimale. En outre, l'ALA et le MAL 
sont difficilement solubles en milieu aqueux. 
En raison des inconvénients présentés par les photosensibilisateurs actuellement 
utilisés, de nombreux nouveaux composés, les photosensibilisateurs dits de deuxième 
génération, ont été synthétisés. La recherche dans ce domaine vise à l'élaboration de 
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médicaments photosensibilisants qui sont chimiquement purs, qui absorbent plus fortement 
à longueurs d'onde élevées et qui présentent des propriétés biologiques améliorées. Avec 
des capacités d'absorption de la lumière meilleures que la PPIX, ces photosensibilisateurs 
de deuxième génération permettraient de diminuer les doses de médicaments et 
d'irradiation.  
Notre groupe a porté son intérêt sur des dérivés de porphyrines tri-cationiques, 
hydrosolubles (PR), dont les structures sont données ci-dessous. Ils sont obtenus par 
substitution du groupe hydroxyl du carboxyphenyl en position meta sur le cycle 
tétrapyrrolique par un groupe méthoxy (P-Me), un groupe N,N´-dicyclohexylureidooxy (P-
DDC), un groupe di-O-isopropylidene-α-D-galactopyranosyl (P-OGal), un groupe α/β-D-
galactopyranosyl (P-Gal) ou par chaîne poly-S-lysine (P-(Lys)n) des chaînes latérales (Figure 
1.1). Ces dérivés porphyriniques ont été synthétisés par le groupe du Professeur Cavaleiro à 
l'Université d'Aveiro (Portugal). 
 
 
Figure 1.1 Noms et structures chimiques des dérives étudiés dérivants de la 5-(4-carboxyphenyl)-
10,15,20-tris(N-methylpyridinium-4-yl)porphyrine 
P-H : 5-(4-Carboxyphenyl)-10,15,20-tris(N-methylpyridinium-4-yl)porphyrin tri-iodide. 
P-Me : 5-(4-Methoxycarbonylphenyl)-10,15,20-tris(N-methylpyridinium-4-yl)porphyrin tri-iodide. 
P-DDC : 5-[4-(N,N′-Dicyclohexylureidooxycarbonyl)phenyl]-10,15,20-tris(Nmethylpyridinium-4-yl)por-phyrin tri-
iodide. 
P-OGal : 5-[4-(1,2:3,4-Di-O-isopropylidene-R-D-galactopyranosyl-6-oxycarbonyl)phenyl]-10,15,20-tris (N-
methylpyridinium-4-yl)porphyrin tri-iodide. 
P-Gal : 5-[4-(R/_-D-Galactopyranosyl-6-oxycarbonyl)phenyl]-10,15,20-tris(Nmethylpyridinium-4-yl)por-phyrin 
tri-iodide. 




Les dérivés tri-cationiques porphyriniques sont des dérivés prometteurs. Ils peuvent 
interagir avec les cellules de la peau chargées négativement après la rupture de la barrière 
du stratum corneum. Il est intéressant de noter que les cellules cancéreuses peuvent porter 
une charge négative en raison de la surexpression de molécules anioniques telles les 
mucines O-glycosylées. Leurs propriétés hydrophiles semblent être une alternative 
intéressante au Photofrin® liposoluble et à l'ALA ou au MAL, pro-médicaments utilisés 
aujourd'hui dans la pratique clinique. La conjugaison à des acides aminés, des peptides et 
des sucres à des photosensibilisateurs peut favoriser un ciblage spécifique dans la mesure 
où ces groupes jouent un rôle clé dans la reconnaissance et le métabolisme de micro-
organismes et de cellules pathologiques. Enfin, les conjugués porphyriniques tri-cationiques 
sont des molécules amphiphiles en raison des charges positives sur les trois groupes 
pyridinium et de la substitution par un groupe sans charge et plus hydrophobe sur le 
quatrième groupe carboxyphenyl. En règle générale les photosensibilisateurs amphiphiles 
sont censés être photodynamiquement plus actifs car pouvant se localiser aux interfaces 
hydrophobes-hydrophiles dans les membranes et à la surface des protéines. Le caractère 
amphiphile est également important car il permet de limiter l'agrégation et, par conséquent, 




L'objectif de cet travail est donc de détailler les caractéristiques photobiologiques de 
ces nouvelles substances. 
Tout d'abord, les propriétés photophysiques et photochimiques des cinq conjugués 
porphyriniques tri-cationiques seront comparées à celle de la molécule mère. L'influence des 
substituants sur les propriétés des états excités singulet et triplet sera étudiée dans différents 
milieux (tampon aqueux, éthanol, et micelles neutres ou chargées négativement) compte 
tenu de la sensibilité de ces paramètres au microenvironnement; 
La deuxième partie concerne l'évaluation des cinétiques d'absorption cellulaire, la 
localisation subcellulaire, ainsi que l'étude des mécanismes de la photocytotoxicité des 
nouveaux dériviés porphyriniques chez une lignée de kératinocytes humains cutanés 
hyperproliférants (NCTC-2544). Une telle étude permet de comparer les différents effets 
biologiques des molécules appartenant à la même classe de composés chimiques, mais 
dotées de propriétés physiques différentes. La justification d'une telle étude est que les 
différents substituants de la porphyrine tri-cationique sont susceptibles d'affecter leur 
pénétration cellulaire et le mode de distribution intracellulaire. En conséquence, une relation 
structure-activité photocytotoxique pourrait être établie. En outre, cette approche est 
préalable à une étude plus approfondie du mécanisme d'action et de la forme dominante de 
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la mort cellulaire. L'élucidation des voies de signalisation conduisant à ces réponses est 
importante, car elle fournit des indices pour mieux comprendre comment la PDT fonctionne 
aux niveaux cellulaire et moléculaire. Par ailleurs, il y a peu d'études concernant la 
participation des MAPK dans le stress induit par la PDT, notamment concernant des 
porphyrines cationiques. Nous examinerons donc le rôle de l'expression des MAPK au cours 
de la mort cellulaire induite par la PDT dans la lignée de kératinocytes NCTC 2544. 
 
PRINCIPAUX RESULTATS ET DISCUSSION 
 
APPROCHE PHYSICO-CHIMIQUE ET PHOTOPHYSIQUE 
 
Spectres d’absorption et coefficients d’extinction molaires 
Selon les conditions de solvant (tampon, PBS, éthanol, TX100, SDD), les spectres 
d'absorption de tous les dérivés présentent les caractéristiques des spectres d'absorption 
des porphyrines avec une bande de Soret (forte bande d'absorbance proche- UV) à ~ 420 
nm et 4 maxima de moindre absorbance vers ~ 520, 550 et 630 - 650 nm. Ces différents 
solvants ont été utilisés pour simuler les différents milieux biologiques. Aucune différence 
majeure n’est observée pour ces différents environnements. Peu de différences sont 
observées dans leurs propriétés d'absorption suggérant que tous sont potentiellement 
intéressants en termes de capacité d'absorber la lumière. Par rapport à la PPIX actuellement 
utilisée en dermatologie oncologique, les propriétés d’absorption de ces 
photosensibilisateurs dans la fenêtre thérapeutique au-delà de 650 nm, où la pénétration de 
lumière est plus élevée, sont plus favorables. 
 
Spectres et rendements quantiques de fluorescence 
Dans un même solvant, tous les dérivés présentent des propriétés de fluorescence 
semblables avec des rendements quantiques de fluorescence très voisins à l'exception de P-
(Lys)n dont le rendement quantique de fluorescence est sensiblement inférieur. Les 
rendements quantiques de fluorescence de ces dérivés dépendent peu des conditions de 
solvant à l'exception des solutions micellaires de SDS où ils sont nettement plus élevés. 
Malgré une excellente solubilité en milieu aqueux, on observe la formation de dimères ou 
d’oligomères de petite taille non covalents favorisant les processus de conversion non 
radiative, qui se traduisent par le raccourcissement de la durée de vie de fluorescence et un 
rendement quantique de fluorescence diminué. 
L'existence d’une fluorescence est particulièrement intéressante dans le contexte de 
ce travail parce que la sensibilité des mesures de fluorescence permettra : 1 / des mesures 
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quantitatives de la concentration des dérivés dans les systèmes cellulaires, et 2 / l'étude de 
leur localisation intracellulaire. En outre, dans l’éventualité d'une utilisation clinique future de 
de ces dérivés, la fluorescence peut être utile pour le diagnostic et la délimitation du tissu 
tumoral. L’utilisation de ces dérivés à des fins diagnostiques sera néanmoins rendue plus 
délicate en raison de rendements quantiques modestes. 
Les rendements quantiques de fluorescence de ces dérivés et la durée de vie de 
fluorescence indiquent que des voies non-radiatives sont impliquées dans la désactivation 
du premier état singulet excité 1S1
* de P-R vers l'état fondamental S0. Ces paramètres 
laissent également présager que la conversion "intersystème" conduisant à la formation de 
l'état triplet 3S1
* de P-R est susceptible de se produire. 
 
Photolyse "laser femtoseconde" 
Les expériences de photolyse par éclair laser résolue à la femtoseconds ont été 
effectuées au laboratoire de Radiation Laboratory de l'Université of Notre Dame (USA, 
Indiana). Cette technique permet d'étudier les événements photophysiques qui ont lieu avant 




*). Bien qu’importants dans la compréhension des processus physico-chimiques 
conduisant à la population du premier état excité 1S1
* de P-R, ils ne concernent pas ceux qui 
caractérisent l'état triplet, l'état excité essentiel en ce qui concerne les capacités 
photosensibilisantes photodynamiques. 
 
Propriétés de l'état triplet 
Les propriétés physico-chimiques de l'état triplet sont étudiées par photolyse par éclair 
laser avec une résolution temporelle inférieure à la microseconde. La résolution temporelle 
des spectres d'absorption transitoires permet de mesurer sa durée de vie. Elle se situe dans 
un intervalle de temps allant de la dizaine à la cinquantaine de microsecondes et elle est 
plus longue dans le PBS que dans les autres solvants. L'état triplet de P-(Lys)n présente la 
plus longue durée de vie. Ceci est probablement du à la présence des chaînes latérales 
poly-lysine volumineuses qui peuvent entraver les processus collisionnels rapide qui 
favorisent le retour de l'état triplet 3T1
* vers l'état fondamental S0. Les durées de vie 
relativement longues de ces états triplets laissent présumer une activité photosensibilisante 
photodynamique de P-R dans les milieux aqueux. 
Un autre paramètre important concernant l'état triplet est son rendement quantique de 
formation (ΦT). Le rendement quantique de formation de l'état triplet de P-R peut être calculé 
à partir des spectres d'absorption de cet état triplet, à condition de connaitre son coefficient 
d'extinction molaire (εT) et la quantité de photons présents dans l'impulsion laser. Les 
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coefficients d'extinction molaires sont obtenus par des méthodes classiques impliquant un 
transfert d'énergie de l'état triplet de P-R vers l'état fondamental du β-carotène. 
Parallèlement, une actinométrie du faisceau laser est réalisée en utilisant une molécule 
(méso-tétraphenylporphyne) dont le rendement quantique et le coefficient d'extinction 
molaire de l'état triplet sont connus. Ainsi des rendements quantiques d'état triplet élevés, de 
l'ordre de 0,5-0,6, sont mesurés pour P-R dans les différents solvants, à l'exception de P-
(Lys)n qui présente des rendements plus modestes. Ceci suggère que les dérivés 
prophyriniques tri-cationiques peuvent être des photosensibilisateurs efficaces dans la 
plupart des environnements. 
 
Formation d’oxygène singulet 
Les données ci-dessus suggèrent que l'oxygène singulet peut être produit avec un 
rendement quantique élevé. La formation de l'oxygène singulet a été quantifiée par la 
mesure de la dégradation de l'histidine dont l'oxydation se produit uniquement via un 
processus photodynamique de type II. Les rendements quantiques de dégradation de 
l'histidine sont de l'ordre de 0,08 à l'exception de celui du dérivé P-(Lys)n plus faible (0,02) en 
accord avec les données concernant les états triplets. Ces rendements quantiques sont nuls 
en absence d'oxygène. Ils sont augmentés en présence de D2O et fortement réduits en 
présence de N3
-, ce qui confirme la formation de l'oxygène singulet. Un étalonnage avec la 
méso-tétraphenylporphyne tétrasulfonée permet de calculer des valeurs théoriques pour les 
rendements quantiques d'état triplet légèrement supérieures à celles obtenues par photolyse 
par éclair laser, mais qui confirment donc le potentiel photosensibilisant de ces dérivés 
porphyriniques tri-cationiques. 
 
APPROCHE BIOLOGIQUE ET CELLULAIRE 
 
Capture cellulaire 
La capture de P-H, P-Me, P-DDC, P-Gal et P-OGal par les kératinocytes NCTC 2544 
est extrêmement rapide et atteint un plateau dans l'heure qui suit le début de l'incubation. 
Dans le cas de P-(Lys)n, environ 3 heures sont nécessaires pour atteindre ce plateau. La 
capture est pour tous les dérivés une fonction linéaire de la concentration d'incubation. Les 
cinq conjugués sont plus efficacement captés par les cellules que P-H (facteur environ x6 
pour P-(Lys)n, environ x5 pour P-Me, P-DDC, et P-OGal, et seulement x2 pour P-Gal). Les 
incubations ont également été menées dans le HBSS, c'est-à-dire sans sérum, pour 
déterminer si les protéines sériques peuvent jouer un rôle particulier dans le processus de 
capture. Nous montrons que seule la capture du dérivé P-(Lys)n est influencée par la 
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présence des protéines, qui interagissent vraisemblablement avec la chaine poly-lysine. 
 
Photocytotoxicité 
La photocytotoxicité des dérivés P-R a été estimée par le test de capture intracellulaire 
du rouge neutre. L'ordre d'efficacité relative PDT - P-OGal > P-DDC = P-Me > P-(Lys)n >> P-
Gal > P-H a été établi. P-H, P-Me, P-DDC, P-Gal et P-OGal ont tous les mêmes capacités 
intrinsèques de production d'oxygène singulet. Il peut être établi par ailleurs que ces dérivés 
ont intrinsèquement les mêmes capacités d'absorption de la lumière. Ainsi si la moindre 
photocytotoxicité de P-H et P-Gal correspond à une moindre capture cellulaire, les 
différences de photocytotoxicité entre P-Me, P-DDC, P-OGal ont probablement pour origine 
des différences de localisation cellulaire et pour conséquences des cibles primaires 
différentes. En ce qui concerne P-(Lys)n sa plus faible capacité intrinsèque à produire 
l'oxygène singulet que P-H et P-Gal, est en partie compensée par une plus forte capacité à 
absorber la lumière. Par ailleurs, Il est important de noter que les dérivés les plus efficaces, 
P-OGal, P-DDC et P-Me, supportent favorablement la comparaison avec la PPIX endogène 
induite par le traitement des cellules avec l'ALA. Étant donné que les quantités de lumière 
absorbée par P-R et PPIX dans les cellules sont proches, P-OGal, P-DDC et P-Me sont des 
photosensibilisateurs aussi puissants que PPIX. 
 
Stress photo-oxydant 
La peroxydation lipidique a été choisie comme un indice global de l'intensité du stress 
photo-oxydant. Elle a été évaluée par la mesure de la formation des substances réactives à 
l'acide thiobarbiturique (TBARS). La production de TBARS augmente de façon linéaire avec 
le temps d'irradiation, P-OGal, P-DDC, P-Me étant les plus efficaces pour induire la 
peroxydation lipidique. En fait, comme pour la photocytotoxicité, la peroxydation lipidique de 
P-OGal, P-DDC, P-Me et P-(Lys)n est supérieure à celle de P-H et P-Gal. 
 
Microscopie de fluorescence 
Les images de fluorescence des cellules traitées avec les derivés porphyriniques tri-
cationiques ont été obtenues avec un système de microscopie de fluorescence très sensible 
de manière à éviter des expositions lumineuses importantes et donc l'interférence avec des 
phénomènes de photoblanchiment et de relocalisation après photoblanchiment. Ces 
expériences de fluorescence intracellulaire confirment que le P-H et P-Gal sont moins 
absorbés par les kératinocytes NCTC 2544 que P-Me, P-DDC et P-OGal. En outre, la 
fluorescence de P-Me, P-DDC, P-OGal et P-(Lys)n est plus particulièrement localisée dans 
les endroits pouvant correspondre à des vésicules d'endocytose ou de pinocytose. A 
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contrario, la fluorescence des cellules traitées avec le P-H et P-Gal est plutôt diffuse 
suggérant une localisation cytoplasmique et dans la membrane plasmique. Il convient de 
noter que les mitochondries et le noyau ne sont pas des sites de localisation de P-R. Ces 
observations démontrent que les substituants méthoxy (P-Me), di-O-isopropylidene-α-D-
galactopyranosyl (P-OGal) et N,N´-dicyclo-hexylureidooxycarbonyl (P-DDC) sont plus 
critiques que la charge électrique de la porphyrine dans le contrôle de leur capture et de leur 
localisation et, par conséquent, dans l'expression de leur efficacité photosensibilisante. 
 
Mécanismes de la mort cellulaire 
Après avoir décrit le rôle de la chaîne substituée sur le potentiel photocytotoxique des 
dérivés porphyriniques tri-cationiques, nous avons étudié les mécanismes de mort cellulaire 
induite par P-R et leur importance relative. Comme P-Me, P-OGal et P-DDC présentent une 
localisation intracellulaire similaire, P-OGal, le photosensibilisateur le plus efficace a été 
choisi pour cette étude. 
 
Rôle de l'apoptose 
Il a été établi par le groupe d’Oleinick que la PDT est un inducteur puissant de 
l'apoptose. La translocation de la phosphatidylsérine de la couche interne vers la couche 
externe de la membrane plasmique est un marqueur précoce de l'apoptose. L'apoptose a 
donc été analysée par cytométrie de flux par l’observation simultanée de l'exposition de 
l'annexine V et de l'incorporation de l'iodure de propidium. Aucun changement significatif du 
pourcentage de cellules positives à l'annexine V est observé jusqu'à 9 h après l'irradiation. 
Des résultats similaires ont été obtenus avec différentes concentrations et durées 
d’incubation de P-OGal et avec différentes doses de lumière. Un autre marqueur bien établi 
de l'apoptose est la fragmentation de l'ADN nucléaire en unités oligonucléosomiques. 
Aucune augmentation significative de la fragmentation d'ADN (dosage immuno-enzymatique) 
n'est observée jusqu'à 24 h après l'irradiation. En outre, aucune activité de la caspase-3, de 
la caspase-8 et de la caspase-9 et aucun clivage de la pro-caspase-3, de la pro-caspase-8 
et de la pro-caspase-9 sont observés jusqu'à 12 h après l'irradiation. Parallèlement, aucune 
fuite du cytochrome c mitochondrial est observée dans les cellules photosensibilisées par P-
OGal. Toutes ces données confirment l'absence d'induction de l'apoptose photosensiblisée 
par P-OGal dans NCTC 2544 cellules. Deux contrôles positifs (5-methoxypsoralène + UVA 
et camptotécine) montrent l'induction de l'apoptose dès 24 h et 9 h respectivement après le 
traitement. Par conséquent, nos observations sont en contraste frappant avec la plupart des 
articles qui attribuent à l'apoptose la mort cellulaire après thérapie photodynamique. 





Rôle de l'autophagie 
Bien que l'autophagie ait été initialement décrite comme une réponse de survie de la 
cellule, elle a également été considérée comme une voie conduisant à la mort dans de 
nombreuses études. Comme pour l'apoptose, nous avons utilisé plusieurs critères pour 
étudier le développement de l'autophagie. Premièrement, l'activité autophagique a été 
étudiée en utilisant un marqueur fluorescent (GFP-LC3) (protéine de fusion entre la "protéine 
fluorescente verte" (GFP) et la chaine légère 3 de la protéine associée aux microtubules 
(LC3). Le processus de protéolyse et le recrutement de membranes d'autophagosomes de 
LC3, marqueur de l'autophagie, a été suivie par microscopie de fluorescence. Après 
irradiation, on observe le développement de multiples vacuoles cytosoliques avec un 
marquage ponctuel de GFP-LC3. Cette augmentation caractéristique du nombre de cellules 
présentant cet aspect vacuolaire de la GFP-LC3 dépend du temps écoulé après l’irradiation. 
Un autre marqueur de l'autophagie est la dégradation de p62/SQSTM1. L'analyse par 
Western blot montre que p62/SQSTM1 diminue (~ 60%) après irradiation des cellules traités 
par P-OGal. Un contrôle négatif a été réalisé avec des cellules traitées par ALA puis 
irradiées. Aucun des marqueurs mentionnés ci-dessus est modifié dans des conditions 
conduisant à une photocytotoxicité comparable à celle induite pour P-OGal. L'induction d'une 
autophagie dans la mort cellulaire induite par P-OGal est d'ailleurs confirmée par un 
traitement des cellules avec la 3-methyladenine (3-MA), inhibiteur bien caractérisé de 
l'autophagie. En effet, la pré-incubation des cellules avec la 3-MA supprime, comme attendu, 
le marquage ponctuel de GFP-LC3 et la dégradation de p62. 
L'évaluation de la contribution de l'autophagie dans la mort cellulaire a été réalisée par 
cytométrie en utilisant l’exposition de l'annexine V et l’incorporation de l'iodure de propidium 
par les cellules mortes. La mort cellulaire photoinduite est inhibée d'environ 40% après une 
incubation avec le 3-MA mais aucune induction d’apoptose est observée après inhibition de 
l'autophagie par 3-MA. Cette série d'expériences suggère que: 1) l'autophagie joue un rôle 
dans la mort cellulaire dans notre système, 2) l’autophagie se produit indépendamment de 
l'apoptose, mais en liaison avec la nécrose. 
Il y a quelques articles récents sur l'induction de la mort cellulaire autophagique par 
thérapie photodynamique. La plupart de ces travaux ont été réalisés avec des cellules 
déficientes pour l'apoptose. En outre, dans plusieurs études, l'autophagie n’a été observée 
qu’après l’inhibition de l'activité des caspases. Il est extrêmement important de noter que 
nous avons utilisé un modèle de cellules compétentes pour l'apoptose dans lequel la 
porphyrine cationique tri-conjuguée induit une mort cellulaire principalement par autophagie 
en l'absence de tout inhibiteur de l'apoptose. L'incorporation de P-R dans les lysosomes ou 
pré-lysosomes dans les environs du réticulum endoplasmique et l'appareil de Golgi et la 
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localisation non-mitochondriale sont en accord avec ces événements non-apoptotiques mais 
leur relation avec autophagie doit être élucidée. On peut supposer que l'autophagie induite 
par la photosensibilisation par P-OGal est un moyen pour la cellule pour supprimer les 
organites endommagés par la photo-oxydation ou pour dégrader les gros agrégats de 
protéines réticulées qui ne peuvent pas être éliminés par le système ubiquitine-protéasome. 
Selon le degré de dommages cellulaires, la persistance de l'autophagie peut conduire à un 
effondrement du métabolisme et, finalement, à la mort cellulaire autophagique. En outre, 
l'autophagie peut être initiée par plusieurs molécules de signalisation dont l'expression est 
modulée au cours de la thérapie photodynamique en réponse au stress oxydatif. Cette 
modulation peut passer ce processus d'une voie de survie à une voie de mortalité. 
 
Participation des MAP kinases dans la mort cellulaire 
Les résultats obtenus suggèrent que l'autophagie est impliquée dans la mort cellulaire 
photoinduite par P-R. En conséquence, on peut poser la question suivante: Les 
photosensibilisateurs peuvent-ils activer/inactiver une voie moléculaire spécifique qui module 
le processus d'autophagie ? Nous avons donc testé les voies de signalisation impliquées 
dans le stress oxydant, en particulier celles faisant intervenir JNK et p38 (généralement 
associées à l'apoptose et à l’autophagie) et ERK1/2 et AKT (généralement associées à la 
survie et la prolifération cellulaire). 
Des immunoblots ont été réalisés pour visualiser la phosphorylation de JNK, p38, 
ERK1/2 et AKT. On observe une rapide, mais transitoire, activation de p38 et de JNK dans 
les cellules photosensibilisées par P-OGal. En revanche, on note une nette diminution dans 
le contenu de p-ERK et p-AKT. Le rôle des MAPK est également conforté par l’action des 
inhibiteurs de JNK (SP600125) et de p38 (SB203580). Après confirmation de leur spécificité 
en exposant des cellules à un stress osmotique, le marquage membranaire par l'annexine V 
et l'incorporation d'iodure de propidium ont été évalués par cytométrie. Le SB203580 mais 
pas le SP600125, augmente la mort par photosensibilisation des cellules. En outre, aucun 
effet significatif sur le pourcentage de cellules positives à l'annexine V est observé après 
photosensibilisation par P-OGal des cellules traitées par les inhibiteurs de p38 et de JNK . 
Pour mieux comprendre comment SP600125 augmente la mort par 
photosensibilisation des cellules, on a mesuré le nombre des spots de fluorescence de la 
GFP-LC3 et effectué des immunoblots de p62. Le marquage ponctuel par GFP-LC3 est 
augmenté dans les cellules traitées avec P-OGal et le SP600125 alors que le SP600125 n'a 
aucun effet sur le niveau de base de GFP-LC3. Comme attendu, le SP600125 au contraire 
du SB203580 augmente la dégradation de p62 après la photosensibilisation. L'ensemble de 
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ces résultats confirment que JNK exerce un effet régulateur négatif sur l'autophagie induite 
par la photosensibilisation par P-OGal. 
Le rôle de JNK dans la mort cellulaire a longtemps été controversé car il présente un 
effet "pro-survie" ou il déclenche la mort cellulaire en fonction de l'état physiologique ou 
pathologique étudié. Cet effet paradoxal est en partie dû à différents modes d'activation de 
JNK. Apparemment, une phase transitoire au début de l'activation de JNK détermine la 
survie des cellules, tandis que l'activation prolongée de JNK peut induire des signaux de 
mort cellulaire. Nos résultats sont en accord avec la première alternative puisque nous avons 
observé une activation rapide et transitoire de JNK associée à un effet de régulation négative 
sur la mortalité des cellules et sur l'autophagie. 
Il existe également des données contradictoires concernant le rôle de p38 dans 
l'apoptose et l'autophagie. Certaines sont en accord avec un rôle de p38 comme inhibiteur 
de l'autophagie alors que d'autres montrent un effet inducteur de l'autophagie. Bien que nous 
ayons observé une activation de p38 après photosensibilisation par P-OGal, nos données 
suggèrent que p38 n'est pas directement impliqué dans l'induction de la mort cellulaire dans 
notre système. L'activation de ERK est un événement en aval dans la voie mitogène. 
L'activation de la voie Ras/Raf-1/ERK1/2 est en mesure de promouvoir des réponses 
cellulaires opposées, "pro-survie" ou antiproliférative, telles que l'apoptose et l'autophagie. 
Les données disponibles indiquent que la PDT peut moduler l'activité de ERK. Nous avons 
trouvé une diminution de p-ERK après photosensibilisation par les conjugués P-R, jusqu'à 
des niveaux pratiquement indétectables après l'irradiation, malgré l'expression de niveaux de 
base élevés. Le rôle de ERK1/2 dans les mécanismes de mort cellulaire induite par la PDT 
dans notre modèle doit cependant être précisée par des études ultérieures. 
L’activation de la PI3-K/AKT est une autre voie de signalisation importante connue pour 
inhiber l'apoptose et pour promouvoir la survie cellulaire. Les données concernant l'effet de 
la PDT sur la phosphorylation de AKT sont quelque peu contradictoires allant de la dé-
phosphorylation et l'activation subséquente de la mort cellulaire impliquant la voie des 
caspases à la stimulation de la phosphorylation de AKT. Nos résultats montrent une 
diminution dépendante du temps de p-AKT après le traitement par la PDT avec les P-R. Il 
convient de noter que plusieurs études ont montré que les voies de signalisation ERK et PI3-
K/AKT peuvent être aberrantes dans divers cancers humains. Comme les conjugués 
porphyriniques tri-cationiques inhibent ERK1/2 et PI3-K/AKT, nous pourrions proposer leur 






CONCLUSIONS ET PERSPECTIVES 
 
L'objectif de ce travail était de détailler les propriétés photobiologiques de six dérivés 
porphyriniques tri-cationiques dans le contexte d'une utilisation potentielle en dermatologie. 
Dans la première partie du travail, nous avons mené une étude approfondie de leurs 
propriétés photophysiques et photochimiques mettant l'accent sur l'influence de la structure 
de la chaîne conjuguée sur les propriétés des états excités singulets et triplets. Cette 
approche nous a permis de montrer que tous possèdent des propriétés d'absorption 
compatibles avec une utilisation thérapeutique. En ce qui concerne leur premier état triplet 
excité, sa durée de vie assez longue (jusqu'à ~ 60 ms) et le rendement quantique élevé de 
sa formation (~ 0,5) - sauf pour le P-(Lys)n pour lequel ces valeurs sont de l'ordre de 3 à 4 
fois inférieures - conduit à une production efficace d'oxygène singulet. L'analyse de ces 
résultats suggère que tous les composés sont potentiellement intéressants mais à un degré 
moindre pour le conjugué poly-lysine. A ce stade des travaux, il était clair que, à l'exception 
du conjugué poly-lysine, la différence éventuelle dans l'activité photocytotoxique de ces 
dérivés ne pouvait pas être expliquée par une plus grande efficacité photodynamique 
intrinsèque. D'autres facteurs peuvent être impliqués tels que la différence dans leur taux de 
pénétration cellulaire et leur localisation intracellulaire 
La deuxième partie de notre travail a été consacrée à l'étude de l'efficacité et les 
mécanismes photocytotoxiques des dérivés porphyriniques tri-cationiques chez des 
kératinocytes cutanés humains en culture. En terme de photocytotoxicité globale nous avons 
pu établir l'ordre d'efficacité suivant P-OGal > P-CDD = P-Me > P-(Lys) n >> P-Gal > PH. En 
particulier, P-OGal, P-DDC, P-Me supportent aisément la comparaison avec PPIX, produit 
de façon endogène par un traitement par ALA et constituant," l'étalon-or" de la PDT topique 
en dermatologie. Une attention particulière a été accordée à l'évaluation des voies de mort 
cellulaire et les mécanismes moléculaires impliqués dans la phototocytoxicité, en utilisant P-
OGal, le dérivé le plus efficace. Nous avons constaté que l'autophagie joue, avec la nécrose, 
un rôle majeur dans la mort cellulaire induite par la photosensibilisation photodynamique par 
P-OGal. Cette observation est en désaccord avec la majorité des articles qui attribuent la 
mort cellulaire induite par PDT à l'apoptose. En fait, l'apoptose n'a pas été observée, même 
après l'inhibition de l'autophagie, probablement en raison de la localisation non-
mitochondriale de P-OGal. Pour faire la lumière sur les mécanismes moléculaires impliqués, 
nous avons étudié le rôle des MAPK dans la photocytotoxicité induite par P-OGal. Nous 
avons montré que JNK exerce une régulation négative de l'autophagie. Nous avons 
également observé une activation de p38 et une inhibition de AKT et de ERK. L'induction 





La conclusion que l’on peut tirer après l'achèvement de ce travail est que les 
porphyrines tri-cationiques substituées que nous avons étudiées, particulièrement P-OGal, 
sont des photosensibilisateurs intéressants dans le contexte d'une utilisation thérapeutique 
en dermatologie. Ceci n'est pas sans poser quelques nouvelles questions et ouvrir la voie à 
quelques perspectives de développement. 
1 - Il serait intéressant de préciser et détailler le rôle de l'autophagie dans la mort 
cellulaire photoinduite par les dérivés porphyriniques tri-cationiques les plus 
efficaces. Il est d'intérêt majeur de clarifier le rôle de la modulation des MAPK dans 
la photocytotoxicité et dans l'autophagie associée. À cet égard, l'utilisation de la 
technologie "siRNA" serait très pertinente pour comprendre le rôle joué par la voie 
JUNK dans le mécanisme de cette mort cellulaire.  
2 - Il serait également judicieux d'étendre cette étude à des lignées de cellules 
squameuses et de carcinomes basocellulaires. 
3 - Ces dérivés porphyriniques tri-cationiques devraient également être testés in vivo 
dans des modèles murins de tumeurs cutanées permettant alors, après l'évaluation 
de leur toxicité aiguë, l’étude de leur pharmacocinétique, de leur sélectivité et de 
leur efficacité. 
4 - Enfin, si les nouvelles études sur des modèles animaux sont encourageantes, des 
"photopatch tests" chez l'homme pourraient être exécutés en préambule à une 
future utilisation clinique. 
 
 
Mots-clés: thérapie photodynamique; porphyrines tricationiques; fluorescence; état excité 
triplet; oxygène singulet; incorporation cellulaire; localisation intracellulaire; photocytotoxicité; 
autophagie; nécrose; MAPK. 
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TÍTULO: ESTUDO DO EFEITO FOTOCITOTÓXICO DE NOVAS MOLÉCULAS DE SÍNTESE. 
POTENCIAIS APLICAÇÕES EM FOTOQUIMIOTERAPIA ANTITUMORAL EM DERMATOLOGIA 
 
INSERM ERI12, Laboratoire de Biochimie, CHU Amiens-Hôpital Nord, place Victor Pauchet, 
80054 Amiens Cedex 1, France 
Clínica Universitária de Dermatologia, Hospital de Santa Maria, Avenida Prof. Egas Moniz, 1649-




A terapêutica fotodinâmica (TFD) tópica é um dos métodos utilizados no tratamento de 
ceratoses actínicas, doença de Bowen e de carcinomas basocelulares superficiais. Apesar 
dos resultados promissores, tem reduzida eficácia no tratamento de lesões com maior 
espessura, pelo que o desenvolvimento de novos fotossensibilizadores mais eficazes é de 
actual relevância. 
Estudámos as propriedades fotofísicas e fotosensibilizantes de cinco novas porfirinas 
tricatiónicas substituídas. Os derivados porfirínicos são moderadamente fluorescentes e têm 
um estado excitado tripleto de longa duração de vida associado a um elevado rendimento 
quântico, à excepção do conjugado com poli-S-lisina. Foi demonstrada a formação de 
oxigénio singuleto a partir do estado excitado tripleto. 
O estudo da sua incorporação celular e fototoxicidade, efectuados numa linhagem de 
ceratinócitos humanos hiperproliferativos, mostrou que três das porfirinas tricatiónicas 
substituídas são superiores à protoporfirina IX induzida pelo ácido aminolevulínico 
(tratamento actual em TFD cutânea). Estes compostos localizam-se preferencialmente em 
vesículas de endocitose ou pinocitose, mas não nas mitocondrias nem nos núcleos. A 
estrutura química da cadeia conjugada condiciona a sua incorporação, a localização e, 
consequentemente, a sua fototoxicidade. 
O estudo dos mecanismos de morte celular, com o derivado porfirínico mais eficaz, mostrou 
a ausência de fixação de anexina V, de activação das caspases 3, 8 e 9, da condensação 
da cromatina, sugerindo que a via apoptótica não é estimulada. A formação de vesículas 
LC3 positivas nas células transfectadas com GFP-LC3 e a degradação da p62 
demonstraram a presença da autofagia. Esta é regulada negativamente pelo JNK. 
Em conclusão, trata-se de fotossensibilizadores eficazes in vitro sendo, contudo, necessário 








A terapêutica fotodinâmica (TFD), ou fotoquimioterapia antitumoral, é uma terapêutica 
antitumoral recente. A base da TFD assenta na utilização de um fotossensibilizador do tipo 
porfirínico. Este interage com a radiação visível passando, por diversos processos 
fotofísicos, ao estádio excitado tripleto. Na presença de oxigénio molecular, a transferência 
de energia do estádio tripleto para o oxigénio molecular conduz à formação de oxigénio 
singuleto, espécie reactiva de oxigénio (efeito fotodinâmico do tipo II). O oxigénio singuleto é 
considerado uma das principais fototoxinas responsáveis pelo efeito terapêutico. Devido à 
sua grande reactividade, o oxigénio singuleto lesa as principais biomoléculas celulares na 
sua proximidade tais como os lípidos, proteínas e ADN, levando à morte das células 
transformadas. 
Em Dermatologia, a TFD tópica usando como pró-fámaco o ácido δ-aminolevulínico (ALA), 
ou o seu derivado metilado, é a mais utilizada por ser a que demonstrou maior eficácia. A 
TFD tópica consiste na aplicação no local a tratar de ALA (pró-fármaco) que, após captação 
selectiva pelas células alvo, leva à síntese endógena de protoporfirina IX, o 
fotossensibilizador. A TFD tópica está aprovada no tratamento de ceratoses actínicas, 
doença de Bowen e carcinoma basocelular superficial. Apesar dos seus resultados 
encorajadores, a TFD cutânea necessita de desenvolvimento para maximizar a sua eficácia 
e poder ser eficiente no tratamento de tumores cutâneos profundos. Uma das estratégias de 




Escolhemos deste modo cinco novos fotossensibilizadores do tipo porfirínico, tricatiónicos e 
hidrossolúveis, substituídos com as seguintes cadeias laterais: 5-(4-Metoxicarbonilfenil)  
(P-Me), 5-[4-(N,N′-Diciclohexilureidooxicarbonil)fenil] (P-DDC), 5-[4-(1,2:3,4-Di-O-
isopropilidene-R-D-galactopiranosil-6-oxicarbonil)fenil] (P-OGal), 5-[4-(R-D-Galactopiranosil-
6-oxicarbonil)fenil] (P-Gal) e poli-S-lisina (P-(Lys)n).  
Estas moléculas foram escolhidas porque: 1) podem ligar-se às células tumorais da pele 
com expressão aumentada de moléculas aniónicas, como as mucinas; 2) as suas 
propriedades hidrofílicas constituem alternativa aos fotossensibilizantes lipofílicos actuais;  
3) a conjugação de diferentes grupos (aminoácidos, péptidos e açúcares) poderão conferir 
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vantagens melhorando a selectividade e captação pelas células tumorais; 4) são moléculas 
anfifílicas pelo que poderão exercer a sua acção fotossensibilizante na interface  
hidrofílica-hidrofóbica das membranas na proximidade de proteínas, fenómeno associado a 
maior eficácia fotossensibilizante. 
O objectivo geral desta tese foi o estudo de cinco novos derivados porfirínicos tricatiónicos, 
em particular: 
1. A caracterização das suas propriedades fotofísicas e fotossensibilizantes intrínsecas, 
preâmbulo indispensável a um projecto deste tipo; 
2. O efeito comparativo das suas propriedades fotosensibilizantes num modelo de 
ceratinócitos humanos hiperproliferativos, seguido do estudo dos mecanismos 
moleculares implicados na morte celular. 
 
RESULTADOS  
Inicialmente, estudámos as propriedades de absorção e de fluorescência por espectroscopia 
convencional dos novos derivados porfirínicos tricatiónicos. O estudo dos estádios excitados 
singuleto dos fotossensibilizadores foi efectuado por “espectroscopia de feixe laser no 
regime de femtosegundos” e pela determinação do tempo de vida da fluorescência. 
Verificámos que as propriedades de absorção destas moléculas são compatíveis com a sua 
utilização terapêutica, e que as suas propriedades de fluorescência permitem a sua 
detecção e quantificação em células vivas. Por “espectroscopia de feixe laser no regime de 
nanosegundo” estudámos o estádio excitado tripleto destas substâncias que se caracteriza 
por uma duração de vida relativamente longa (> 50 ms) e um rendimento quântico elevado 
(~0,5) permitindo antever uma forte probabilidade de formação de oxigénio singuleto a nível 
celular. A formação de oxigénio singuleto, evidenciada de forma indirecta pela oxidação da 
histidina como substrato específico, é idêntica em todos os derivados porfirínicos à 
excepção do substituído com a cadeia poli-S-lisina que tem menor eficácia.  
Após a caracterização das propriedades fotofísicas e fotoquímicas, estudámos as 
propriedades fotobiológicas dos novos derivados porfirínicos através de abordagem ex-vivo 
usando linha celular de ceratinócitos humanos hiperproliferativos (NCTC 2544). Este modelo 
celular foi escolhido atendendo a que a TFD tópica é usada em lesões pré-neoplásicas e 
neoplásicas cutâneas epiteliais, respectivamente, ceratoses actínicas e doença de Bowen. 
Estudámos a incorporação, a indução de “stress” oxidativo, a fotocitotoxicidade e a 
localização intracelular dos derivados porfirínicos. Demonstrámos que todos os derivados 
porfirínicos são fotocitotóxicos, neste modelo celular, com a seguinte ordem de eficácia 
relativa: P-OGal > P-DDC = P-Me > P-(Lys)n >> P-Gal > P-H. Um resultado interessante foi a 
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constatação de que três dos derivados porfirínicos são ligeiramente mais fotocitotóxicos que 
a protoporfirina IX induzida pelo tratamento das células com ácido δ-aminolevulínico,  
pró-fármaco utilizado actualmente na prática clínica. Observámos a correlação entre a 
eficácia fotocitotóxica dos derivados porfirínicos e a sua capacidade de induzir a 
peroxidação lipídica. Verificámos que a eficácia fotocitotóxica depende da elevada 
incorporação celular e da localização intracelular dos derivados porfirínicos. Os derivados 
porfirínicos mais eficazes localizam-se em vesículas de endocitose e pinocitose, não tendo 
sido evidenciado a sua presença mitocondrial ou nuclear. 
A fim de esclarecer os mecanismos moleculares de morte celular, prosseguimos o estudo 
com o derivado porfirínico mais fotocitotóxico (P-OGal). Começámos por estudar que vias de 
morte celular são induzidas pela TFD com P-OGal em ceratinócitos NCTC 2544. A apoptose 
é habitualmente descrita como a via de morte celular predominante induzida pela maioria 
dos fotossensibilizadores usados em TFD. No entanto, ao contrário do habitualmente 
considerado, não observámos o aparecimento de marcadores de apoptose após TFD com 
P-OGal, nomeadamente, fixação de anexina V (citometria de fluxo), activação das caspases 
3, 8, 9 (actividade enzimática e immuno blotting), de condensação da cromatina (técnica 
ELISA) e libertação de citocromo c mitocondrial (imunofluorescência). Podemos, deste 
modo, admitir que a apoptose não constitui via preferencial de morte celular induzida  
pelo P-OGal.  
Esta observação levou-nos a estudar vias alternativas de morte celular, nomeadamente a 
autofagia e a necrose. Após TFD com P-OGal verificámos, por microfluorescência, a 
formação de vesículas LC3-positivas em células NCTC 2544 transfectadas com GFP-LC3, 
sugerindo a presença de autofagia na morte celular. Esta hipótese foi confirmada pela 
observação da degradação de p62, por técnica de immuno blotting. Após inibição da 
autofagia com 3-metiladenina observámos uma redução de aproximadamente 40% na 
fotocitotoxicidade total induzida pelo P-OGal. Podemos, deste modo, concluir que na morte 
celular induzida pelo P-OGal participam simultaneamente a autofagia e necrose. O facto de 
a apoptose não constituir via preferencial de morte celular poderá ser consequência da 
reduzida presença mitocondrial do derivado porfirínico, uma vez que uma localização 
lisossomial ou pré-lisossomial na proximidade do retículo endoplasmático parece favorecer 
os fenómenos anti-apoptóticos e pro-autofágicos. 
Atendendo a que as MAPKs participam na regulação das vias de morte celular induzidas 
pelo “stress” oxidativo, decidimos estudar por immuno blotting a expressão de p38, JNK, 
ERK1/2 e AKT. Verificámos, após TFD com P-OGal, a activação transitória do p38 e JNK, 
associada à inibição do ERK1/2 e AKT. Demonstrámos, ainda, que o JNK exerce regulação 
negativa na fotocitotoxicidade. Consideramos potencialmente relevante salientar que vários 
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tumores têm uma expressão aberrante de ERK1/2 e AKT, pelo que a sua inibição pelos 
novos derivados porfirínicos poderá resultar em vantagem terapêutica futura.  
 
CONCLUSÃO 
Neste trabalho demonstrámos que as porfirinas tricatiónicas estudadas possuem 
propriedades fotofísicas e fotosensibilizantes intrínsecas compatíveis com a sua utilização 
como agentes fotoquimioterapêuticos eficazes. A abordagem celular demonstrou que a sua 
incorporação e localização intracelulares dependem fortemente da natureza da cadeia 
lateral de substituição e condicionam a eficácia fotocitotóxica. Paralelamente à necrose, a 
autofagia parece estar fortemente implicada. Contribuímos para a clarificação do papel das 
MAPKs na morte celular induzida pela TFD. Atendendo aos resultados, as nossas 
perspectivas futuras passam pela realização de técnicas, como o small interfering RNA, que 
permitirão detalhar o papel das MAPKs no processo de autofagia. A nossa abordagem 
deverá, igualmente, evoluir para o estudo destes novos derivados porfirínicos em linhas 
celulares de carcinoma basocelular e em modelos animais. 
 
Palavras-chave: Terapêutica fotodinâmica; porfirina tricatiónica; fluorescência; estado 
tripleto; oxigénio singuleto; captação celular; localização intracelular; fotocitotoxicidade; 
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Topical photodynamic therapy (PDT) has been approved for treating actinic keratosis, 
Bowen’s disease and basal cell carcinoma. Despite promising results, PDT still lacks efficacy 
in treating deeper lesions, and the search for new photosensitizers is of current interest.  
In this work, photophysical and photosensitizing properties of new water-soluble tri-cationic 
porphyrin derivatives (P-R) were investigated. Except for the poly-S-lysine conjugate, rather 
fair fluorescence and long-lived excited triplet state with a high quantum yield (~0.5) have 
been characterized. Quantitative formation of singlet oxygen from the excited triplet has been 
observed. 
Uptake in and photocytotoxicity toward cultured proliferating human skin keratinocytes have 
shown that three of them compare favourably with protoporphyrin IX induced by  
δ-aminolevulinic acid treatment, protocol currently used in Dermatology. They localize in 
endocytotic or pinocytotic vesicles but not in mitochondria or nuclei. The nature of the 
conjugated side chain is critical in controlling the uptake and localization of P-R and the 
photocytotoxic efficacy. 
Molecular mechanisms of cell death have been studied using the most efficient derivative  
(Di-O-isopropylidene-α-D-galactopyranosyl substituted). Lack of annexin V binding, caspase 
activation and chromatin condensation has shown the absence of apoptosis. 
Photocytotoxicity correlates with the appearance of LC3 marked vesicles in GFP-LC3 
transfected cells and p62 degradation, suggesting that autophagy along with necrosis, plays 
a major role. JNK exerts a negative regulatory effect on autophagy.  
In conclusion, P-R are interesting photosensitizers which merit further studies in cellular and 
animal models.  
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1.1  OBJECTIVES OF THE WORK IN THE VIEW OF THE ROLE AND LIMITATIONS OF 
PHOTODYNAMIC THERAPY  
 
Photodynamic therapy (PDT) uses the combination of a photosensitising drug and light to 
cause selective damage in the target tissue. The local rather than systemic nature of the 
photodynamic therapy effect should be highlighted because it contributes to both the 
limitations and the opportunities for PDT as a successful treatment of cancer. A limitation of 
PDT is that it cannot cure advanced disseminated tumors because irradiation of the whole 
body with appropriate doses is not possible. Nevertheless, PDT can be a valuable selective 
and curative therapy with many potential advantages over available alternatives in early or 
localized diseases, either neoplasms or certain infectious disorders. For some advanced 
cancers, PDT can improve quality of life and may lengthen survival. 
 
In dermatology, intravenous administration of Photofrin® - the first PDT drug approved by the 
FDA in 1993 - was shown to be effective in treatment of several cutaneous lesions but 
systemic administration of this drug was shown to be unjustified for large-scale treatment of 
localized pathologies. Furthermore, the complex and variable mixture of more than 60 
compounds with different properties and activity which constitutes Photofrin® added to the 
long-lasting cutaneous photosensitivity due to its low selectivity for tumour tissues; and its 
slow elimination rate from the body have limited its use in dermatological practice. 
Photodynamic therapy using topical applications of either δ-aminolevulinic acid (ALA) or its 
methyl ester (MAL) pro-drugs has partially resolved these problems as it is simple and 
convenient. It permits topical pro-drug delivery and thus is not associated with substantial 
systemic toxic effects, namely, long-lasting cutaneous photosensitivity. Although approved 
for the treatment of non-melanoma skin cancer, such as Bowen’s disease (BD) and 
superficial basal cell carcinoma (sBCC), as well as for pre-neoplasic skin lesions, such as 
actinic keratosis (AK), ALA and MAL still present several clinical limitations. They have 
limited skin penetration and, as Photofrin®, have low absorbance coefficients in the red 
region corresponding to the optical therapeutic window irradiation (see Section 1.7). 
Moreover, ALA and MAL are rather insoluble in water. 
 
Owing to the disadvantages presented by the photosensitizers presently used, many new 
compounds - the so-called second generation photosensitizers - have been synthesized. As 
detailed in Section 2.1, research in this area is aimed at the development of photosensitizing 
drugs that are chemically pure, that absorb more strongly at longer wavelengths and that 
have improved biological properties. The second-generation photosensitizers present 
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stronger absorption coefficients at longer wavelengths than for protoporphyrin IX (PPIX) and 
thus, a PDT treatment with any of these compounds would require lower doses of drug and 
light for efficacy. Phthalocyanines were first thought to represent a better option than 
porphyrins for improving topical PDT because of their superior absorbance in the 700 nm 
region (molar absorptivity: ~2×105 M-1cm-1). However, they are not currently used in the PDT 
of epidermal skin lesions as they tend to form aggregates with reduce skin uptake and 
photosensitizing properties. Furthermore, the phthalocyanine ring resists biodegradation 
which may determine long-lasting cutaneous photosensitivity. In fact, none of the previously 
referred systemically administered photosensitizers have been specially developed for 
topical application to treat skin lesions. Finally, achievement of effective PDT through the 
injection of photosensitizers directly into the lesion has been unsuccessful. 
 
To summarize, the main current efforts in relation to skin PDT are related to: 1) the 
development of new photosensitizers with better (photo)biological activity, 2) the 
improvement of the selectivity of the treatment thus minimizing its side-effects, 3) an easy 
formulation especially in view of large scale use on an out-patient basis in dermatological 
practice. 
 
A strategy that can be used to overcome these challenges is to design new photosensitizers 
with different structures, electric charges and hydrophobicity. These factors will determine 
how photosensitizers interact with themselves and with their surroundings, how they are 
accumulated by cells, to which sites, which molecular pathways they modulate and the type 
of programmed cell death they induce. Structure-activity relationship studies must thus be 
performed to identify and quantify the contribution of the physicochemical characteristics that 
may affect the biological activity of the compounds. 
 
Our group has focused his interest on tri-cationic porphyrin derivatives. Effective 
photosensitizers have been synthesized whose water solubility and biological activity have 
been improved by conjugating cationic meso-tetra-substituted porphyrins to a methyl (P-Me), 
a dicyclohexylureidooxy group (P-DDC), a di-Oisopropylidene-α-D-galactopyranosyl group 
(P-OGal), a α/β-D-galactopyranosyl group (P-Gal) or a poly-S-lysine chain (P-(Lys)n) side 
chains (Figure 1.1).  
 
 




Figure 1.1 Names and chemical structures of 5-(4-carboxyphenyl)-10,15,20-tris(N-methylpyridinium-4-
yl)porphyrin derivatives under study. P-H: 5-(4-Carboxyphenyl)-10,15,20-tris(N-methylpyridinium-4-
yl)porphyrin Tri-iodide. P-Me: 5-(4-Methoxycarbonylphenyl)-10,15,20-tris(N-methylpyridinium-4-
yl)porphyrin Tri-iodide. P-DDC: 5-[4-(N,N′-Dicyclohexylureidooxycarbonyl)phenyl]-10,15,20-
tris(Nmethylpyridinium-4-yl)porphyrin Tri-iodide. P-OGal: 5-[4-(1,2:3,4-Di-O-isopropylidene-R-D-
galactopyranosyl-6-oxycarbonyl)phenyl]-10,15,20-tris(N-methylpyridinium-4-yl)porphyrin Tri-iodide. P-
Gal: 5-[4-(R/_-D-Galactopyranosyl-6-oxycarbonyl)phenyl]-10,15,20-tris(Nmethylpyridinium-4-
yl)porphyrin Tri-iodide. P-(Lys)n: Porphyrin-poly-S-lysine conjugate. 
 
Tri-cationic porphyrin derivatives are promising molecules. (1) They may bind to negatively 
charged skin cells after the disruption of the stratum corneum barrier. It is of note that cancer 
cells may carry a net negative charge due to over-expression of anionic molecules such as 
O-glycosylated mucins. (2) Their hydrophilic properties appear to be a valuable alternative to 
the liposoluble Photofrin® and ALA/MAL pro-drugs used nowadays in the clinical practice.  
(3) The conjugation of amino-acids, peptides and sugars to photosensitizers further favors 
specific targeting as such groups play key roles in the recognition and metabolism of 
microorganisms and pathological cells. Finally, (4) the tricationic porphyrin conjugates are 
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amphiphilic photosensitizers due to their positive charges and their side chain conjugated to 
the hydrophobic porphyrin ring. Amphiphilic photosensitizers are thought to be more 
photodynamically active as they can localize to the hydrophobic-hydrophylic interfaces in 
membranes and at the surface of proteins. Amphiphilicity is also important because it can 
limit aggregation and, consequently, improve the photosensitizing properties of the molecule. 
 
As a consequence, the main goal of this thesis is to elucidate the photobiological/biochemical 
characteristics of new photoactive substances - namely: tri-cationic porphyrin conjugates – 
which make them suitable for therapeutic applications in dermatology.  
 
To this end, specific topics will be developed as follows: 
 
Chapter 2-  State of the art and bibliographic synthesis 
 
Chapter 3-  Experimental methods 
 
Chapter 4- As a pre-requisite for the analysis of their photobiological activity, the fourth 
chapter presents the physico-chemical properties of the tri-cationic conjugates 
and a thorough study of their photophysics with emphasis on the influence of 
the conjugation on their excited state properties 
 
Chapter 5-  The fifth chapter deals with the photocytotoxicity effectiveness of tri-cationic 
porphyrin derivatives in cultured proliferating human skin keratinocytes. 
Photosensitizers photodynamic activity are determined as a function of their 
physicochemical characteristics, cellular uptake kinetics and photosensitizer 
intracellular localization. Finally, attention is paid to the assessment of cell death 
pathways and molecular mechanisms involved in the photocytotoxicity induced 
by tri-cationic porphyrin derivatives, the induction of a specific death mode 
might be susceptible to result in a therapeutic advantage 
 
Chapter 6-  General Conclusions and Perspectives 
 
44 
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2.1 PHOTODYNAMIC THERAPY: AN OUTLINE  
 
After a short historical overview, I will detail in this first part of the introduction the following 
topics: 
- Historical overview 
- Basic principles of photodynamic therapy 
- Photosensitizers 
- Photodegradation and photomodification 
- Subcellular localization and relocalization 
- Basis for tumor selectivity 
- Principles of light interaction with tissue and light sources used for PDT 
 
2.1.1  HISTORICAL OVERVIEW 
 
Light has been used in the treatment of various diseases from antiquity. Ancient Egyptian, 
Indian and Chinese cultures (3000 BC-1500 BC) used the beneficial effect of the sun to treat 
a variety of diseases including vitiligo, psoriasis and even psychosis [1]. The ancient Greeks 
used whole-body sun exposure or heliotherapy in the treatment of different diseases. Around 
500 BC, the famous Greek physician, Herodotus, the father of heliotherapy, introduced the 
importance of sun exposure for the restoration of health [1]. However, only rather recently 
has the therapeutic effect of sunlight been used to a significant degree in medicine, when 
ancient habits like lying nude in the sun became a popular  
pastime (Figure 2.1). 
 
 
Figure 2.1 Children take sun at a sanatorium in the Swiss Alps, the region in which heliotherapy 
originated [2]. 
 
The Danish physician Niels Finsen further developed phototherapy and was awarded a 
Nobel Prize in 1903 for his work on the bactericidal effects of phototherapy after having 
successfully treated smallpox using red light (in 1893) and lupus vulgaris, a cutaneous 
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tuberculosis, with ultraviolet light generated by an arc lamp (in 1895) [3]. Phototherapy uses 
light in the treatment of disease while photochemotherapy involves the administration of a 
chemical agent followed by the exposure to light of tissues in which the agent is localized [4]. 
The concept of cell death being induced by the interaction of light and chemicals has been 
recognized for 100 years. The therapeutic use of photochemotherapy, as we know it, begins 
in 1900 when Raab reported that the combination of acridine orange and light can destroy 
living organisms. Raab, a medical student working for von Tappeiner in Munich, described 
the lethal effect of combining acridine red and light on Infusoria, a species of paramecium 
responsible for a type of malaria [5]. In a series of successive experiments he established 
that this lethal effect on the paramecium occurred to a greater extent with acridine plus light 
than with acridine alone, light alone or acridine exposed to light and then added to the 
paramecium. Raab, therefore, concluded that it was not the light but rather “some product of 
the fluorescence” that induced in vitro toxicity. He postulated that this effect was caused by 
the transfer of energy from light to the chemical, similar to that seen in plants after the 
absorption of light by chlorophyl. In 1903, using eosin and sunlight in the treatment of a 
number of human skin conditions, Jesionek and Tappeiner demonstrated the basic principle 
of phototherapy [6]. In order to distinguish these phenomena from the sensitization of 
photographic plates by dyes, the term Photodynamische Wirkung (photodynamic effect) was 
coined for the oxygen-requiring photosensitized reactions in biological systems. Von 
Tappeiner also predicted the potential future application of “fluorescent substances” in 
medicine [6-8]. 
 
At the same time as Raab's discovery, Prime, a French neurologist, reported photosensitive 
reactions in sun-exposed areas, in a patient who had been given parenteral eosin for the 
treatment of epilepsy [9]. In 1908, Haussmann introduced a new concept in 
photochemotherapy by using hematoporphyrin prepared from bovine blood and the related 
tetrapyrrole derivative, chlorophyll, in photodynamic therapy of cultured cell and mice [10]. 
The first report of endogenous porphyrin photosensitisation was given in 1913 by Meyer-Betz 
[11]. After injecting himself 200mg of hematoporphyrin, Meyer-Betz noted severe pain and 
swelling of that part of the body exposed to light, showing a massive phototoxic reaction. His 
pictures are shown in figure 2.2 before and after treatment. 
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Figure 2.2 First report of exogenous porphyrin photosensitisation. In 1913, after injecting himself 
200mg of HpD, Meyer-Betz noted severe pain and swelling of the part of his body exposed to light, 
showing a massive phototoxic reaction. This illustration shows the pictures of him before and after 
treatment [11]. 
 
The first report of fluorescent porphyrin localization in a malignant tumour appeared in 1924 
when a Frenchman from Lyon, Policard, observed the characteristic red fluorescence of 
hematoporphyrin in an experimental rat sarcoma illuminated with ultraviolet light from a 
Wood’s lamp [12]. Since then, porphyrins and hematoporphyrin derivatives (HpD) have been 
studied and used for diagnosis.  
In the 40’s, the term photodynamic therapy was introduced by Blum, according to the original 
definition by Von Tappeiner, as a photosensitized reaction in the presence of oxygen [13]. 
Latter in the 50’s Ronchese activated endogenous fluorescent molecules in tumor tissue to 
delineate its boundaries [14]. At the same time, Figge et al. [15] and Rasmussen-Taxdal et 
al. [16] administered natural porphyrins to patients and tumor-bearing animals in an attempt 
to more accurately detect tumor tissue by fluorescence. Winkelman used synthetic 
porphyrins (tetraphenylporphyrins) to detect tumor tissue [17-19]. However, the 
photodynamic therapy field was silent until the collaboration of Richard Lipson and Samuel 
Schwartz in the 1960’s. Schwartz had isolated a tumor localizing impurity from 
hematoporphyrin preparations that was later named hematoporphyrin derivative. Lipson was 
investigating how to detect tumor tissue by observing the intratumoral fluorescence of 
hematoporphyrin. Unable to obtain reproducible results with hematoporphyrin, Lipson used 
Schwartz’s HpD as a tumor detection agent and found that it could be used as a 
photosensitizer to destroy tumor tissue [20]. 
In the 1970’s, Dougherty rediscovered that fluorescein diacetate could photodynamically 
destroy TA-3 cells in vitro [21]. Dougherty then began treating tumor-bearing animals with 
fluorescein and found that it could work as a photosensitizer [22]. Following this observation, 
Weishaupt et al. identified the cytotoxic product of the photochemical reaction to be singlet 
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oxygen [23]. However, fluorescein has a low singlet oxygen quantum yield and a long 
wavelength absorption in the green portion of the electromagnetic spectrum that does not 
penetrate deeply into skin. Porphyrins were then examined as photosensitizers because they 
are efficient singlet oxygen producers and have absorbance maxima in the red portion of the 
electromagnetic spectrum. Schwartz’s HpD was then re-discovered since it has been proved 
to have a high singlet oxygen quantum yield, an absorbance maximum in the red, and is 
selectively retained in tumor tissue [21]. After several years a purified version named 
Photofrin, was produced. In the following years Photofrin was approved for use in the United 
States against early- and late-stage lung cancers and esophageal cancers and dysplasias 
with other indications pending [21].  
As I will show later, photodynamic therapy has been increasingly adopted over the last few 
decades and many new photosensitizers and light delivery systems have been developed 
(this will be fully detailed in Section 2.1.3 and Section 2.1.8, respectively). By now, PDT with 
various photosensitizers has been clinically applied and approved for the treatment of 





Chemical name Approval (Potential) Indications 
Benzvix Benzyl δ-aminolevulinic acid No a Gastrointestinal tumors 
 
BOPP Boronated protoporphyrin No a Brain tumors 
Hexvix Hexyl δ-aminolevulinic acid Yes b Bladder cancer 
 
Levulan  δ-Aminolevulinic acid  Yes c Actinic keratosis, Bowen’s disease, Basal cell 
carcinoma 
  No a Head and neck tumors, gynecological tumors 
Lu-Tex  Lutetium texaphyrin No a Cervical cancers, prostate cancer, brain tumors 
Metvix  Methyl δ-aminolevulinic acid  Yes d Actinic keratosis, Bowen’s disease, Basal cell 
carcinoma 
Pc-4  Phthalocyanine-4  No a Cutaneous/subcutaneous lesions of diverse solid 
tumor origins 
Photochlor  2-(1-Hexyloxyethyl)-2-devinyl 
pyropheo-phorbide-alpha 
No a Basal cell carcinoma 
Photofrin Porfimer sodium  Yes e Barrett’s high-grade dysplasia 
 Hematoporphyrin derivative, Yes f Cervical dysplasia and cervical cancers 
 polyhematoporphyrin Yes g Endobroncheal cancer 
  Yes h Esophageal cancer 
  Yes f Gastric cancer 
  Yes I Papillary bladder cancer 
  No a Cholangiocarcinoma, brain tumors 
Photosense  Aluminum phthalocyanine  Yes j Head and neck cancer 
Foscan Temoporfin Meso-tetrahydroxy-
phenyl chlorine 
Yes k Palliative therapy of head and neck cancer 
  No a Prostate cancer, pancreas cancer, 
cholangiocarcinoma 
SnET2  Tin ethyl etiopurpurin  No a Breast cancer, Kaposi sarcoma, prostate cancer 
Visudyne Verteporfin Benzoporphyrin 
derivative monoacid ring A  
Yes e Age-related macular degeneration 
  No a Basal cell carcinoma 
 
Table 2.1 Overview of photosensitizing agents currently used in clinical application (a Not yet approved; 
b European Union (EU); c EU, USA; d EU, Australia; e Canada, EU, UK, USA; f Japan; g Canada, Denmark, 
Finland, France, Germany, Ireland, Japan, The Netherlands, UK, USA; h Canada, Denmark, Finland, France, 
Ireland, Japan, The Netherlands, UK, USA; I Canada; j Russia; k EU, Iceland, Norway) 
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While PDT has focused on cancer since 1975, it has become clear within the past decade 
that PDT may also be of interest for the treatment of gram-positive and gram-negative 
microbial infections (since it overcomes the problem of (multi-) drug resistance of bacteria) 
and could be useful in the management of viral, fungal and parasitic diseases. 
 
2.1.2 BASIC PRINCIPLES OF PHOTODYNAMIC THERAPY 
 
Phototherapy can be defined as the use of light alone for therapeutic purposes (eg. 
ultraviolet B irradiation for the treatment of vitiligo) while photochemotherapy involves the 
therapeutic use of light in combination with a chromophoric chemical, a chromophore called 
a photosensitizer. The photosensitizer triggers the photochemotherapeutic reaction (eg. 
ultraviolet A irradiation in combination with 8-methoxypsoralen for the treatment of psoriasis 
and cutaneous T cell lymphoma). As defined by Blum (see Section “Historical overview”) 
photodynamic therapy is a modality of photochemotherapy in which the photosensitized 
reaction requires the presence of oxygen, as will be fully detailed below. 
Photodynamic therapy is, nowadays, a medical technology that has been developed for the 
removal of harmful or unwanted cells, mainly to treat cancer [24]. It consists of the systemic 
or topical application of a drug (a dye or a dye precursor), called a photosensitizer (P), that 
localizes more or less selectively in the target tissue at nontoxic concentrations. The principle 
is based on the capacity of these substances to be excited by light and to restitute energy in 
a chemical form by transferring excess energy to molecular oxygen. The latter is transformed 
into an activated species called “singlet oxygen” (1O2) as will be detailed below [25-26]. 
A photosensitizer molecule (P) in its ground state (1P0) is characterized by paired electrons 
with a total spin of S=0 and a spin multiplicity of 1 thus called the singlet state. Illuminating 
the chromophore with light brings it to an excited singlet state in which one electron of the 
occupied orbital of highest energy of the ground state is brought to a previously unoccupied 
orbital of higher energy. Depending on the energy of the excitation wavelength, the 
photosensitizer undergoes a transition to an excited singlet state 1P1
*, 1P2
*,.... or 1Pn
* (in the 
order of increased energetic states). The shorter the wavelength, the higher the energy and 
consequently the higher is the excited singlet state. Then the molecules in the upper singlet 
states (1Pn
*, n≥2) are rapidly deactivated (within less than a picoseconds) into the 1P1
* state. 
In their first excited singlet state (1P1
*) most molecules return to the ground state by losing 
their excess energy to the environment as heat (so-called internal conversion followed by 
vibrational relaxation). Another deactivation path from 1P1
* consists in the emission of a 
fluorescence (radiative process). As a result, the shape of the fluorescence emission 
spectrum is not dependent on the excitation wavelength. Furthermore, the emitted quanta 
have lower energies and higher wavelengths than those used for excitation of the molecule 
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[27-28]. It is important to note that most molecules undergo a return process via the internal 
conversion followed by vibrational relaxation. As a consequence, their singlet states 1P1
* 
have a very short life and the molecules exhibit neither fluorescence nor photosensitizing 
properties. The fluorescence pathway is thus favored by the relative inefficiency of internal 
conversion and vibrational relaxation which is associated with a longer lifetime of 1P1
* in the 
nanosecond range. Beside internal conversion/vibrational relaxation or fluorescence 
emission, the excited singlet state (1Pn
*) can also cross to an isoenergetic level of the triplet 
state, most generally the first excited triplet state (3P1
*), where two electrons are unpaired 
and have the same spin. This non-radiative process is called intersystem crossing (ISC). 
Most PDT photosensitizers have high quantum efficiency for this transition. Then, the return 
to the ground state from the first excited triplet state 3P1
* can occur via phosphorescence 
(radiative process) or via intersystem conversion to 1P1
* followed by vibrational relaxation. 
Because these processes are thermodynamically unfavorable, they are therefore relatively 
slow. As a result, triplet states are generally characterized by a relatively long lifetime (up to 
seconds). From 1P1
* or 3P1
*, whose lifetime is long enough, photochemical reactions with the 
environment may occur confering photosensitizing properties to the molecules. Because of 
the longer lifetime of the triplet excited state (compared to that of singlet excited states) most 
photosensitizing processes occur via the triplet state. This sequence of reactions can be 
summarized by the simplified “Jablonski diagram” (Figure 2.3).  
 











































































Figure 2.3 Simplified Jablonski diagram showing porphyrin (singlet and triplet states) [adapted from 
Kohen et al., 2002 [29]] 
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An overview of photophysical processes in photosensitizer molecules is also given in Table 
2.2. 
 
Process Reaction Timescale [s] Rate (s-1) 






Internal conversion 1Sn,..., 
1S2 → 
1S1 + heat  
∼10−13−10−12 
 
Internal conversion  1S1 → 




Intersystem crossing 1S1 → 
3T1 + heat 
∼10−7 - 10−6 
kISC[
1S1] 
Chemical reaction 1S1 +X → S0 + reaction product 
or 1S1 → S’ (photoproduct) 
 kR(S)[
 1S1] 
Fluorescence  1S1 → 




Internal conversion  3T1 → 
1S0 + heat  
∼10−11−10−6 
KICT[3T1] 
Phosphorescence  3T1 → 




X*: unstable chemical  
X* →1S1 → 
1S0 + hυChem  >10
−6 kC[A*] 
Chemical reaction  3T1+X→






Table 2.2 General characteristics of primary photophysical/photochemical processes in aromatic 
molecules. (kx rate constant, 
1Sn singlet state molecule, 
3Tn triplet state molecule, [
1Sn or 
3Tn] 
concentration of excited molecules, X reaction substrate). 
 
Damage to the environment produced by 3P1
* which will not be detailed here [30]. As an 
example we may mention the photoaddition of psoralens to DNA. Other pathways constitute 
the so-called photosensitized reactions. In such processes the photosensitizer will modify the 
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environment without direct reaction. Most photosensitized reactions involve molecular 
oxygen. They are called photodynamic reactions. 
 
The literature distinguishes two photodynamic processes depending on the intervention of 
molecular oxygen (more correctly called dioxygen). In its ground state, molecular oxygen 
(e.g. oxygen we breathe) possesses 2 unpaired electrons in isoenergetic orbitals. Thus these 
2 electrons have the same spin. Consequently, the ground state of oxygen is a triplet state 
and its low-lying excited state is a singlet state. This makes possible an energy transfer 
between the first excited triplet state of the photosensitizer and the triplet ground state of 
oxygen. The ground state of the photosensitizer is restored while oxygen becomes excited 
as a singlet state, as illustrated by the following scheme: 
 




* → ISC→ 3P1
* 
3P1






Scheme 2.1 Singlet oxygen generation via photosensitization (P = Porphyrin; ISC = Intersystem 
Crossing). Note that 3O2 as well as 
1O2 are conventional notations since 
3O2 is a ground state molecule 
while 1O2
* is a molecule in the first excited singlet state.   
 
The energy required for the triplet to singlet transition of oxygen is 22 kcal/mol corresponding 
to a photon energy of 1274 nm (infrared light). Thus, relatively low energy is needed to 
produce singlet oxygen.  
Singlet oxygen, which is the lowest excited electronic state of oxygen, is cytotoxic. It readily 
reacts with electron-rich biomolecules such as unsaturated lipids, amino acids and DNA. In 
homogenous solutions, the 1O2 lifetime varies from the µs (aqueous media) to several 
hundreds of µs (in some organic solvents). In cells, there is much controversy regarding the 
lifetime and diffusion distance of the transient oxygen species. Recent studies have shown 
that the intracellular lifetime of singlet oxygen is ~3 µs in a viable, metabolically active, H2O-
containing cell [31]. This lifetime is significantly longer than that previously reported [32]. The 
intracellular diffusion distance of singlet oxygen has been estimated to be 2–4x10-6 cm2s-1 
[33]. This short singlet oxygen lifetime and resulting limited diffusion distance makes PDT a 
highly selective form of cancer treatment due to the localized effect it produces. Therefore, 
the site of its generation is also the site of initial damage. Photosensitizing reactions of this 
type are known as Type-II photodynamic reactions and are characterized by their 
dependence on oxygen concentration [34]. This type II process is thus defined as an 
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interaction between the excited triplet state of the photosensitizer and oxygen. It is the 
primary process of the photosensitized sequence of events. Another process related to type 
II reaction, although generally not frequent, is a charge transfer for 3P1









In contrast to type II reactions, where molecular oxygen interacts directly with the 
photosensitizers, there exists a so-called type I process in which molecular oxygen 
intervenes after the reaction of the 3P1
* with the substrate (Sub). Most frequently, the initial 
step in this type I reaction is an electron (or hydrogen atom) transfer between 3P1
* and the 
ground state of the substrate: 
 
3P1
* + Sub0 → P
-• + Sub+• 
 
Then, molecular oxygen can react with the semioxidized substrate, leading to oxidative 
damage. Note that during this process, the formation of superoxide anion leads to the 
photosensitizer regeneration: 
 




The superoxide radical-anion can in turn damage the biological environment.  
 
Photosensitizers are characterized by photophysical parameters which help to understand 
their photobiological activities. The relevant singlet and triplet state parameters are the 
excited singlet and triplet transient absorbance spectra, the fluorescence quantum yield (ΦF), 
the triplet-state quantum yield (ΦT), the triplet-state energy (∆ET), the singlet state (τS) and 
triplet-state (τT) lifetimes. The ΦF is the probability for a photosensitizer to emit fluorescence 
when returning to the 1S0 ground state after absorption of a quantum of light. The ΦT is the 
probability for a photosensitizer to convert to the 3T1 state, after absorption of a quantum of 
light. From them, important parameters of their chemical reactivity can be deduced: the rate 
constant for the interaction of 3T1 with oxygen (kR(T)), the singlet oxygen quantum yield (Φ∆) 





process to generate 1O2. The singlet oxygen quantum yield (Φ∆) is defined as the probability 
that a photosensitizer generates 1O2 after absorption of a quantum of light. The S∆ parameter 
is defined by the equation [35]: 
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Φ∆ = S∆ ΦT 
Nearly all photosensitizers employed in PDT yield high Φ∆ (∼0.3 to 0.8) [36].  
The singlet oxygen quantum yield depends on the rate of the chemical reaction of the P 
triplet state and is reduced by processes such as phosphorescence, internal conversion from 
the triplet to the singlet ground state, or chemical reactions of the photosensitizer excited in 
the singlet state manifold. Finally, the energy of singlet oxygen (∆E∆) is the energy difference 
between 1O2 and 
3O2 (∆E∆ = 94 kJ mol
-1 = 7882 cm-1 = 0.97 eV). 
Aggregation of photosensitizers may change their photophysical properties. It shortens τF 
and τT and decreases Φ∆ by dissipating the energy through internal conversion. Therefore 
highly aggregated photosensitizers are generally considered to be less effective 
photosensitizers than monomeric forms in vivo [37]. It appears that amphiphilicity contributes 
to aggregation modulation which in turn determines how compounds accumulate into various 
targets within a tumor cell. Amphiphilic molecules, that are partially hydrophobic and 
hydrophilic, are thought to bind most efficiently to membranes and/or proteins at the interface 
between the hydrophilic surface and hydrophobic interior of proteins and membranes. 
Several researchers have suggested that amphiphilic photosensitizers are more 




After reading this brief photophysical and photochemical review, it turns out that an ideal 
photosensitizer must absorb as much as light as possible, and possess a high ability to 
trigger photosensitized reactions, mainly by efficient intersystem conversion to its excited 
triplet state. An ideal photosensitizer should also be minimally toxic, taken up more quickly by 
abnormal (target) tissue than by normal tissue, cleared rapidly from normal tissue and 
activated at wavelengths that penetrate the target tissue. 
  
This group of chemicals includes ‘first-generation’ derivatives of natural porphyrins, which 
became available about 30 years ago, and a broad group of new ‘second-generation’ and 
‘third-generation’ synthetic compounds, which are currently under laboratory and clinical 
investigation. 
 
2.1.3.1  FIRST GENERATION PHOTOSENSITIZERS 
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Porphyrins, as illustrated in Figure 2.4, are tetrapyrrole macrocycles. As a result of the 
extended conjugation, porphyrins are strongly colored compounds. The visible absorption 
spectrum shows an intense Soret band around 400 nm and weaker bands in the visible-near 





Figure 2.4 The tetrapyrrolic porphyrin ring: note the 22 π electron system. 
 
Porphyrins and other closely related tetrapyrrolic pigments occur widely in nature with major 
roles in various biological processes. For example, heme, the iron (II) protoporphyrin-IX 
complex, is the prosthetic group in hemoglobins and myoglobins responsible for oxygen 
transport in red blood cells and oxygen storage in tissue. Heme is also essential for the 
structure and function of cytochromes. 
 
In 1884, Nencki isolated the first pure porphyrin by preparing hematoporphyrin hydrochloride 
directly from isolated heme [39]. In 1912, Kuster first proposed the structure of porphyrins as 
four pyrrole units linked by four methine bridges [40]. This structure was later confirmed in 
1926 when Fisher synthesized etioporphyrin-1 [41] thereby demonstrating that the aromatic 








Hematoporphyrin Etioporphyrin-1  
 
Figure 2.5 Early porphyrins synthesized by Nencki and Fisher 
 
Haematoporphyrin (Hp) was first isolated from haemoglobin using concentrated sulfuric acid 
[42]. It has been shown later that treatment with sulfuric and acetic acids led to 
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hematoporphyrin derivative (HpD) [43] a very complex mixture of several components with 
about 50% identifiable as oligomeric haematoporphyrins and protoporphyrins having a low in 
vivo photosensitizing activity [44-45]. It turned out that HpD had better tumour localizing 
properties than crude Hp [20]. Chromatographic analysis of tumour extracts showed that it 
was mainly the “impurities” that were retained in the tumours. Many groups attempted to 
identify these impurities [46-48], and it was concluded that they were composed of dimers, 
oligomers and aggregates of porphyrins. Kessel et al. showed that diethers and diesters 
were central [49]. Kessel proposed that aggregates were monomerized in tumour cells and 
became trapped, rendering the cells photosensitive.  
HpD was further chromatographically purified by Dougherty’s group to Photofrin, which is still 
the most widely used clinical PDT photosensitizer [25, 48]. The HpD chemical purification 
allows for the preparation of porfimer sodium (Photofrin®). The latter is a lyophilized and 
concentrated form of monomeric (haematoporphyrin, protoporphyrin and 
monohydroxyethylvinyl- deuteroporphyrin) and oligomeric (dimer to hexamer derivatives of 
haematorphyrin units linked through ether or esters bonds) porphyrins. It also contains a 














































Figure 2.6 Classification of porphyrin-based photosensitizers molecules. 
 
Photofrin® was approved for treatment of early stage lung cancer in 1998 and for Barrett’s 
esophagus in 2003. The clinical applicability of Photofrin® has been limited by several 
factors. First, its longer wavelength light absorption peak occurs at too short wavelength (630 
nm) to allow deep light penetration in tissue (about 5–10 mm in therapeutic PDT). Second, 
Photofrin® is a complex mixture of oligomers. Finally, administration of Photofrin® results in 
Chapter 2 Bibliographic Synthesis 
58 
cutaneous photosensitivity lasting up to 6 weeks. These limitations have inspired the 
development of a second generation of photosensitizers with longer-wavelength light 




2.1.3.2  SECOND GENERATION PHOTOSENSITIZERS 
 
The second generation photosensitizers (phthalocyanines, naphthalocyanins, 
benzoporphyrins, chlorins, purpurins, texaphyrins, porphycenes, pheophorbides, 
bacteriochlorins, etc.) were introduced to overcome the problems encountered with HpD [50-
55]. Various chemical modifications of the tetrapyrrolic ring of the porphyrins characterize the 


















Figure 2.7 Chemical structure of porphyrin-derived sensitizers (►- reduced). 
 
Unlike HpD and Photofrin®, they may be obtained as chemically pure substances. They are 
effective generators of singlet oxygen and have high absorbance in the far red (660–700 nm) 
or near infrared (700–850 nm) regions. At these wavelengths, the penetration depth into 
mammalian tissues is up to 20 mm, as developed in Section 2.1.8.2 “Light interaction with 
tissue and light sources” [42, 56]. The serum half-lives of the second-generation sensitizers 
are short and tissue accumulation is selective and quick (within 1–6 h after injection). In 
addition, the risk of burns by accidental sun exposure is low because clearance from normal 
tissues is rapid. Toxicity to skin and internal organs in the absence of light (so-called ‘dark’ 
toxicity) is absent or minimal. 
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Most sensitizers currently under investigation belong to two chemical groups: the 
phthalocyanines and the chlorins. The joining of four benzenes or naphthalene rings to the β-
pyrrolic positions of porphyrins and the substitution of the methine-bridge carbons with 
nitrogen produce phthalocyanines and naphthalocyanines, respectively. Polar substituents 
are often linked to avoid solubility problems caused by their strong hydrophobicity [42]. The 
presence of aluminium, zinc(II), silicon(IV) and other ions gives hexacoordination and 
guarantees a satisfactory yield of singlet oxygen generation (Table 2.3) [57].  
 
Chlorins differ from porphyrins by the hydrogenation of a double bond of one pyrrole ring 
(figure 2.7). They exhibit a high extinction coefficient and an absorption peak in the far red 
waveband [57] and a rapid, high and selective accumulation in the target tissue. 
 
The second generation photosensitizers benzoporphyrin derivative monoacid A (BPD-MA 
(Verteporfin; Visudyne®, QLT Inc. and Novartis Opthalmics) and meta-tetra hydroxyphenyl 
chlorin (m-THPC; Foscan®, Biolitec AG) are approved for clinical use (Table 2.1) [58-60]. 
Benzoporphyrin derivative monoacid ring A is a semisynthetic porphyrin derived from 
protoporphyrin which is approved for the treatment of age-related macular degeneration [61]. 
It has poor water solubility but it can be formulated successfully, either in liposomes or 
emulsions [62]. In preclinical trials, it was observed that Verteporfin® preferentially targeted 
neovasculature. This selectivity has been exploited for the treatment of choroidal 
neovascularization (CNV), an abnormal growth of vessels in the retina associated with age-
related macular degeneration, the leading cause of blindness in the developed world. 
Verteporfin® was approved in the U.S. under the tradename Visudyne® for CNV treatment in 
2000.  
 
Mesotetrahydroxyphenyl chlorin (m-THPC) (Temoporfin, Foscan®; Biolitech Pharma, 
Edinburgh, Scotland, UK) is another second generation photosensitizer, a pure synthetic 
chlorin compound, hydrophobic, which is activated by 652 nm light [63]. The major 
advantages of mTHPC are a short duration of skin photosensitivity (15 days), a high 
quantum yield for singlet oxygen, and depth of tumor necrosis of up to 10 mm in preclinical 
models [64]. mTHPC has been used for treatment of pleural mesothelioma [65], head-and-
neck cancers [66-67], esophagus [68-69], prostate [70-71], pancreas [72], arthritic joints [73], 
and skin cancers [74]. It has been approved in Europe in 2001 for the PDT of head-and-neck 
cancers and other tumors. 
 
Mono-L-aspartyl-chlorin e6 (NPe6, Porphyrin Products Inc., Logan, UT, USA) and chlorin e6 
(Dialek Ltd, Minsk, Belarus) are hydrophilic compounds with some amphiphilicity and similar 
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photobiological properties [42, 75-76]. The hydrophobic Tin ethyl etiopurpurin (SnET2) 
(Purlytin®, Miravant Medical Technologies, CA, USA) has been proposed for dermatological 
indications [58-60, 77]. 
 
Several other second generation photosensitizers are currently under clinical evaluation. 
These include BOPP (boronated porphyrin; Pacific Pharmaceuticals Inc.), hypericin 
(Pharmaceuticals Inc.), HPPH (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a, 
Photochlor; Roswell Park Cancer Institute), AlPcSn (sulfonated aluminium phthalocyanine, 
Photosense; State Research Center), ATMPn (porphycene; Glaxo-Wellcome Inc.), 
lutetium(III) texaphyrin (Lu-Tex, Antrin; Pharmacyclics Inc.), motexafin lutetium (MLu), etc. 
[78-80]. 
 
Near-infrared absorbing photosensitizers may be useful for the treatment of highly pigmented 
tumours, such as melanoma metastases, which do not respond to treatment with 
photosensitizers that absorb in the visible range. Bacteriochlorins display a significant 
absorption around 780 nm with a high extinction coefficient (150000 M−1cm−1) and might be 
particularly useful for the PDT of pigmented tumours [57]. Light with wavelengths longer than 
850 nm cannot be used because it does not yield enough energy to trigger a photochemical 
reaction. 
 
2.1.3.3  THIRD GENERATION PHOTOSENSITIZERS 
 
Second generation photosensitizers bound to carriers for improving the effectiveness of PDT, 
are often called “third generation photosensitizers” [50, 81]. Briefly, different approaches 
have been developed to improve photosensitizers targeting into tumour cells such as 
photoimmunotargeting (eg. monoclonal antibodies directed against specific antigens on 
cancer cells) and peptide mediated targeting (eg. peptides that mimick the natural ligands of 
receptors that are specifically overexpressed on cancer cells) [50, 81-82]. Theoretically, 
these approaches have several advantages: high affinity of the binding moiety to the receptor 
or antigen on the targeted cell surface; direct and more specific localization with increased 
efficiency and selectivity; and lower dose of photosensitizer. 
 
Other strategies recently developed to improve the delivery of photosensitizers to target 
tissue involve lipoprotein-mediated delivery and photosensitizer encapsulation in colloidal 
carriers (eg. liposomes, oil-dispersions, biodegradable polymeric particles and hydrophilic 
polymers) to facilitate drug delivery [82-84].  
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In this context, we have synthesized a meso-tetrakis(pentafluorophenyl)chlorin bearing a N-
benzylisoxazolidine ring (FC) conjugated to four β-cyclodextrins (CDFC) to further assess the 
potential interest of this new class of chlorins as PDT photosensitizers. We have shown a 
good photocytotoxic effectiveness of CDFC towards cultured human keratinocytes. The 
study of their excited singlet and triplet state properties by means of time resolved femto and 
nanosecond spectroscopies demonstrates that the presence of four β-cyclodextrin 
macrocycles on CDFC leads to a long-lived triplet state which is formed in a good yield in 
aqueous media. Microenvironmental-dependent interactions of the cyclodextrin moieties with 
the fluorinated chlorin ring in the singlet and triplet excited states have been observed 
(aqueous media, buffer, ethanol and neutral Triton X100). These results are not included in 
the present thesis as they are outside its major objectives. However, they have been recently 
published and the article is presented as Annex I.   
 
2.1.3.4  δ-AMINOLEVULINIC ACID AND ITS DERIVATIVES 
 
a) Heme biosynthesis pathway 
 
The study of porphyria diseases showed that metal-free porphyrins can be endogenously 
produced [85-89]. Each of the porphyrias has a specific enzyme defect in the pathway of 
heme biosynthesis. There are 8 enzymes involved in the synthesis of heme, and, with the 
exception of the first one, defects of these enzymes lead to tissue accumulation and 
excessive excretion of porphyrins and/or their precursors, such as δ-aminolevulinic acid and 
porphobilinogen. In the cytoplasm, ALA is metabolized by porphobilinogen synthase, also 
called ALA dehydratase (ALAD), which induces the condensation of two molecules of ALA to 
yield porphobilinogen (PBG). The concerted action of porphobilinogen deaminase (PBGD) 
and uroporphyrinogen III (co)-synthase combines four molecules of PBG and cyclizes the 
tetrapyrrole chain catalyzing ring closure to form uroporphyrinogen III [90]. Uroporphyrinogen 
decarboxylase then removes four acetic acid carboxyl groups, converting them to methyl 
groups, to form coproporphyrinogen III. The latter is oxidized by the mitochondrial 
coproporphyrinogen oxidase, which decarboxylates and oxidizes the propionic side chains to 
vinyl groups leading to protoporphyrinogen IX. The subsequent oxidation of the tetrapyrrole 
ring, which adds more double bonds, is catalysed by protoporphyrinogen oxidase in the 
mitochondrion. It is the final step in the synthesis of PpIX [91]. Then, iron incorporation into 
the tetrapyrrole structure is catalysed by ferrochelatase in the inner mitochondrial membrane 
resulting in heme synthesis.  
 
b)  ALA effects on porphyrin formation and mechanism of action 
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Heme biosynthesis is normally so tightly regulated that the concentrations of intermediate 
products are below the threshold of photosensitization. In 1951 Berlin et al. demonstrated 
that excess administration of exogenous ALA bypasses the cellular feedback control 
mechanism leading to abnormally large quantities of PpIX in humans [92-93]. Later on, Batlle 
et al. found that addition of ALA to the culture medium of soybean callus, a vegetable 
tumour, led to accumulation of porphyrins associated with fluorescence during UV exposure, 
inhibition of growth, and, finally destruction of tissue [94]. Clinical research on erythropoietic 
protoporphyria revealed that PpIX was an efficient photosensitizer. Protoporphyrin IX was 
shown to cause skin photodamage via mitochondrial destruction [92, 94]. In 1987, two 
groups proposed to use ALA as a porphyrin precursor in PDT [95-96]. It was demonstrated 
that exogenous ALA-induced PpIX together with light led to inactivation of Friend 
erythroleukemic cells [95]. In 1990 Kennedy et al. reported the first clinical trials using ALA-
PDT for the treatment of malignant and precancerous skin abnormalities [97]. PpIX has a 
high absorption peak corresponding to the Soret band at about 405 nm and other absorption 
maxima, the Q-bands, at approximately 510, 545, 580 and 630 nm. As detailed below, 
although the Q-bands are 10–20-fold smaller than the peak in the Soret band, most clinical 
studies have used 625–633 nm red light, which allows for a deeper penetration into the skin 
[42]. However, green and blue wavelengths were found to be just as effective as red light for 
the treatment of actinic keratosis (AK), while being less painful [98-99]. 
 
c) ALA pharmacokinetics 
 
Introduction of ALA as a PpIX precursor was a milestone in the development of PDT for 
several reasons. It is naturally produced in the body, and shows low cytotoxicity. It is the only 
PDT agent that is a biochemical precursor of the photosensitizer. Endogenously produced 
PpIX is rapidly cleared from the body (24–48 h) because natural clearance mechanisms 
exist. Although ALA is usually administered topically, it can also be administered 
intravenously or orally. Topical delivery of ALA avoids systemic photosensitivity, because the 
drug can be selectively applied on the areas to be treated. Moreover it is selectively uptaken 
by target cells. A short time interval (1–8 h, depending on the mode of administration) is 
needed between the administration of ALA and the maximal accumulation of PpIX in target 
tissues [100-102]. 
 
d) Methyl aminolevulinate advantages over ALA 
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In 1999, ALA was approved for the treatment of actinic keratoses. However, the hydrophilic 
nature of ALA was thought to limit its penetration through biological membranes. In 
mammalian cells, it is taken up mainly by active transport mechanisms, that is the Na+/Cl- 
dependent β-amino acid transporters, including those of glycine, and gamma aminobutyric 
acid (GABA) [103]. These systems require energy, depend on pH and temperature, are 
saturable and slow, and are only slightly faster in tumour cells [104-105]. 
 
Chemical derivatization of ALA, were proposed to improve ALA delivery and porphyrin 
production. A large number of derivatives have been synthesized in the search for 
compounds that penetrate the plasma membrane of targeted cells and diffuse through 
epidermal layers more easily than ALA itself does. Most of the results indicate that many of 
the esters are more efficient in inducing porphyrin accumulation in cells in vitro than ALA 
itself. The methyl ester, MAL is more lipophilic than ALA and, in WiDr adenocarcinoma cells, 
is taken up by active mechanisms mainly through transporters of non-polar amino acids such 
as L-alanine, L-methionine, L-tryptophan and glycine. Most importantly, MAL is also taken up 
by passive transmembrane diffusion [106]. This mechanism does not require energy and it is 
unsaturable. It is very efficient in normal cells and even more in neoplastic cells. The plurality 
and efficiency of these various mechanisms determine the enhanced penetration of MAL in 
comparison to ALA and the difference is even more significant in malignant cells [101]. 
 
As the esterified form is more lipophilic than ALA, it was anticipated that MAL could penetrate 
more deeply into lesions. Peng et al. [107] reported that MAL penetrated to a 2 mm depth in 
BCC, contrasting with a more limited penetration with ALA [108]. Other investigators also 
found highly variable ALA uptake into nodular and infiltrating BCC [109]. However, Ahmadi et 
al. showed, in human skin biopsies, that ALA applied for 4 h penetrates to at least 2 mm 
depth from the lesion surface [110]. Using similar protocols, ALA is reported to produce 
higher PpIX levels than MAL, but with less selectivity for the diseased tissue [111-112].  
 
Soon after cell penetration, MAL is rapidly demethylated to ALA and therefore the 
subsequent metabolic steps are the same as those described for ALA [104]. When excess 
PpIX is synthesized, it can diffuse from the mitochondrion to the endoplasmic reticulum and 
also to the plasma membrane, which are the other known sites of cellular damage through 
PDT [113]. These agents are relatively selectively concentrated in the target tissue, possibly 
related to alterations in surface permeability and tumour porphyrin metabolism. The rate of 
ALA-induced porphyrin synthesis and accumulation is higher in malignant and premalignant 
cells than in their normal counterparts with a 10:1 ratio of PpIX accumulation in tumours of 
the keratinocyte lineage in comparison to surrounding healthy skin [111].  






e)  ALA and MAL: therapeutic efficacy and diagnosis 
 
As I will present on Section “Clinical applications of PDT” on Section 2.3, ALA (Levulan®, 
DUSA Pharmaceuticals) and ALA methyl ester (MAL: Metvix®, PhotoCure ASA) are widely 
used for the treatment of skin premalignancies and malignancies. Meanwhile, ALA hexyl 
ester (Hexvix®, PhotoCure ASA) is being developed for the diagnosis of bladder cancer 
(Table 1). 
Briefly, PDT with topically applied ALA or MAL is an effective treatment for lesions less than 
2mm depth [100]. Recent studies have attempted to compare the efficacy of MAL-PDT and 
ALA-PDT in diseased tissue, with application of each prodrug for 3h [112]. Patients with 
nodular BCC were randomly assigned to either ALA-PDT or MAL-PDT (ALA ⁄MAL for 3 h, 
600–730 nm, 75 J/cm2, 100 mW/cm2) and in each group half the tumours were debulked 
prior to PDT. On histological analysis after 8 weeks, no difference was found in lesional 
response. A further randomized double-blind study compared ALA and MAL for the treatment 
of extensive scalp AK [114]. MAL was applied for 3 h, but ALA for 5 h (580–740 nm, 50 
J/cm2, 50 mW/cm2). No significant difference in mean lesion count reduction was observed 1 
month after treatment, although pain was more intense on the ALA side. 
 
Besides its usefulness in therapy, ALA and MAL can also be applied for diagnostic purposes 
[115-118]. After topical or systemic ALA application, PpIX is induced in epithelial tumours, 
with a high tumour to surrounding tissue ratio, and the tumours can be visualized under 
exposure to blue light. Fluorescence images can be utilized either to guide biopsy sampling 
or as an aid during surgery [119].  
 
f)  Novel ALA derivatives and strategies to increase production of PpIX by the target tissue 
 
New ALA derivatives are continuously being designed [120-121]. Therapy and diagnosis with 
ALA are being used in dermatology [100, 122-124], gynaecology [125-130], urology [131-
134], gastroenterology [135-138], neurosurgery [119], etc. Low doses of ALA-PDT are 
already useful for photorejuvenation [139-141] and photochemoprevention of skin tumours 
[142-145]. Several other methods, such as use of different formulations (creams, lotions, 
gels, etc. alone, with penetration enhancers and/or iron chelators), physical methods 
(curettage, ultrasound, iontophoresis, electroporation and electrophoresis) were also 
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proposed to improve ALA delivery and porphyrin production. A stable nanoemulsion-based 
ALA formulation, BF-200 ALA, is currently under clinical development for PDT of AK, 
showing patient and lesion complete clearance rates after illumination of 96.4% and 98.8%, 
respectively [146]. The accumulation of PpIX and other porphyrin intermediates is dependent 
on the activity of ferrochelatase and the availability of iron. The source of ferrous iron is 
probably the intramitochondrial pool. The simultaneous delivery of ALA together with the iron 
chelators, such as ethylenediaminetetraacetic acid (EDTA) and desferrioxamine, increases 
the rate of accumulation of porphyrins [147]. 
 
2.1.3.5  CHARACTERISTICS OF A GOOD PHOTOSENSITIZER 
 
As I highlighted earlier, a photosensitizer should ideally possess several properties (Table 
2.3) that may be associated with therapeutic efficacy and tolerability.  
 
Purity • Single pure substance of known composition that is stable at room 
temperature. 
Selectivity • Accumulation within tumor tissue is favorable. 
• Subcellular localization within organelles which induce apoptosis rather 
than necrosis  
Toxicity • Minimal toxicity in the absence of light and only cytotoxic in the presence of 
light of defined wavelengths.  
• Photosensitizer should not yield toxic metabolites. 
• Eliminated quickly enough to avoid generalized skin photosensitization. 
ADME • Optimal absorption, distribution, metabolism and excretion (ADME) 
properties.  
Quantum yield • High single oxygen quantum yield for photochemical event. 
Activation • Absorb light wavelengths between ~700 and 850 nm for maximum light 
penetration in the optical window for PDT. 
• Stable enough to avoid photobleaching 
Mutagenicity • Neither mutagenic nor carcinogenic effects 
Cost and 
availability 
• Inexpensive and commercially available. 
 
Table 2.3 Characteristics of an ideal photosensitizer 
 
First, the ideal photosensitizer is preferably a pure compound with a constant composition 
and no toxicity in the absence of light. It should also be selectively enriched in the target 
tissue and eliminated from the body quickly enough to avoid generalized skin 
photosensitization. 
 
As previously mentioned, efficient triplet energy transfer is required for 1O2, formation. As a 
consequence, the photosensitizer should also have a high triplet state yield, with a triplet 
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state energy larger than the energy of singlet oxygen (> 94 kJmol-1). Optimally, it should not 
self-aggregate, as the aggregation decreases triplet state yield and singlet-oxygen yield 
[148]. 
 
The photosensitizer should absorb light of longer wavelengths so that the therapeutic effect 
of PDT can be as deep as possible [57]. However, the absorption wavelengths should not be 
too long as the triplet state energy can be too low for producing 1O2 [148]. Also, the 
photostability of a compound often decreases when its absorption wavelength increases 
[148]. Preferably, the photosensitizer should not strongly absorb light of the region 400–600 
nm, to reduce the risk of generalized photosensitivity caused by sunlight [148].  
 
In addition to those I mentioned above, there are other characteristics that could prove useful 
in PDT. Strong absorption of the light used in PDT decreases the amount of photosensitizer 
required for a certain therapeutic effect. However, this should be cautiously taken into 
account as a too strong absorption of photosensitizers may limit the penetration of light into 
the tissue and thus reduce the treatment depth (this phenomenon is known as selfshielding) 
[61]. The photosensitizer should also be stable enough to avoid degradation processes, e.g. 
photobleaching. However, the photobleaching tendency can be an advantage as well, 
because it can shorten the duration of generalized photosensitivity after PDT [149], and also 
because it can increase the treatment selectivity.  
 
The use of photosensitizers that need a short period of incubation before irradiation (within a 
few hours after administration) makes it possible to complete the treatment within a single 
visit to the hospital [150]. The fluorescence emitted by the photosensitizer is also useful in 
tumor detection, in the estimation of tumor size and limits, and in the determination of the 
photosensitizer concentration. However, as the triplet state quantum yield of strongly 
fluorescing compounds cannot be high, the compounds developed as photosensitizers for 
PDT are probably different from those intended to act as fluorophores for tumor detection 
[51]. 
 
Finally, synthesis of the photosensitizer should be relatively easy while the starting materials 
should be readily available and cheap. Its large-scale production should also be feasible to 
make it cost-effective and widely applicable [151]. 
 
2.1.4 PHOTODEGRADATION AND PHOTOMODIFICATION OF PHOTOSENSITIZERS 
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Upon illumination, all photosensitizers are chemically modified [32, 149, 152-155]. 
Photobleaching is the destruction of the photosensitizer by light-mediated processes. It was 
observed that light degrades photosensitizers in solution according to the following equation 





Photosensitizer degradation by light through singlet oxygen mediated processes can occur 
due to: (1) photosensitizer fragmentation, resulting in loss of absorbance and fluorescence, 
and/or (2) photosensitizer modification, forming fluorescent photoproducts, which are often 
photosensitizers themselves and usually more water-soluble than the parent compounds 
[149, 157-161]. These processes have a high probability, since the photosensitizers are 
close to the reactive molecules, in the biological environment. 
The main photoproducts of porphyrin photofragmentation do not absorb in the visible spectral 
region and are non-fluorescent. Photobleaching is therefore followed by the decrease in the 
fluorescence over time assuming that fluorescence intensity and concentration are 
proportional [156]. It was proposed that one pathway of porphyrin photodegradation may be 
epoxidation at the double-bond between the ring and the methine bridge of Hp, HpD, PpIX 
and mesoporphyrin [162]. Formation of bilirubin and biliverdin that are quite photolabile 
pigments may be the result. As a consequence, photodegraded photosensitizers may lose 
their photodynamic activity [149, 153, 155]. On the other hand, other photolytic pathways 
may also take part. It has been shown that photomodification of porphyrins such as PPIX 
typically creates chlorines, accompanied by a red shift of fluorescence. For PPIX, it has been 
published that some of the photoproducts are more effective photosensitizers than the 
mother molecule [155, 161, 163]. 
As stated above, most photosensitizers are photodegraded and phototransformed according 
to first order processes, i.e. the degradation rates are independent on the initial dye 
concentration. However, as opposed to homogenous solutions, in biological samples, 
photodegradation does not follow simple exponential kinetics due to heterogeneous binding 
to biological structures and oxygen depletion during light exposure [157, 164-167]. There are 
large differences in the photostability of the different photosensitizers. Water-soluble dyes 
tend to be more stable than the lipophilic ones, at least when present in cells and tissues 
[156, 162]. The reason for this might be related to the intracellular localization of the 
photosensitizer. Binding of a photosensitizer to a protein are also important as it generally 
decreases photosensitizer photostability. Aggregates of a photosensitizer are more 
photostable than monomers [168]. Although photobleaching decay constants for several 
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porphyrins have been measured in solution, there is no agreement as to whether 
photobleaching has any effect on PDT activity [156, 169]. Photobleaching of a 
photosensitizer may nevertheless limit its efficacy in PDT and has to be taken into account 
when choosing optimal light fluences and photosensitizer concentrations. On the other hand, 
photobleaching can prevent photodamage to normal tissue adjacent to the tumour area [157, 
165]. Photobleaching requires singlet oxygen just as tumour destruction does. Thus, 
photodegradation rates may be used for clinical dosimetry [156, 166-167, 170-171]. 
 
2.1.5 CELLULAR UPTAKE OF PHOTOSENSITIZERS 
 
Photosensitizer uptake kinetic is a major determinant of the photocytotoxic efficacy as it 
determines the final photosensitizer intracellular concentration. It depends on the structural 
features of the photosensitizers such as: the net ionic charge which can range  
from -4 anionic to +4 cationic charges; the degree of hydrophobicity expressed as the 
logarithm of the octanol/water partition coefficient; the degree of asymmetry and the 
existence of conjugated chains [54]. 
 
The different uptake pathways of photosensitizers in tumor tissues are summarized in Figure 
2.8.  
 





























































Figure 2.8 Overview of photosensitizer uptake pathways in tumour tissue [adapted from Osterloh et 
al., 2002 [172]]   
 
Porphyrins can diffuse as monomers or small aggregates through the plasma membranes of 
tumor cells or they may bind to membrane proteins. Photosensitizers which are hydrophobic 
and electronically neutral (or have two or less negative charges) may diffuse across the 
plasma membrane, and then relocate to other intracellular membranes. These 
photosensitizers also tend to have the greatest uptake by cells in vitro, especially when 
present at relatively low concentration in the cell culture medium. Photosensitizers which are 
less hydrophobic and have less than two negative charges tend to be too polar to diffuse 
across the plasma membrane, and are therefore taken up by endocytosis [54].  
Low-density lipoproteins (LDL)-bound photosensitizers target LDL apoB/E receptors at the 
surface of all cell membranes whereas other porphyrin-protein assemblies such as modified 
LDL-porphyrin complexes are recognized by macrophage scavenger receptors. 
Photosensitizers bound to monoclonal antibodies target specific antigens at the surface of 
neoplastic cell membranes and porphyrin-peptide conjugates with nuclear localization 
sequences are taken up by endocytosis, and can target the cell nucleus. Highly aggregated 
porphyrins are taken up by phagocytosis. In the case of vehicle-bound porphyrins in topical 
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formulations, they are incorporated via plasma membrane fusion or receptor or non-receptor-
mediated endocytosis. High density lipoprotein (HDL)-porphyrin complexes target the tumor 
stroma and preferentially accumulate in macrophages.   
 
2.1.6 SUBCELLULAR LOCALIZATION AND RELOCALIZATION 
 
Along with cellular uptake, an important factor determining the outcome of PDT is how the 
photosensitizer interacts with cells within the target tissue or tumor. The structural features of 
the photosensitizer also determine its affinity for sub-cellular organelles and thus the primary 
targets of PDT-mediated damage. The knowledge of the photosensitizer localization allows 
to predict the consequences of specific photodamage to cellular organelles and the 
subsequent steps leading to photokilling. Data obtained from localization studies may also be 
useful as they may suggest an indication of PDT efficacy [173]. 
 
PDT sensitizers with known clinical or pre-clinical efficacy can target 
mitochondria/endoplasmic reticulum (ER), ER alone, ER/lysosomes or lysosomes alone. It is 






















Figure 2.9 Sites of localization of different photosensitizers using murine leukemia L1210 cells in 
culture (ALA, δ-aminolevulinic acid; PC4, sulfonated aluminium phthalocyanine; BPD benzoporphyrin 
derivates; m-THPC, mesotetrahydroxyphenyl chlorin; CPO, porphycene; SnET2, tin ethyl etiopurpurin; 
AIPc, sulfonated aluminium phthalocyanine; LCP, zinc octyloxyethilporphyrin; LuTex, lutetium 
texaphyrin; MCP monocationic porphyrin, NPe6, mono-L-aspartyl-chlorin e6; SnOPA, tin 
octaethylpurpurin amidine; LCI lysyl chlorin e6 imide). [adapted from Kessel et al., 2004 [175]] 
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Depending on the nature of the photosensitizer, mitochondria, lysosomes and cytoplasmic 
membranes, but not the nucleus, are primary targets of PDT-mediated damage [176]. The 
main targets of PDT are summarized below. 
 
2.1.6.1  MITOCHONDRIA 
 
Mitochondria have long been considered as a main target of photodynamic damage since 
ATP, required to power cellular functions, is produced by this organelle. Depending on the 
photosensitizer, PDT damage to the mitochondrial proteins may constitute the primary event 
in a chain leading to breakdown of the electron transport chain, disruption of the 
mitochondrial-membrane potential and mitochondrial swelling and, ultimately, cell death 
[177]. A direct consequence of mitochondria damage is the inhibition of proteins required to 
maintain the electrochemical gradient across the inner-mitochondrial membrane. Malate 
dehydrogenase, succinate dehydrogenase, and cytochrome c oxidase are inhibited by HpD-
PDT. On the other hand, no inhibition of glucose phosphate isomerase, pyruvate kinase, and 
lactate dehydrogenase (all cytosolic proteins) is observed after HpD-mediated PDT [178]. 
Thus, cytosolic proteins are less susceptible to photo-oxidation than mitochondrial 
membrane bound proteins because the singlet-oxygen lifetime is reduced in aqueous 
environment. It has been demonstrated that the susceptibility of the protein to PDT correlates 
with the degree to which it is embedded into a membrane. Cytochrome c oxidase resides 
within the inner mitochondrial membrane. Succinate dehydrogenase is anchored in the inner 
mitochondrial membrane but protrudes out in the mitochondrial matrix. On the other hand, 
malate dehydrogenase floats free in the mitochondrial matrix [179]. Another mitochondrial 
protein complex - the permeability transition pore (PT pore) - [180] constituted by 
hexokinase, the peripheral-benzodiazepine receptor (PBR), the voltage-dependent anion 
channel, creatine kinase, the adenine nucleotide translocator and cyclophyllin D [181] has 
been proposed as a PDT target. Furthermore, cells expressing higher levels of PBR are 
more susceptible to Photofrin-PDT than cells expressing normal levels of PBR [182]. The 
activity of the adenosine triphosphatase, which extracts energy from the proton gradient 
across the mitochondrial membrane to form adenosine triphosphate (ATP), is reduced after 
in vitro HpD-PDT [183]. 
 
Mitochondrial swelling and leakage of markers from the mitochondria occurs only after 
oxidative phosphorylation inhibition due to photo-oxidation of mitochondrial proteins such as 
cytochrome c oxidase [177, 183]. As a result, and as will be discussed in Section 2.2.2, 
mitochondrion-localized photosensitizers are usually associated with apoptosis induction 
[184]. 
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2.1.6.2  LYSOSOME 
 
Photosensitizers may also localize in lysosomes [185]. Although lysosomal disruption may 
not be directly cytotoxic [186], acid hydrolases that leak out of the damaged lysosomes may 
degrade cellular components. However, PDT mediated by tetraphenylporphyrin (TPPS) 
which localizes mainly in the lysosomes, disrupts lysosomes but does not significantly 
decrease cell viability [185]. To relate the lysosomal localization and cellular insensitivity to 
lysosomal damage, Moan et al. suggested that lysosomes are a primary localization site but 
not the photodynamic target [187]. Upon illumination, lysosomes may rupture and the 
photosensitizer could relocalize to more susceptible organelles such as the mitochondrial 
and nuclear membranes. Dependent on the prevalent phenomenon, lysosomal localization 
can elicit either a necrotic or an apoptotic response as will be further discussed in Section 
2.2.2. 
 
Lysosomal subcellular localization is the basis for photochemical internalization, a novel PDT 
modality [188-189]. By photochemical internalization, lysosome-localized toxins, immune-
response modulating molecules and DNA can be released into the cytoplasm of cells. 
Release of lysosome-localized fluorophores in the cytoplasm leads to an increase in the 
fluorescence intensity caused by deaggregation and has been demonstrated both in vitro 
and in vivo [190]. 
 
2.1.6.3  MEMBRANES 
 
Many photosensitizers accumulate in the plasma membrane [174]. Photo-oxidation of cellular 
membranes is an efficient way to kill tumor cells [191]. Photodynamically active 
photosensitizers may have no inherent affinity for specific membrane protein but may 
partition into the surrounding lipid layers. Membranes, especially mitochondrial membranes, 
may thus act as localization sites for photosensitizers. Damage to cell membranes after PDT 
have been shown by a number of methods: ESR, electron microscopy, microscopic 
observation of blebs and cell expansion [192]. Although direct photo-oxidation of cell 
membrane lipids may not be lethal, it may still have an important role in low-dose PDT as 
peroxidized lipids may produce potent second messengers leading to cell death.[193].  
Membrane effects also cause increased attachment to a substratum and intracellular matrix 
after PDT in adherent cells, and decreased attachment of suspended cells [194-195]. These 
membrane effects may be of great importance for reducing the metastatic potential of 
surviving tumor cells.  
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2.1.6.4  NUCLEUS 
 
The nucleus is another organelle that may be sensitive to photodynamic damage. Since DNA 
encodes genetic information, any lesion that occurs in the genome creates an extremely 
dangerous situation for the cell. The mechanisms of DNA damage induced by photodynamic 
therapy are not well understood. PDT can cause guanine base oxidation, cross-linking of 
DNA strands or sister chromatid exchange [196-197]. As anionic photosensitizers localize 
outside the nucleus, they produce little direct DNA damage [198]. Only a small fraction of 
DNA, localized close to the nuclear membrane may thus be damaged by PDT [199]. 
However, a particular attention must be paid to cationic photosensitizers as they may interact 
with DNA negative charges. DNA damage can be observed after HpD- or cationic-porphyrin-
mediated PDT in vitro [200]. However, when PDT-DNA damage and X-ray induced DNA 
damage are compared, data show that there is less DNA damage from PDT treatment after 
equitoxic doses [201]. Treatment with X-ray produced 80% more strand breaks, 5% more 
sister-chromatid exchanges, and more chromatid aberrations than PDT does. Furthermore, 
PDT-induced strand breaks are more efficiently repaired than those caused by X-ray 
irradiation [202]. Thus, the mutation potential of Photofrin and aluminium phtalocyanine-
mediated-PDT is insignificant compared to that of X-ray irradiation [203]. Recently, the ability 
of HpD, m-THPC, and methylene blue to damage DNA in vitro was examined. No DNA 
damage was observed after m-THPC-PDT, while minor damage have been observed with 
HpD- and methylene blue-PDT. These damage are transient and resolved 4h after treatment 
[204]. In conclusion, DNA damages are not the major initial contributors to the PDT response 
but they can be a major factor during cell death. 
 
2.1.6.5  PHOTOSENSITIZER RELOCALIZATION 
 
Light exposure can also change the intracellular localization of a photosensitizer molecule, a 
process called photorelocalization [205-208]. It is significant after rather low exposures, or 
multiple exposures, where the first illuminations might contribute to a change in the mobility 
of the photosensitizer within the cell [187, 206]. For some hydrophilic sensitizers, 
photorelocalization from lysosomes to the nucleus occurs. The resulting damage to the DNA 
increases the quantum yield of cell destruction of these photosensitizers [187, 206, 208]. 
 
2.1.7  THE BASIS FOR TUMOR SELECTIVITY 
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As referred before, tumor selectivity is one of the major advantages of PDT. Several theories 
have been proposed for the mechanisms explaining why photosensitizing drugs are 
selectively taken up and/or retained in tumour tissues. These theories are based on special 
properties of tumours cells, or on physiological differences between tumours and normal 
tissues [209-214]. The reasons for selective uptake of photosensitizers in neoplastic and 
altered tissues may be of enzymatic, morphological or environmental character as will be 
presented below. The low tumour pH (related to poor vascularity of tumours leading to 
enhanced glycolytic activity followed by an increase in lactate levels) causes preferential 
accumulation of drugs that protonate and become more lipophilic as they enter acid tumours 
via the blood supply [215]. Tumours contain many macrophages that can ingest and 
monomerize aggregated photosensitizers as well as lipoprotein bound drugs [216]. Lipophilic 
photosensitizers preferentially bind to lipoproteins. More low-density lipoprotein (LDL) 
receptors are found on the surface of tumour cells as compared to normal cells [217]. 
Tumours have a poor lymphatic drainage and a leaky vasculature [216, 218]. Differences in 
water content and in other physiological parameters between tumours and normal tissue play 
a role for tumour localization of drugs. A large interstitial space is often found in tumours. 
When compared to normal tissues, a higher content of collagen seems to be present in 
several tumours [219].  
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Tumours are already deprived of oxygen, prior to PDT [220], and additional PDT-induced 
vascular damage in vascularized stroma may inactivate them selectively [221-225]. 
Alterations of metabolic steps in heme synthesis may be the main reasons for increased 
ALA-induced accumulation of PpIX in neoplastic cells and tissues. Thus, in some malignant 
cells and tissues, the porphobilinogen deaminase activity is increased [86, 226-229], while 
the ferrochelatase activity is reduced [86, 226, 228, 230]. Since ferrochelatase catalyzes the 
insertion of ferrous iron into the PpIX ring, the amount of the labile iron pool influences PpIX 
accumulation [231]. The importance of available iron on PpIX production was demonstrated 
using iron chelators [147, 232-234]. As mentioned above, tumours and normal tissues differ 
with respect to physiological structures. This may affect PpIX production and accumulation, 
and lead to tumour selectivity. Due to inflammation, many tumours may have a slightly 
elevated temperature [235-236]. The rate of biosynthesis of PpIX increases steeply with 
increasing temperature [237-239]. Stratum corneum is the main barrier for penetration of 
topically applied drugs from the skin surface into tumours and other tissues [240]. When 
ALA, or its derivatives, is applied topically on cutaneous tumours, some tumour selectivity is 
caused by a compromised stratum corneum [101, 212]. Differences between tumour and 
normal cells with respect to proliferation, differentiation, mitochondrial content, pH, etc. may 
lead to selective PpIX accumulation and retention [209, 241-247]. Interactions between these 
factors may exist depending on the nature of disease, its localization and stage, and on the 




Photodynamic therapy can be applied only to tumours and other lesions that can be reached 
by light, either directly or through optical fibers. The PDT of skin diseases is made easy by 
the accessibility of the skin to light application.  
 
2.1.8.1  PRINCIPLES OF LIGHT PENETRATION 
 
Light propagation through tissues implicates processes of refraction, reflection, absorption 
and scattering (Figure 2.10). 
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Figure 2.10 Interaction between light and tissue [adapted from Plaetzer et al., 2009 [248]] 
 
Reflection from the interface between two media and refraction are governed by Fresnel’s 
law and Snell’s law, respectively, and their impact on the loss of intensity are determined by 
the relative values of their refractive indices [249]. Since both processes depend on the angle 
of incidence, they can be minimized by applying the light beam perpendicular to the interface 
between the two media. Scattering and refraction cause a widening of the light beam 
resulting in a loss of fluence rate (given as power per unit area of light in [W.m−2]) and a 
change in the directionality of the light beam.  
Scattering in tissue is ruled by quite complex variables (Figure 2.10). Inelastic scattering 
(Brillouin scattering and Raman scattering) does not seem to play an important role in this 
case. For elastic scattering, neither Rayleigh scattering nor Mie scattering completely 
describe the effects observed in tissue where photons are mainly scattered in the forward 
direction. The experimentally observed scattering shows weaker wavelength dependence 
than that predicted by Rayleigh’s theory, but the effect is stronger than that given by Mie 
scattering [250-251]. Scattering of light in tissue has thus the most pronounced effect on light 
intensity and directionality. Besides scattering, absorption of light quanta is most relevant for 
the loss of light intensity with increasing penetration depth. The reduction in intensity caused 
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by both processes can be mathematically described by an exponential function similar to 
Lambert–Beer’s law. The intensity at a given depth x can be calculated [252], by the 
equation: 
 
Ix = I0 e
-(αabs+αsca)x 
 
 with Ix being the intensity at depth x and I0 the intensity at the media interface. The 
parameters αabs and αsca represent the absorption and scattering coefficients, respectively. 
Thus small changes in the attenuation coefficient lead to large changes in the fluence rate 
with depth. Therefore it is advantageous to have photosensitizers that absorb near 800 nm to 
maximize the treatment depth in many different tissues. The inverse of the attenuation 
coefficient is the attenuation depth which describes the depth that light entering tissue is 
reduced to 1/e (approximately 37%) of its initial intensity. Typical values of the attenuation 
depth range from 1 to 3 mm for non-pigmented tissues [253-254]. Dougherty has reported 
that the destructive effects of PDT extend to two attenuation depths or about 5 to 6 mm, 
indicating that as little as 10 percent of the entering light is required for a photodynamic effect 
[255]. 
 
2.1.8.2  LIGHT INTERACTION WITH TISSUE IN PDT 
 
To be useful in PDT, a light source must emit wavelengths in the absorption spectrum of the 
photosensitizers. All porphyrin-like compounds have a strong absorption band around  
400 nm (called the Soret band) and weaker satellite absorption bands (Q-bands) between 
600 nm and 800 nm. The amount of photoactivation depends on the amount of absorbable 
light that reaches the photosensitizer in the target tissue.  
 
Light entering tissue is absorbed by the dominant chromophores (hemoglobin, melanin and 
water), each of them absorbing light at different wavelengths. Depending on the absorption 
spectra of the chromophores, the penetration depth will change with the wavelength. The 
absorption spectra of these molecules define the optical window for PDT in tissue  
(Figure 2.11) [27, 54, 256], and determine how deeply the light will penetrate. 
 








Wavelength/ nm  
 
Figure 2.11 The “optical window” for photodynamic therapy [adapted from Kohen et al., 2002 [29]] 
 
Long wavelengths penetrate more deeply into tissue, but this advantage is limited by how 
strongly the photosensitizer absorbs light at these long wavelengths. If absorption is low, 
time of exposure to light may be extended or the amount of deposited light energy may be 
increased to achieve photoactivation. There is a need for designing optimal combinations of 
photosensitizers, light sources and treatment parameters for each PDT application. 
 
The so-called “optical window” of living tissue is between 600 nm (beyond the absorption of 
heme) and 1300 nm (below the absorption of water). Thus, to get optimal depths, 
photosensitizers absorbing in this region must be used, preferably at the highest possible 
wavelengths. One should keep in mind that hemoglobin (Hb) and HbO2 show different 
absorption in the range of 600-700 nm, which is commonly used for PDT. The oxygen 
concentration changes during PDT because of vessel damage and direct consumption of 
oxygen in the photosensitizing process itself. In vivo, there might also be a significant 
difference in the amounts of HbO2 and Hb between non-tumor and tumor tissue due to a 
possible lower oxygenation and pH of the latter [36]. This will lead to a change in the 
penetration spectrum and has to be taken into account [257]. 
Theoretically, photons up to 1240 nm (corresponding to the gap between the energy of 
ground state oxygen and that of singlet oxygen) might be used. However, photons above 
about 850 nm will hardly generate singlet. Indeed, one has to produce a triplet state whose 
energy level is high enough to allow an efficient energy transfer to molecular oxygen. For 
treatment of deep lesions it is desirable to apply a photosensitizer with a high absorbance in 
the red region. Many of the second generation photosensitizers absorb at longer 
wavelengths than the traditionally used 630 nm for HpD. For PDT of solid tumors, the 
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effective penetration depth, defined as the depth x, where Ix decreases to 37% of I0 (see 
above) is of great relevance [27]. For clinical treatment with Photofrin, the penetration depth 
of the 630 nm excitation light is approximately 3–5 mm, depending on the tissue [258]. The 
use of photosensitizers with absorption peaks at wavelengths >700 nm (or even higher) 
should, at least, double the penetration depth thus enabling treatment of thicker tumors [253, 
259]. 
 
Light absorption leads to heat generation. Generally, fluence rates above about  
150 mW.cm−2 would give hyperthermia [260]. Recent studies have shown that a low fluence 
rate is preferable since depletion of oxygen occurs at high fluence rates [224, 261-265].  
At the same time, the exposure time needs to be considered. Thus, the fluence rate 
influences the direct photochemical oxygen consumption and, therefore, plays a critical role 
in clinical PDT [264-265]. 
 
2.1.8.3  LIGHT SOURCES AVAILABLE FOR PDT 
 
Light sources available for PDT belong to two broad groups: non-coherent (broadband lamps 
and diode lamps) and coherent sources (lasers) [266-267]. Coherent light originates from 
photons emitted in a resonance mode and that are in phase. Their usefulness mainly 
depends on a few photophysical characteristics: the emission spectrum, irradiance, spatial 




Lasers produce highly coherent monochromatic light that can be efficiently delivered by 
quartz fiber optics. With lasers, specific areas can be more easily targeted. Lasers permit to 
minimize exposure times at selected wavelengths. Pulsed gold vapor, continuous-wave 
argon pumped dye, copper vapor, potassium–titanium–phosphate (KTP) and pulsed-dye 
lasers have been used in dermatologic PDT. 
 
Unlike lamps, lasers allow for the exact selection of wavelengths matching the absorption 
peak of the photosensitizer and provide a highly homogeneous light beam. This light can be 
led through optical fibers and focused directly on the target. Argon dye, KTP dye, metal 
vapour, copper and gold lasers have been used for clinical PDT [266-268]. Lasers emit 
continuous wave or pulsed light, with pulse lengths down to a few femtoseconds. It has been 
hypothesized that high-intensity pulsed light could penetrate deeper into tissues than 
continuous wave light by causing a transient decrease in the absorption of chromophores in 
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tissue by the first part of the pulse [269]. This process allows the rest of the pulse to pass 
through tissue with less attenuation. Whether a pulsed laser is better than a continuous-wave 
light source in PDT is still unclear. Most clinical studies have shown no significant differences 
in PDT efficacy of pulsed and continuous wave light [269-273]. Nevertheless, several studies 
have suggested that pulsed light therapy may be useful for treatment by topical PDT of acne, 
actinic keratosis and photorejuvenation. A controlled investigative study, performed in 
healthy human skin in vivo following microdermabrasion, showed that intense pulsed light  
sources (IPL) such as filtered broadband flashlamps, produced evidence of minimal 
activation of photosensitizer, with a dramatically smaller photodynamic reaction than seen 
with a conventional continuous wave broadband source [273]. 
Lasers allow shortening of the treatment time as they emit a high fluence of monochromatic 
light corresponding to the absorption peak of the photosensitizer. In addition, they keep 
damage to surrounding tissues to a minimum because they can be focused with great 
precision on very small target areas with sharp boundaries [266]. However, they are 
expensive, have low reliability and portability and can illuminate only small areas of the skin 
surface. In addition, their high output is unnecessary in clinical conditions because, during 
PDT, the light intensity is kept in the range of 150–200 mW/cm2 to trigger photochemical 
reactions without producing ablative hyperthermic effects [274]. Lasers are necessary for the 
PDT of internal organs or the experimental investigation of ‘second generation’ 
photosensitizers, which have narrow absorption peaks in the far red and near-infrared 
regions. However, for porphyrin based PDT of dermatological conditions, lasers have not 
shown therapeutic advantages over the cheaper and more practical incoherent light sources.  
 
b)  Non-coherent sources 
 
Non-laser sources such as broadband high-pressure lamps or fluorescent lamps spans the 
whole visible range, with large infrared and negligible ultraviolet emissions. For dermatology, 
they are superior than laser systems because of their large illumination field, low cost, small 
size, and simple construction [266, 275-277]. 
Metal halogen lamps are widely used because they are cheap and have a high power 
density that keeps light exposure times within practical limits. They can be used as sources 
of white light (e.g. slide projector lamps) or can be equipped with optical filters that allow a 
selection of a waveband of 100–200 nm while cutting-off shorter wavelengths that are not 
necessary for drug activation, and infrared wavelengths that can overheat the skin causing a 
burning sensation. 
The only fluorescent lamp useful for PDT is the Blu-U® (Dusa) light system. Its emission peak 
in the Soret band is sufficient for an effective irradiation of porphyrin-sensitized skin. A blue 
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fluorescent lamp is routinely used in Levulan® ALA-PDT of AK in the U.S.A. There are now 
several reports that blue, green and red light can be effective in topical PDT of AK, but the 
more deeply penetrating red light is superior when treating BD and BCC [278]. 
Light emitting diodes (LEDs) are small solid-state semiconductors with a high and reliable 
emission with peak emission of 631nm and a narrow bandwidth of 20–50 nm without infrared 
emission. LEDs have a deeper PDT action in tissue than a filtered halogen lamp of  
560–740 nm emission, and hence LED may be more effective in treating the deeper parts of 
tumours [279]. They can be arranged in grids or panels to give a broad field of illumination. 
The power output and the uniformity of the irradiation field of both broadband lamps and LED 
lamps must be carefully checked during any single exposure and at regular intervals with an 
appropriate radiometer or a spectroradiometer. They are simple to use and do not have 
special electrical requirements.  
In dermatology, non-coherent halogen, xenon arc and metal halide lamps, fluorescent tubes, 
LED and IPL are the most frequently used light sources for PDT.  
 
c)  Lasers versus non-coherent light sources 
 
Lasers and non-coherent light sources have been used for PDT and usually show similar 
efficacies [266, 280-281]. Since coherence is lost within a few tenths of a millimeter of 
penetration into human tissue, this property is not of any importance for PDT. Light doses are 
principally related to the emission spectrum of the light dose and the peak of absorption of 
the drug. After ALA sensitization, 37 J/cm2 of light from an LED lamp peaking at 630 nm or 
75–100 J/cm2 of a filtered incoherent lamp centered in the red waveband gives similar 
biological effects [282]. 
Light exposure using a laser at a defined wavelength allows accurate light dosimetry at the 
surface of the lesion. For broad-band sources the depth of light penetration, the extinction 
coefficient of the photosensitizer, and the spectral intensity can all vary across the bandwidth 
of light used. Therefore, the light doses reported with the use of a laser, filtered light and 
white light are not directly comparable. 
No single light source is ideal for every possible indication of PDT, even with the same 
photosensitizer. Choice of light sources should be based on: reliability, size, simplicity of 
maintenance, cost, photosensitizer absorption (fluorescence excitation and action spectra), 
disease (location, size of lesions, accessibility). In the last few years, LED sources have 
shown considerable development, with improvements in design making these relatively 
inexpensive sources convenient for wide area irradiation and popular for patient use, e.g. the 
AKTilite® 16 and 128 (Galderma) and the Omnilux® (Photo Therapeutics Ltd, Altrincham, 
U.K.). Furthermore, a report has recently introduced the concept of ambulatory PDT to 
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reduce hospital attendance for PDT [283]. In a pilot study of five patients with Bowen’s 
disease, PDT was performed with ALA and a portable LED device, where low irradiance light 
exposure took place over 100 min (ALA 4 h, 637 nm, 75 J/cm2, 12 mW/cm2. Four of five 
patients were in clinical remission after a median of 9 months. 
 
2.2 BIOCHEMICAL EFFECTS OF PHOTODYNAMIC THERAPY 
 
In this second part of the introduction, I will review the biological effects induced by PDT with 
emphasis on:  
- the direct cytotoxic effect of PDT on tissue and the role of vascularization 
- the mechanisms of cell death in PDT 
- the changes in cell signaling after PDT 
 
2.2.1 DIRECT CYTOTOXIC EFFECT OF PDT ON TISSUE AND THE ROLE OF VASCULARIZATION 
 
At the tissue level, the targets of PDT include tumor cells, the microvasculature of the tumor 
bed as well as normal microvasculature, and the inflammatory and immune host system. 
PDT effects on all these targets may influence each other, producing a cascade of responses 
(Figure 2.12).  
 




















• Cytotoxic T cells
• Antibody mediated
cytotoxicity




Tumor destruction and possible cure











PS localizes in tumor tissue and is excited by
visible light, producing singlet oxygen and ROS
 
 
Figure 2.12 Pathways of PDT-mediated tumor destruction illustrating possible contributions from 
direct tumor cell killing, vascular damage and host immune response. 
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The relative importance of each for the overall tumor response has yet to be fully defined. It 
seems clear, however, that the combination of all these components is required for long-term 
tumor control [25].  
 
2.2.1.1  DIRECT CYTOTOXIC EFFECTS OF PDT ON CANCER CELLS 
 
It is generally accepted that PDT exerts a direct cytotoxic effect caused by the irreversible 
photodamage to vital subcellular targets such as the plasma membrane and intracellular 
membranes of the mitochondria, lysosomes, Golgi apparatus and endoplasmic reticulum. As 
I discussed previously in Section “Subcellular localization and relocalization”, the intracellular 
localization of the photosensitizer coincides with the primary site of photodamage [284-288]. 
This is because the photogenerated singlet oxygen has a very short lifetime and, thus, very 
limited diffusion in biological systems [153]. However, several studies have shown the 
relocalization of certain photosensitizers after irradiation [206, 289-290]. As a consequence, 
the photodamage can rapidly propagate to other subcellular locations than the primary site. 
Moreover, other reactive oxygen species resulting from the singlet oxygen attack may 
migrate at longer distances from the site of formation. Among them, hydrogen peroxide can 
be converted into the more reactive hydroxyl radicals.  
 
Due to the high reactivity of singlet oxygen and hydroxyl radicals, virtually all macromolecular 
constituents, such as proteins, DNA and lipids, are directly affected by PDT. Proteins are 
prominent targets of singlet oxygen or free radical attack in cells subjected to photooxidative 
stress. Damage to proteins is often due to oxidation of essential methionine, tryptophan, 
histidine, or cysteine residues. It can thus cause protein modification resulting in enzyme 
inactivation, dysfunction of cellular membrane pumps, membrane and intra-cellular receptor 
damage and the modification of structural proteins. Since most dyes do not accumulate in 
cell nuclei, PDT induces much less DNA damage [291]. Finally, membrane lipids may also 
be important targets in cells subjected to a photooxidative stress, especially if the responsible 
photosensitizing agent is amphiphilic and localizes in the membrane bilayer. Singlet oxygen 
and other ROS can react with membrane lipids including unsaturated triacyl glycerols, 
cholesterol and phospholipids. The resulting intermediates of peroxidative reactions, such as 
lipid hydroperoxides, are potentially dangerous because they may propagate the initial 
peroxidative stress from one membrane to another one in cells. They may also participate in 
cell death pathway as will be discussed later. Whenever cellular detoxifying and antioxidant 
enzymes or agents are overwhelmed during PDT, the described oxidative stress leads to a 
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progressive failure of cellular machinery and ultimately to cell death as I will discuss in 
Section 2.2.2 and 2.2.3. 
 
The early effects of PDT carried out with lipophilic sensitizers are detectable within a few 
hours after treatment and include biochemical changes such as inactivation of membrane 
enzymes, increased membrane permeability, formation of blebs, disruption of membranes, 
inhibition of cell division, breakdown of the respiratory process and cell lysis. On the other 
hand, hydrophilic photosensitizers photochemically inactivate cells through the release of 
lysosomal hydrolases or, alternatively, the photosensitizer may be released from the 
lysosomes before or during light exposure producing photochemical damage to other 
subcellular targets [42]. Such effects are related to the light and drug doses used [292]. An 
inverse relationship between these two doses has been found. Comparable biological effects 
can be produced by combining a relatively high photosensitizer dose with a low light dose or, 
conversely, a low drug dose with a high light dose. The cell genotype was also found to 
determine whether cell death occurs by apoptosis or necrosis [285, 293-297]. Indeed, 
apoptosis was the predominant mode of cell death when murine leukemia P388 cells were 
photosensitized with chloroaluminum phthalocyanine (AlPc), using low light doses, whereas 
necrosis was observed for higher light doses [293]. Similar results were obtained in studies 
where human bladder carcinoma HT1197 cells were subjected to 5-aminolevulinate (ALA)-
induced PDT [298] and in CNE2 cells, TWO-1 cells (human nasopharyngeal carcinoma cells) 
and AY-27 cells (chemically-induced rat bladder carcinoma cells) photosensitized with 
hypericin [297, 299]. In addition, it has been found that biological effects can be modulated 
by different combinations of doses. With low light and drug doses, cell viability may be 
maintained while other traits (signaling activity, cytokine formation, receptor expression) may 
be altered. At higher doses of one or both components of PDT, the disruption of cell 
membranes and organelles causes necrosis, which contributes to the formation of an 
inflammatory state. At intermediate combinations of light and drug, cells may undergo 
apoptosis [292]. These findings indicate that the type of cell death switches from apoptosis to 
necrosis with the increase in the strength of the insult [300] as will be further detailed in the 
Section “Cell death pathways”. 
 
As was just mentioned, exposure of tumors to PDT in vivo can reduce the number of tumor 
cells through direct photodamage. However this may be insufficient for tumor cure as it has 
been demonstrated in several studies on rodent tumor systems [61, 301-302]. After 
employing curative procedures with several photosensitizers, it was shown that the direct 
photodynamic tumor cell death was less than 2 logs and in most cases less than 1 log, 
 i.e., far short of the 6–8-log reduction required for tumor cure. Non-homogenous 
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photosensitizer distribution within the tumor might be one of these limitations. Korbelik and 
Krosl [303] have also shown that both photosensitizer accumulation and tumor cell kill 
decrease with the distance of tumor cells from the vascular supply.  
Another parameter that can also limit direct tumor cell kill is the availability of oxygen within 
the tissue undergoing PDT treatment. Two mechanisms can produce such limitations: the 
photochemical consumption of oxygen during the photodynamic process and the effects of 
PDT on the tissue microvasculature. Since oxygen in the tissue environment is consumed 
during PDT, rapid and substantial reductions in tissue oxygen tensions on illumination of 
photosensitized tissues were reported [304]. Photofrin–PDT produces very low levels of 
oxygenation in fractions of the tumor by decreasing the rate of oxygen diffusion from the 
capillaries and the radius of oxygenated tissue volume around them [305]. To minimize this 
phenomenon, the fluence rate can be adjusted downward to slow oxygen consumption 
sufficiently to facilitate the maintenance of (tumor) tissue pO2 levels during treatment. 
Another approach toward maintenance of tissue oxygenation during PDT is the fractionation 
of light delivery [265, 305]. This consists of very short light and dark intervals, allowing 
reoxygenation during the dark periods. Generally, treatment regimens using a low fluence 
rate or intermittent light, show superior effectiveness in delaying tumor regrowth [306]. 
Recent clinical studies have shown that oxygen depletion also occur during PDT in patients. 
The kinetics for this depletion varied from very rapid (within seconds of light exposure) to 
slow (>10 minutes of light exposure) or no effect at all in basal cell carcinoma lesions in 
patients undergoing Photofrin (1mg/kg)–PDT at a light dose rate of 150 mW/cm2 [225]. 
 
2.2.1.2  ROLE OF VASCULARIZATION 
 
Along with oxygen consumption within the tissue undergoing treatment, the oxygen supply in 
the tissue can also be diminished by the damaging effects of PDT on the microvasculature 
[307]. Vascular shutdown can be readily observed following PDT [308] and can lead to 
severe and persistent post-PDT tumor hypoxia/anoxia [309]. The mechanisms underlying the 
vascular effects of PDT differ greatly with different photosensitizers. Photofrin–PDT leads to 
vessel constriction, vessel leakage, leukocyte adhesion and thrombus formation, all 
apparently linked to platelet activation and release of thromboxane [308, 310]. PDT with 
certain phthalocyanine derivatives causes primarily vascular leakage [311], while PDT with 
NPe6 results in blood flow stasis primarily because of platelet aggregation [312]. All these 
effects may include components related to damage to the vascular endothelium. PDT may 
also lead to vessel constriction via inhibition of the production or release of nitric oxide by the 
endothelium [313]. On the other hand, administration of agents inhibiting nitric oxide 
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synthase or scavenging nitric oxide appears to enhance tumor cure, apparently by enhancing 
the PDT induced disruption of vascular perfusion [314]. In preclinical experiments, the 
microvascular PDT responses can be partially or completely inhibited by the administration of 
agents that affect eicosanoid generation, such as indomethacin [223], various thromboxane 
inhibitors [223], and aspirin [315]. This inhibition can markedly diminish the tumor response 
[316]. Recent studies have also revealed important differences between PDT effects on 
normal and tumor vasculature [262, 317]. It has also been suggested that monitoring  
PDT-induced changes in tumor oxygenation may be a valuable prognostic indicator of 
photodynamic therapy effectiveness [318]. 
 
2.2.2 MECHANISMS OF CELL DEATH IN PDT 
 
Although PDT can induce many cellular and molecular signaling pathway events in cells, its 
main purpose is to induce cell death [319]. The concentration, physical chemical properties 
and subcellular location of the photosensitizer, the concentration of oxygen, the appropriate 
wavelength and intensity of the light, as well as the specific properties of the cell type may all 
influence the mode and extent of cell death [248, 319-321]. 
 
Programmed cell death (PCD) is defined as a genetically encoded form of suicide occurring 
in a predictable place and time during embryonic development [322]. Three morphologically 
distinguished forms of PCD have been characterized during development. Type I PCD is 
characterized by phenotypic changes involving nuclear condensation and general cellular 
shrinkage. Type II PCD is distinguished by a lysosomal-dependent digestion of the cell and 
the presence of autophagic vacuoles (autophagosomes). Type III PCD is marked by cellular 
swelling and a rapid loss of plasma membrane integrity. These processes are defined as 
apoptosis, autophagic cell death and necrosis, respectively, and are cellular programs known 
to play a crucial role in normal development, tissue homeostasis and in eliminating abnormal 
and damaged cells (Figure 2.12) [323]. 
 
A presentation of the intervention of PCD in PDT is presented below whereas the detailed 
molecular mechanisms will be discussed in Section “Changes in cell signaling after PDT”. 
 
 







Figure 2.12 Morphological characteristics of apoptosis and non-apoptotic cell death. Apoptosis is 
characterized by membrane blebbing, cytoplasmic shrinkage, chromatin condensation, exposure of 
phosphatidylserine on the cell surface and, in a later stage, the formation of apoptotic bodies. Death 
by autophagy is characterized by the double membrane vesicles containing cytosolic organelles. 
During necrosis, cells swell and loose their membrane integrity [adapted from Sun et al., 2009 [324]] 
 
2.2.2.1  APOPTOTIC CELL DEATH IN PDT 
 
The word apoptosis (Greek: apo – from, ptosis – falling) is based on the morphology of the 
dying cells, which include cellular shrinkage, membrane blebbing and eventually 
fragmentation into membrane bound apoptotic bodies [325]. The major biochemical features 
of apoptosis are activation of intracellular proteases, especially caspases, and 
internucleosomal DNA fragmentation. 
 
During apoptosis the cells shrink, the nuclear chromatin becomes pyknotic and condenses 
against the nuclear membrane. Eventually the cytoplasm and the nucleus break up into 
apoptotic bodies. Although the cytoplasmic organelles remain intact, DNA is digested at 
internucleosomal sites, giving rise to fragments that are multiples of 180–200 bp [326-327]. 
Simultaneously, the cell membrane loses its asymmetry and phosphatidylserine becomes 
exposed on the cell surface. These changes ensure that apoptotic cells are immediately 
recognized by neighboring cells and/or phagocytised with the result that many cells can be 
deleted from tissues in relatively short time [328]. It is believed that this type of cell death 
does not to trigger inflammation [329].  
 
Several external signals may trigger two major apoptotic pathways, involving either activation 
of death receptors in response to ligand binding (extrinsic or death receptor pathway), or the 
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release of pro-apoptotic proteins from mitochondria to cytosol (intrinsic or mitochondrial 
pathway) [326-327]. The extrinsic pathway is activated by apoptotic stimuli comprising 
extrinsic signals such as the binding of death-inducing ligands to cell surface receptors. The 
extrinsic pathway is mainly activated by ligand-bound death receptors such as TNF-TNFR1, 
FasL-Fas and TRAIL-DR4 or -DR5. Activation of cell surface receptors from the tumor 
necrosis factor (TNF) gene family therefore activates the initiator caspase-8 via adaptor and 
scaffolding proteins.  
 
In other cases, apoptosis is initiated following intrinsic signals including DNA damage 
induced by irradiation or chemicals, growth factor deprivation or oxidative stress. This 
process is triggered by disruption of mitochondrial function, which causes the release of 
cytochrome c to the cytosol [330]. Released cytochrome c binds Apaf-1 and induces its 
oligomerization, in the presence of dATP. This complex, termed apoptosome, recruits and 
activates the initiator caspase-9 [331-332]. Some evidence has indicated that the two 
pathways are linked and that molecules involved in one pathway can influence the other 
[333]. In both pathways, the activation of initiator caspases (caspase-8 or caspase-9) leads 






































Figure 2.13 Diagram of the apoptotic process. The two major apoptotic pathways, the death receptor-
mediated, or extrinsic pathway, and the mitochondria-mediated-pathway are represented [adapted 
from Jin et al.,2005 [334]] 
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a) Extrinsic pathway 
 
The extrinsic pathway has been shown to be activated by photodynamic therapy. A transient 
increase in the protein levels of the surface death receptor Fas and of its ligand FasL 
occurred after photosensitization of human epidermoid carcinoma A431 cells with silicon 
phthalocyanine 4 (Pc 4). A multimerization of the Fas protein and its interaction with the 
adaptor molecule FADD was also observed [335]. Accordingly, caspase-8 cleavage was 
observed in the human epidermoid carcinoma A431 cells photosensitized with Pc 4, and pre-
incubation of the cells with rhFas:Fc fusion protein partially inhibited cell death [335]. 
Antibodies against Fas or FasL also reduced apoptotic death of nasopharyngeal cells 
subjected to PDT with Hypocrellin A and Hypocrellin B [336]. In in vivo studies, in which NR-
S1 tumor-bearing mice were treated by PDT with Photofrin, Fas-positive tumor cells were 
observed in the same area where many TUNEL positive tumor cells were found and 
expression of Fas and FasL was also observed in the tumor cells surrounding TUNEL-
positive cells [337]. Activation of caspase-8 was found to mediate apoptotic death of human 
promyelocytic HL-60 cells photosensitized with Rose Bengal [338]. In this model, inhibition of 
caspase-8 impeded cytochrome c release from mitochondria and cleavage of procaspase-3, 
suggesting that caspase-8 acts upstream of these events. In fact, caspase-8 cleaves Bid 
(BH3-interacting domain death agonist), generating a truncated Bid fragment [339] that 
initiates mitochondrial outer membrane permeabilisation (MOMP) through the multidomain 
pro-death molecules Bax or Bak [340]. In turn, Bax/Bak translocation to mitochondria induces 
the release of cytochrome c into the cytosol and subsequent activation of the executioner 
caspases. Besides promoting death by activating the pro-apoptotic proteins Bax and Bak, 
Bid may also inactivate prosurvival proteins [341], thereby inducing the release of 
cytochrome c and connecting the extrinsic and intrinsic pathways. Bcl 2, on the contrary, 
impedes the cytochrome c release in the cytosol thereby inhibiting apoptosis. 
 
Although the fast kinetics of caspase-8 activation in HL-60 cells subjected to PDT with Rose 
Bengal may suggest that singlet oxygen generated during photoactivation of the sensitizer 
directly induces multimerization-mediated activation of the Fas receptor, even in the absence 
of the FasL, a rapid upregulation of the Fas and FasL protein levels was observed in human 
epidermoid carcinoma A431 cells photosensitized with Pc4 [342]. By contrast, a direct effect 
of the photosensitizer on the activation of the Fas receptor is supported by studies showing 
that ultraviolet A radiation induces formation of the Fas–FADD–caspase-8 death complex in 
HL-60 cells in a FasL-independent manner [343]. Despite evidence indicating a role for the 
death receptor-mediated mechanism in apoptotic death of PDT treated cells it was found that 
FADD null mouse embryonic fibroblasts still undergo apoptosis when photosensitized with  
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Pc 4 [344]. These results indicate that in this case other mechanisms may be involved in 
apoptotic death induced by PDT. 
 
b) Intrinsic pathway 
 
Photosensitization of different cell types was also shown to stimulate the intrinsic pathway of 
apoptosis. This effect is more obvious with some sensitizers that target mitochondria [288], 
these organelles playing a central role in apoptosis. In this case, it is not surprising that PDT 
can induce apoptosis rapidly, both in vivo [337] and in vitro [345]. However, since 
photosensitizers may also be accumulated in other cellular compartments (e.g. lysosomes, 
endoplasmic reticulum, Golgi apparatus), local damage induced by photosensitization may 
be propagated to the mitochondria by various means [346-347]. 
Studies using different cell models and various sensitizers have shown that 
photosensitization induces a rapid release of cytochrome c from the mitochondria. The 
intracellular Ca2+ chelator BAPTA inhibited PDT induced cytochrome c release and caspase-
3 activation, suggesting that the increase in the intracellular Ca2+ levels may trigger 
cytochrome c release from mitochondria [348]. A drop in mitochondrial membrane potential, 
concurrent with a drop in ATP levels and a decrease in cell respiration, was also observed in 
the early phase of the response of promyelocytic K562 cells to photodynamic treatment with 
hematoporphyrin [349]. Studies on human epidermoid carcinoma A431 cells suggested that 
PDT causes an up-regulation of glycolytic phosphorylation as a compensatory mechanism to 
overcome mitochondrial dysfunction and to provide energy equivalents required for apoptotic 
cell death [349]. Indeed, glycolytic ATP production constitutes a strict requirement during the 
initial events of the demise process [349]. 
 
2.2.2.2  AUTOPHAGIC CELL DEATH IN PDT 
 
Autophagy (from the Greek, “auto” oneself, “phagy” to eat) refers to any cellular degradative 
pathway involving the delivery of cytoplasmic component to the lysosome. Autophagy is a 
physiological process that plays an important role in the turnover of cellular proteins and 
other macromolecules. Moreover, it is the major catabolic route for eukaryotic cells to 
salvage essential molecules, and to maintain an amino acid level sufficient to sustain protein 
synthesis during nutritional deprivation.  
 
At least three forms have been identified— macroautophagy, microautophagy, and 
chaperone-mediated autophagy— which differ on the mode of intracellular component 
delivery to the lysosome and their physiological functions. Macroautophagy (herein referred 
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to as autophagy) is the most important regulated catabolic mechanism used by eukaryotic 
cells to degrade long-lived proteins and organelles. Unlike apoptosis, which relies on the 
activation of caspases that cleave several target proteins [350], autophagic cell death is 
caspase independent [351]. Indeed, autophagic cell death has been demonstrated in cells 
with defects in the apoptosis machinery [352] and in cells grown in the presence of caspase 
inhibitors [353]. Cells undergoing autophagic death look different from cells undergoing 
apoptosis. The characteristic cellular morphology of apoptosis results from caspase cleavage 
of cytoskeletal and other structural proteins [350]. In apoptotic cells, although early 
degradation of the cytoskeleton is observed, organelles are preserved until fairly late in the 
process. By contrast, autophagic cell death is characterized by the accumulation of large 
numbers of autophagic vesicles, in which organelles are degraded early in the process, while 
the cytoskeleton persists intact and functional until late in the process [354]. Morphologic 
changes, such as chromatin condensation or membrane blebbing, may also occur in 
autophagic cell death, but there is no DNA fragmentation or formation of apoptotic bodies 
[355]. 
 
Autophagy includes the delivery to the lysosome of cytoplasmic components sequestered 
inside double-membrane vesicles. The first steps are characterized by the formation (vesicle 
nucleation) and expansion (vesicle elongation) of an isolation membrane, the phagophore. 
The extremities of the phagophore then fuse (vesicle completion) forming the 
autophagosome, a double-membrane vesicle that sequesters the cytoplasmic material. 
Then, autophagosomes fuse with lysosomes to become autolysosomes, where sequestered 
cellular components, together with the inner membrane, are digested [356]. Amino acids and 
fatty acids generated by this process can be used for protein synthesis, or can be oxidized by 
the mitochondrial electron transport chain to produce adenosine triphosphate (ATP) for cell 
survival under starvation conditions [357]. 
 
Virtually all cells have autophagy at low basal levels to maintain homeostatic functions such 
as protein and organelle turnover. Autophagy can be rapidly activated whenever cells need 
to generate intracellular nutrients and energy, e.g. growth factor withdrawal, starvation, or 
high bioenergetic demands. Autophagy is also upregulated when cells need to discard 
damaged cytoplasmic components, for example, during oxidative damage or infection, or to 
undergo structural remodeling during developmental transitions. Nutritional status, hormonal 
factors, and other clues like temperature, oxygen concentrations, and cell density also play a 
role in the control of autophagy [358-360]. 
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In most circumstances, autophagy is a stress adaptation pathway that promotes cell survival. 
Besides defending cells against metabolic stress, autophagy functions include the elimination 
of defective proteins and organelles, the prevention of abnormal protein aggregate 
accumulation and the removal of intracellular pathogens. These functions are critical for 
autophagy-mediated protection against cancer, aging, neurodegenerative diseases, as well 
as infection. However, in addition to promoting cell survival, autophagy can lead to cell death. 
In an apparent paradox, autophagy is also considered as a form of nonapoptotic 
programmed cell death called “autophagic” or “type II” cell death. Autophagy role in cell 
death pahway in different settings has been recently shown using knockdown of Bax/Bak 
and Atg genes. Wei et al. showed that exposure to a variety of apoptotic stimuli does not 
induce apoptosis in Bax/Bak-deficient mouse embryonic fibroblasts [361]. It has been 
revealed, by electron microscopy, that drug treated Bax/Bak-deficient cells contain numerous 
double membrane vesicles. These vesicles have been confirmed to be autophagosomes as 
they show a punctate distribution of GFP-LC3 (GFP-LC3 is specifically concentrated on 
autophagosomes during autophagy while is normally spread throughout the cytoplasm in 
basal conditions) [352]. This nonapoptotic form of cell death was shown to be inhibited by 3-
methyladenine (3-MA) and wortmannin, which suppress autophagosome formation, or by 
silencing Atg5 and Atg6, using several different methods [352]. Thus, these results show that 
autophagosome formation has a role in cell death induced by certain cytotoxic drugs, 
suggesting the existence of an alternative death mechanism to apoptosis termed autophagic 
cell death. It was also shown that a pancaspase inhibitor induces nonapoptotic death in the 
presence of autophagic characteristics, which is inhibited by silencing of Atg5 and Atg7 [353]. 
 
Autophagy may not be simply the result of crossing a quantitative threshold of self-digestion. 
In fact, cells subjected to prolonged growth factor deprivation can lose the majority of their 
mass via autophagy and fully recover when placed in optimal culture medium [362]. The 
factors that regulate whether autophagy is cytoprotective or cytotoxic, and that determine 
whether cytotoxicity occurs by self-cannibalism or by specific degradation of cytoprotective 
factors, are not yet entirely understood. Although autophagy can independently determine life 
and death decisions of the cell, it has also been linked to apoptotic death pathways.  
 
The understanding of the molecular basis of autophagic death is still limited. It is currently 
known that autophagy depends on proteins involved in the formation of autophagosomes 
such as PI3 kinase type I and III [352-353]. PI3 kinase type I may be activated by growth 
factors such as insulin. Autophagy inhibition by PI3 kinase type I is dependent on PDK1 and 
AKT which regulates mammalian target of rapamycin (mTOR). It is still unclear how the 
activation of mTOR inhibits autophagy. This mechanism may involve phosphorylation of 
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Atg13, which is part of a protein complex with Atg1, a serine/threonine kinase. As mTOR is 
regulated by many other proteins, it is assumed that the autophagy regulation is likely to be 
very complex. On the contrary, PI3 kinase type III, which includes Atg6 in its complex, 
promotes the nucleation of autophagic vesicles whose progression is mediated by two 
ubiquitin-like conjugation systems: the Atg12 and the Atg8 pathways (Figure 2.14). 
 
There are a few recent reports on the induction of autophagic cell death by photodynamic 
therapy although most are dealing with apoptosis-deficient cells or cells whose caspase 
activity has been inhibited. Due to the high reactivity of photogenerated ROS it is possible 
that autophagy is initiated in an attempt to remove oxidatively damaged organelles or to 
degrade large aggregates of cross-linked proteins, produced by photochemical reactions, 
which cannot be removed by the ubiquitin–proteasome system. Alternatively, the function of 
autophagy could be orchestrated by dedicated signaling molecules and switched from a 
































Figure 2.14 Diagram of the autophagic process. A) The cellular events during autophagy are 
represented. Autophagy has distinct stages: 1) vesicle nucleation (formation of the isolation 
membrane/phagophore) regulated by Class III PI3K and Atg6, 2) vesicle elongation and completion 
(growth and closure to form the autophagosome) regulated by Atg 8 or Atg12-Atg5 complexes, 3) 
fusion of autophagosome with the lysosome to form an autolysosome followed by the autophagosome 
inner membrane lysis and breakdown of its contents. B) Shown here are some of the regulatory 
pathways that have been targeted pharmacologically for experimental or clinical purposes. Inhibitors 
and activators of autophagy are shown in red and green, respectively [adapted from Levine et al., 
2008 [363]]  
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Cell death modalities in hypericin-mediated PDT have been examined in wild type MEFs and 
in apoptosis-deficient Bax−/−Bak−/− MEFs. In these cells all the biochemical hallmarks of 
apoptosis are prevented while photokilling continues through the induction of a non-apoptotic 
cell death pathway associated with the ultrastructural and biochemical features of autophagy 
[364]. The blockade of autophagy by the PI3K class III inhibitor wortmannin, in apoptosis-
deficient DKO cells results in a significant reduction of cell death, which evidences that PDT 
can stimulate an autophagic cell death pathway, at least under conditions of apoptosis 
inhibition. Further studies suggested that PDT-induced ER photodamage with a porphycene 
called CPO induces autophagy in both L1210 and DU145 cultures [365]. Both apoptosis and 
autophagy were shown to occur in L1210 cultures following PDT with CPO. In these cells 
there was an equilibrium between autophagy and apoptosis, with inhibition of either process 
leading to enhanced activity by the other. In the case of PDT with CPO it appears that the 
induction of autophagy leads to cell death. The basis for this death, in the context of PDT, 
possibly lies in the ability of CPO to photodamage Bcl-2 as its downregulation has been 
shown to induce/facilitate the development of autophagy [366-367]. This hypothesis is based 
on the observation that Bcl-2 and/or Bcl-xL can inhibit not only apoptosis but also Beclin 1-
dependent autophagic cell death [368], through a direct interaction, which has been recently 
shown to require the BH3 domain in Beclin 1 [369]. Nevertheless, the induction of both 
apoptosis and autophagy occurs also in HeLa cells following hypericin-mediated PDT 
regardless of a reduction in the levels of expression of anti-apoptotic Bcl-2 proteins [370], 
thus suggesting that other molecular determinants can play a key role in this process. 
 
Recent studies have suggested that the specific ROS-damaged subcellular site is a factor 
which could potentially influence the outcome of the autophagic process in PDT-treated cells. 
For instance, when ER is the main photo-damaged organelle and mitochondria are spared 
from major alterations as reported in Bax-deficient cells, autophagy could target the ER for 
extensive engulfment and degradation resulting in the activation of a cell death pathway 
[371]. 
 
2.2.2.3 NECROTIC CELL DEATH IN PDT 
 
In contrast to apoptosis, necrosis has been considered as an uncontrolled form of cell death. 
Morphologically, necrosis is characterized by vacuolization of the cytoplasm, loss of 
membrane integrity and cellular swelling, as illustrated in Figure 2.12. The resulting release 
of intracellular components into the microenvironment can provoke an inflammatory 
response. Although necrosis is usually a consequence of pathological traumas such as 
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infection or ischemia, it can be induced by TNFα or Fas ligand via their respective death 
receptors [372]. The latter observation points to the fact that necrosis may not be such an 
uncontrolled form of cell death as initially suggested. Growing evidence supports a 
‘‘sequence’’ of events that characterize necrotic cell death at both the morphological and 
biochemical levels, thereby reflecting a programmed course of events in the dying necrotic 
cell, and contributing to a definition of necrotic cell death. It is thus suggested that Type III 
PCD—programmed necrosis—is not due to a well described signaling cascade, but is the 
result of interplay between several signaling pathways. 
 
The lack of caspase and lysosomal involvement distinguishes programmed necrosis from 
other types of PCD. Programmed necrosis is characterized by early swelling of intracellular 
organelles such as mitochondria, ER, and Golgi apparatus, followed by loss of plasma 
membrane integrity. After signaling or damage induced lesions, signs of controlled necrotic 
processes, such as mitochondrial dysfunction, enhanced generation of reactive oxygen 
species, ATP depletion, or proteolysis by calpains and cathepsins, can be observed [373]. In 
addition, programmed necrosis is also associated with nuclear degradation that is 
accompanied by the release of nuclear factors such as high mobility group box 1 (HMGB1) 
that triggers a potent inflammatory response [374]. Recent reports describe that this 
programmed necrosis is firmly regulated and, depending on the cell death system and/or 
PCD insult, implicates different proteins, such as TRAIL, TRADD, TRAF2, JNK1, RIP1, 
XRCC1, AIF, calpains, Bax, or Drp1 [375]. 
Death receptor-induced necrosis might depend on the kinase RIP1 (receptor-interacting 
protein 1). As a matter of fact, cells with downregulated RIP1 as well as RIP1-deficient Jurkat 
cells show partial resistance to Fas-induced cell death [376]. Receptor-interacting protein 1 
likely targets the mitochondria resulting in excess formation of ROS [377]. ROS are 
considered to play a central role in necrosis, since the ROS scavengers efficiently prevent 
necrosis induced by several treatments [378-379]. 
Besides death receptor/triggered necrosis, DNA damage can result in necrosis as well. This 
necrotic death is mediated by PARP-1, a protein involved in DNA damage repair. 
Overactivation of this enzyme results in a drop of cellular NAD+ and ATP, suggesting the 
connection with mitochondria [380]. In agreement with this hypothesis, PARP-1 activation 
has been shown to induce AIF translocation from the mitochondria to the nucleus, mediating 
a caspase independent death [381]. PARP-1-mediated necrosis has been shown to depend 
on the proteins RIP1, TRAF2 and JNK1 [382]. These observations altogether indicate that 
necrosis should no longer be exclusively viewed as an unregulated process. A regulated 
form of necrosis–also called necrosis-like programmed cell death – might be considered as a 
different type of cell death, besides accidental necrosis [383]. 
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2.2.3 CHANGES IN CELL SIGNALING AFTER PDT  
 
Several signal transduction pathways are activated by PDT [176]. PDT induces an acute 
stress reaction leading to changes in cellular metabolism which may result in cell death. 
Depending on certain conditions, cells subjected to PDT may die from necrosis, apoptosis or 
autophagy. Important signal transduction pathways determining the outcome of PDT imply 
mitogen activated protein kinases (MAPKs) expression, lipid metabolism effects, calcium 
intracellular levels, expression of transcription factors, cyclic nucleotides, cell adhesion 
molecules, as well as inflammatory cells and mediators (Figure 2.14). The understanding of 






































































Figure 2.14 Diagram representing some of signalling mechanisms activated in PDT-treated cells 
[adapted from Almeida et al., 2004 [384]]  
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2.2.3.1  ROLE OF MAPK’S MODULATION IN PDT 
 
The mitogen activated protein kinases (MAPKs) are a group of serine/threonine protein 
kinases, activated by dual phosphorylation on a tyrosine and a threonine residue. The MAPK 
pathway is a signaling cascade that plays a critical role in cell growth, differentiation, and cell 
survival through the activation of intracellular substrates including transcription factors, such 
as Elk-1, c-jun, and activating transcription factor 2 [385]. MAPKs are a superfamily of three 
related kinases that are activated by several extracellular stimuli. Three members of this 
family of kinases are the extracellular signal regulated kinases (ERKs), the c-Jun NH2 
terminal kinases/stress activated protein kinases (JNK/SAPKs), and the p38 MAPK. A variety 
of mitogenic or stress stimuli may activate ERKs leading to the production of proteins 
required for cell proliferation and/or differentiation [386]. In contrast, JNK and p38 are 
downstream members of two stress-signaling cascades. Their activation begins with 
autophosphorylation of a primary kinase (MAP3K), that acts on an intermediate kinase 
(MAP2K: M2K3/4/6 for p38; M2K4/7 for JNK) and ultimately activates the terminal MAPK 
[387-388]. Of the several known stress-activated MAP3Ks, apoptosis signal regulating kinase 
1 (ASK1) is the best characterized in terms of regulatory mechanism. ASK1 is inactive when 
associated with reduced thioredoxin (Trx) or glutaredoxin (Grx), which acts as a redox 
sensor. Upon oxidative conversion from the dithiol to disulfide form, Trx or Grx dissociates 
from ASK1, thus permitting its activation and hence activation of downstream MAPKs [389-
390]. JNK and p38 are activated primarily by environmental stresses such as UV light [391], 
heat shock [392], osmotic stress [393], hypoxia/anoxia [394] and other cellular stress [392], 
and participate in cell apoptosis in response to those insults [395]. Nonetheless, the role of 
each MAPK in cell death is dependent on the cell type and on the physiological context [385]. 
 
Reactive oxygen species induced by PDT have been shown to efficiently trigger a variety of 
cellular signaling pathways. The activation of MAPKs by PDT has been showed in different 
cell models using several photosensitizers [396]. While exposure of different types of cancer 
cell lines to PDT generally results in the activation of the stress-activated protein kinases 
JNKs and p38 MAPK, it usually causes inhibition or only transient activation of the ERKs. 
The activation patterns and functions of the MAPK after photochemical treatment are, 
however, strongly dependent of the cell type, photosensitizer, its cellular localization, and the 
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a) Role of epidermal growth factor receptor/ ERKs / AKT 
 
One of the well-characterized MAPK signaling cascades is the pathway that induces 
mitogenesis upon stimulation by growth factors. The epidermal growth factor receptor 
(EGFR) is a tyrosine kinase involved in the initiation and progression of various cancers 
especially within their proliferative, angiogenic, invasive, and metastatic aspects [320]. The 
binding of growth factor to the receptor tyrosine kinase sequentially activates Ras and Raf. 
Raf then phosphorylates MEK, which in turn activates ERKs [385]. Activation of ERK has a 
critical role in cell proliferation and survival in many cell types. Blocking of the ERK pathway 
using dominant-negative mutants of ERK or using the MEK inhibitor PD98059 has been 
shown to abolish cell proliferation [397], enhance cell sensitivity to cisplatin treatment [398], 
and increase cytosine arabinoside-induced apoptosis [399]. Photodynamic therapy has been 
shown to exert an effect on EGFR and ERK phosphorylation. Hypericin-PDT of membrane 
fractions irreversibly inhibits phosphorylation of the EGFR, as well as the insulin receptor 
[400]. Similarly, there is an increased down-regulation of protein expression and 
phosphorylation of EGFR, after PDT which induces apoptosis causing a tumor regression 
state in metastases [401]. The true relevance of these findings on apoptosis induction must 
still be assessed because many non specific events might also take part in cell death at 
these high PDT doses. A downstream event in the mitogenic pathway is the activation of 
ERK, member of the MAPK family of kinases. It has been found that after PDT treatment of 
cells, ERK’s expression is significantly decreased in relation to increased cell death [402]. 
Using hypericin as photosensitizer in various cell lines, Assefa et al. [403] showed an 
irreversible inhibition of EGF-induced ERK-2 activation with no direct relationship with 
cytotoxicity. On the contrary, in other studies it was shown that PDT has no influence on this 
member of the MAPK family. In this regard, Tao et al. [404] showed that in PAM212 cells, 
ERK activity is insensitive to BDP- PDT. A similar absence of effect on ERK-activation has 
been observed with 5-ALA based PDT in HaCaT cells [405]. Also  
Pc 4 - PDT in mouse lymphoma L5178Y-R cells and in CHO cells [406] did not induce ERK 
activation. Moreover, other recent studies shed new light on the effect of the duration of the 
ERK activation in the negative regulation of apoptosis. ERK activation following Photofrin-
mediated PDT was functionally associated with survival of the PDT-resistant LFS087 cells, 
whereas ERK activation in the PDT-sensitive GM38A cells was found to be poor and very 
transient [407]. Hence, a rapid down-modulation of the ERK pathway which is observed with 
some photosensitizers may be implicated with the induction of apoptosis in photosensitized 
cells. 
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AKT is another important cell survival signal transducer that exerts its anti-apoptotic effects in 
a variety of ways, including phosphorylation of Bad, a pro-apoptotic protein, and inhibition of 
caspase-9. The phosphorylated Bad then associates with protein β−14.3.3, which sequesters 
Bad from Bcl-xL, thereby preventing cell death. An alternative mechanism whereby AKT 
promotes survival is through phosphorylation and activation of IκB kinase. The latter induces 
IκB degradation allowing NF-κB to enter the nucleus and to activate the transcription of anti-
apoptotic genes [408]. In turn, proteins activated by phosphorylated AKT promote cell 
survival [409-410]. A few studies have shown that oxidative stress stimulates AKT 
phosphorylation. Singlet oxygen generated by Rose Bengal elicited AKT phosphorylation in 
mouse NIH 3T3 fibroblasts [409]. Bozkulak et al. also found that Photofrin-mediated PDT 
induced strong AKT phosphorylation while the PI3-K inhibitors blocked this response [411]. 
 
b) Role of p38 / JNK 
 
Under similar conditions as those used for the study of the ERK pathway, PDT was able to 
activate the SAPK/JNK pathway, as well as the p38/HOG1 protein [405-406]. Activation of 
JNK and p38 MAPK, but not of ERK1 and ERK2, was observed for murine Pas 212 
keratinocytes in response to the oxidative stress produced by photoactivation of 
benzoporphyrin derivative, at near cytotoxic levels [404]. Similar findings were reported for 
human HaCaT keratinocytes and for the hypopharyngeal carcinoma FaDu subjected to ALA-
PDT [412], and in human adenocarcinoma HeLa cells treated with low hypericin-PDT doses 
[370, 406]. When this mode of sensitization was used, an increase in the phosphorylation 
(activity) of p38 MAPK was also observed in the human melanoma cell lines Bro and SkMel-
23 [405]. Photoactivation of Pc 4 also increased the activity of JNK in murine LY-R leukemic 
lymphoblasts and CHO cells, whereas the activity of p38 MAPK was stimulated only in CHO 
cells. Simultaneously, a reduction in the phosphorylation of ERK2 was observed in CHO 
cells, but not in LY-R leukemic lymphoblasts [406]. In different models it has been shown that 
the SAPK/JNK pathway is involved in apoptosis induction, either via c-jun or via the 
phosphorylation (and thereby inactivation) of the anti-apoptotic Bcl-2 [413]. Taken together 
the results suggest that the role of MAPKs in PDT may depend on the cell type, the 
photosensitizer used and/or the light dose used. Recently, JNK activation, after 
pheophorbide-a based PDT, was shown to have an inhibitory effect on multidrug resistance 
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c) Role of cell line and/or photosensitizer 
 
As previously referred to, the available evidence suggests that the effect of PDT on the 
activity of MAPKs depend on the cell line and/or photosensitizer used. Tong et al. [407] 
compared the effect of Photofrin mediated PDT on the activation of MAPKs in immortalized  
Li–Fraumeni syndrome (LFS087) cells and in a normal human fibroblast cell line (GM38A). 
Immortalized Li–Fraumeni syndrome cells are more resistant to Photofrin-mediated PDT than 
normal human fibroblasts. They also showed a sustained activation of JNK1, p38 and 
ERK1/2 [415]. In contrast, photosensitization of the normal human fibroblast cell line GM38A 
induced a transient activation of the three MAPKs, followed by the reduction in ERK1/2 
phosphorylation after the initial peak. The reduction of ERK1/2 phosphorylation was 
correlated with an up-regulation of mitogen-activated protein kinase phosphatase 1 (MKP-1) 
which dephosphorylates ERK1/2 [407]. The sustained activation of ERK1/2 in the LFS087 
cell line is suggested to result from the low expression of MKP-1. Inhibition of ERK1/2 
phosphorylation with PD098059 increased the sensitivity of LFS087 cells to Photofrin-
mediated PDT, suggesting that this pathway protects the cells from cell death [407]. In 
contrast, blocking the p38 MAPK in LFS087 cells or in human adenocarcinoma HeLa cells 
had no effect on cell survival following Photofrin-mediated PDT [415]. 
 
Hypericin is probably the best characterized photosensitizer in terms of its effects on MAPK 
activity and the role of MAPKs in cell death. Photoactivated hypericin stimulated JNK and 
p38 MAPK activities and it produced an irreversible inhibition of the activity of ERK2 in A431 
(human epidermoid carcinoma cells), human HaCaT keratinocytes, murine L929 fibroblasts 
and human adenocarcinoma HeLa cells [396]. The effect of photosensitization with hypericin 
on the activity of stress-activated kinases in human HaCaT keratinocytes was not affected by 
pretreatment with the antioxidant, N-acetylcysteine, [396], in contrast with the role of reactive 
oxygen species in the activation of JNK1 and p38 MAPK in photosensitized murine 
keratinocytes [404]. The biological functions associated with PDT-induced activation of 
MAPKs are thus controversial and complex [406].  
 
2.2.3.2  ROLE OF LIPID METABOLISM IN PDT 
 
Singlet oxygen and other ROS are powerful oxidants that can react with many biomolecules. 
These include unsaturated triacyl glycerols, cholesterol and phospholipids. Programmed cell 
death has been induced by a variety of oxidizing conditions, including H2O2 treatment [416], 
ionizing radiation [417], UVA radiation [418], and dye/visible light treatment [419]. Various 
studies have implicated lipid peroxidation in oxidant-induced programmed cell death by 
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showing, for example, that DNA laddering is inhibited by phenolic antioxidants [416]. Other 
studies have also shown that both exogenous and endogenous peroxides can trigger 
leukemia cell apoptosis. Similar results were obtained when HL-60 cells were 
photodynamically challenged using either Photofrin or aluminum phthalocyanine disulfonate 
as photosensitizer [419].  
 
The extent of peroxidative injury in a photodynamically stressed cell may determine whether 
it ultimately survives or dies by apoptosis or necrosis [420]. This can be considered as a 
graded pattern of responses to membrane damage that increases in the following order: 1) 
no net damage when constitutive antioxidant capacity is sufficient to either prevent or repair 
peroxide lesions; relatively mild oxidative injury, which is sublethal and may trigger the 
induction of antioxidant proteins for increased cytoprotection [421-422]; 2) more extensive 
damage, which triggers apoptosis or autophagy after some undefined threshold has been 
reached, beyond which both constitutive and inducible repair capacity is exceeded; and 3) 
very extensive damage with membrane lysis, which abrogates any type of programmed 
metabolic response and leads to necrosis. In some cases, lipid peroxidation has been 
assigned a specific role in signal transduction based on various lines of evidence. Lipid 
metabolites such as arachidonate and diacylglycerol have been implicated in the 
upregulation of defense strategies against oxidative damage, such as heme oxygenase (HO-
1) [422-423]. Lipid hydroperoxides (LOOHs) are also postulated to play an important role in 
cytoprotective as well as apoptotic signaling associated with the photooxidative stress. 
However, whether fatty-acid LOOHs or phospholipid-LOOH-derived, or by-products of chain 
reactions of lipid peroxidation such as 4-hydroxynonenal are also important still need 
clarification. 
 
Beside inducing lipid peroxidation, PDT also modulates lipid metabolism by activating 
phospholipases. The rapid release of arachidonic acid metabolites has been observed in 
several cases after PDT and may result from the activation of phospholipase A2,  
(a membrane enzyme activated by Ca2+) subsequently leading to either apoptosis or survival 
[424]. Ceramides are other stress-induced secondary messengers that are generated from 
sphingophospholipids (which are part of the cell membrane) by sphingomyelinases. 
Ceramides may acts as secondary signal effectors molecules participating in the regulation 
of diverse cellular processes including apoptosis, cell senescence, cell cycle, and cellular 
differentiation [425]. In some in vitro systems, ceramide levels and apoptosis are both 
increased after PDT treatment. Ceramides have been shown to activate a number of 
enzymes involved in stress signaling cascades including both protein kinases and protein 
phosphatases. [320]. 
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2.2.3.3  ROLE OF INTRACELLULAR CALCIUM HOMEOSTASIS IN PDT 
 
Plasma membrane is one of the critical targets of PDT. Examination of the mechanism of cell 
lysis indicates that oxidative damage of membrane transport proteins induces a rapid 
impairment of ionic homeostasis of Na+, K+, Ca2+, etc., while membrane integrity is still 
retained at this time [426]. As a result, PDT has been shown to raise the levels of total 
intracellular Ca2+ within in vitro cancer cells. This has been associated with cell death, or 
under certain conditions, with cell survival [80]. The calcium chelator BAPTA inhibited the 
release of cytochrome C, caspase-3 activation and apoptotic death of Chinese hamster V79 
cells photosensitized with pheophorbide and of HeLa cells photosensitized with  
2,4,5,7-tetrabromorhodamine indicating that Ca2+ plays a role in PDT-induced apoptosis 
[427]. However, in some cell types it was observed that elevation of the Ca2+ following 
photosensitization promotes cell survival and buffering of the intracellular Ca2+ enhanced cell 
death [428-429]. 
 
The increase in intracellular Ca2+ concentration after PDT treatment occurs via the influx of 
Ca2+ through ion channels, release of Ca2+ stored in the endoplasmic reticulum and 
mitochondria, and/or activation of ion exchange mechanisms [424]. Some of the differences 
between the stores of Ca2+ contributing to the Ca2+ rise may be due to the specificity of the 
photosensitizers, and particularly of their targets within the cells. As an example, 
phthalocyanine photosensitization was shown to cause a rapid depolarization of the plasma 
membrane (in less than 1 min) [426] and activation of phospholipase C [430]. Phospholipase 
C is a membrane bound enzyme that triggers the breakdown of phosphatidylinositol-4,5-
bisphosphate leading to an intracellular release of inositol-1,4,5-trisphosphate (I(1,4,5)P3) 
and consequent mobilization of Ca2+ from intracellular storage sites. Moreover, IP3 in 
synergism with its phosphorylated product, I(1,3,4,5)P4, enhances Ca
2+ influx through 
receptor-operated Ca2+ channels (ROCCs) of the plasma membrane [431]. Membrane 
depolarization induced by PDT also contributes to stimulate the Ca2+ influx through voltage-
operated Ca2+ channels (VOCCs) [426]. The plasma membrane Ca2+-ATPase has a high 
Ca2+ affinity, and it was recently shown to be inactivated in cells undergoing apoptosis due to 
cleavage by caspases [432]. Since the effector caspases are rapidly activated in PDT, the 
inactivation of the plasma membrane Ca2+-ATPases may also contribute to the rise in the 
Ca2+, particularly in regions close to the plasma membrane. 
 
An increase in intra-cytosolic Ca2+ activates a wide variety of cellular responses such as the 
release of arachidonic acid through an activation of phospholipase A2, induction of the 
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protein kinase C dependent generation of superoxide radicals and condensation of chromatin 
around the nucleus. Increased Ca2+ together with the activation of protein kinase C and 
various clotting factors, such as PAF, convertin, Hageman and Christmas factor (Factor IX), 
contribute to the formation of intravascular thrombis. It has been clearly demonstrated that an 
increase in cytosolic Ca2+ stimulates the release of the von Willebrand factor [433], an 
adhesive glycoprotein synthesized by endothelial cells, which mediates the adhesion of 
platelets to the injured vessel walls. Since Ca2+ occupies a central role in 
excitation/contraction coupling in smooth muscle cells by initiating Ca2+-calmodulin-
dependent processes, illumination of blood vessels pretreated with a photosensitizing agent 
produces long-lasting contractions of the affiliated vascular smooth muscle cells [434]. 
Interestingly, these sustained contractions are primarily caused by an increase in the 
permeability of the plasma membrane to Ca2+ and not by an enhanced intracellular release 
or delayed sequestration of Ca2+ [434]. Chelation of extracellular Ca2+ with 
ethylenediaminetetraacetic acid (EDTA) completely inhibits the von Willebrand factor release 
[433] and relaxes the contracted smooth muscle cells within a few minutes [434]. All results 
indicate that extracellular and intracellular release of inorganic ions, such as Ca2+, 
potentiates the cell killing effects of photosensitizing agents. Thus, Ca2+ is an important link 
between many of the pathways activated by PDT and plays a vital role in the effect of PDT. 
 
2.2.3.4  ROLE OF TRANSCRIPTION FACTORS EXPRESSION IN PDT 
 
Transcription factors are proteins which bind to enhancer regions of genes and interact such 
that transcription only occurs from a small group of promoters in any cell [176]. Transcription 
factors act as intracellular messengers between receptor-generated signals and the 
activation-associated changes in gene expression. They often form large transcriptional 
complexes with a variety of other transcription factors and accessory proteins, allowing them 
to participate in gene transcription modulation [320]. 
Activator protein-1 (AP-1) is a family of transcription factors that is activated by a variety of 
physical and chemical stresses. Activator protein-1 is a homo- or heterodimeric protein 
complex, composed of Jun (c-Jun, Jun-B, Jun-D), Fos (c-Fos, Fos-B, Fra-1, Fra-2), Maf  
(c-Maf, MafB, MafA, MafG/F/K and Nrl) and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) –
family proteins. Activation of AP-1 has been demonstrated for a number of tumour cell lines 
and for several photosensitizers [435-436]. Inhibition of protein kinases, with staurosporin, or 
of phospholipase A2, with quinacrine, blocked the induction of c-fos mRNA in RIF-1 cells 
sensitized with Photofrin [435], suggesting that these pathways may participate in the 
signaling mechanisms leading to activation of early response genes contributing to cell 
death. 
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Another transcriptional factor shown to be modulated by PDT is NF-κB. Under resting 
conditions, the transcription factor NF-κB is present in the cytoplasm as homo- or 
heterodimers, formed by association of subunits belonging to a protein family that includes 
p50, p52, p65 (RelA), RelB and c-Rel. These complexes are sequestered in the cytoplasm 
by proteins belonging to the IκB family, including IκBα, IκBβ, IκBε, p100 and p105, inhibitors 
of NF-κB. Stimuli leading to NF-κB activation typically initiate a specific signal transduction 
cascade leading to phosphorylation of IκBs. Once phosphorylated, IκB is selectively 
ubiquitinated and degraded by the 26S proteosome, releasing NF-κB that is then 
translocated to the nucleus where it participates in the transcriptional activation. PDT has 
been shown to induce NF-κB activity in various cell models using different photosensitizers, 
but limited information is available concerning its role [437]. The expression of a dominant 
negative mutant of IκBα increased apoptotic death of HCT-116 cells photosensitized with 
APP, suggesting that NF-κB regulates the expression of gene(s) encoding proteins with an 
anti-apoptotic activity [438]. 
 
2.2.3.5  ROLE OF CYCLIC NUCLEOTIDES IN PDT 
 
Nitric oxide (NO) plays an important role in tumor cell biology since it increases blood flow in 
the tumor, thereby promoting tumor growth and facilitating metastasis [439]. Photodynamic 
therapy induces NO production in the photosensitized tissues. Moreover, subcutaneous 
tumors generating low levels of NO were found to be more sensitive to PDT with Photofrin 
than those containing high levels of NO. The protective mechanism induced by NO was 
mediated by the activation of protein kinase G, and occurred upstream of the caspase-9 
processing [440]. On the other hand, recent results indicate that the generation of NO 
increases the ALA-induced accumulation of protoporphyrin IX and subsequent photo-
damage in cancerous cells by decreasing the levels of mitochondrial iron-containing 
enzymes. Based on the fact that the production of NO in some cancerous cells is elevated, 
NO in the cells may be responsible for the susceptibility to ALA-induced PDT [441]. 
 
Photosensitization of human bladder transitional carcinoma cells (clone T24) with HPD 
induced the intracellular accumulation of cAMP. This rapid and transient increase may be 
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2.2.3.6  ROLE OF CELLULAR ADHESION AND CELL COOPERATIVITY IN PDT 
 
Mammalian cells adhere to the extracellular matrix and to each other through specific 
membrane protein receptors [320]. These are classified into the following groups: selectins, 
cadherins, integrins and immunoglobulin G superfamily, such as intracellular cell adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule- 1 (VCAM-1). These specific 
membrane proteins work as signal transduction receptors triggering intracellular signaling 
pathways that regulate cell behavior, development, tissue inflammation as well as migration 
and penetration into underlying tissues. PDT was shown to induce alterations in the 
attachment of cancer cells to the substratum and between each other [442]. Photofrin PDT 
was shown to cause a dose-dependent decrease of enzymatic cell detachment by 
trypsin/EDTA in human glioma U251n and U87 cells [443]. These changes may be in part 
caused by the damage to adhesion molecules located within the cell membranes as well as 
the modulation of their expression. Several studies have shown that the modulation in 
cellular adhesion induced by PDT is directly correlated with the metastatic potential of cancer 
cells [444]. 
Another relevant aspect resulting from intercellular contact is cell cooperativity. It has been  
shown that cells subjected to PDT communicate [445]. This may be responsible for the 
formation of patches of damaged cells in PDT-treated monolayers. This observation is not 
due to clonal effects, but rather to “rescue” or “killing” factors transmitted between the cells. 
Such cooperativity, which has been demonstrated for a number of tumour cell lines and for 
several photosensitizers, almost certainly play a role for the efficiency of PDT and may 
explain the surprisingly deep necrosis sometimes observed after PDT [446]. 
 
2.2.3.7  ROLE OF CYTOKINE EXPRESSION AND INFLAMMATORY MODULATION IN PDT 
 
PDT of tumors causes a rapid induction of an inflammatory response, characterized by the 
infiltration of leucocytes, mainly neutrophils, into the sensitized tumor. A PDT-induced 
generation of tumour-specific immune cells directed against both strongly and poorly 
immunogenic types of cancer has been reported [447]. PDT was less effective in the cure of 
tumours T-cell-deficient nude mice than in immune competent mice, providing evidence for 
the involvement of changes of the immune system in PDT-mediated tumour clearance [448]. 
PDT can modify the immune response and reduce the severity of experimentally induced 
immune diseases at doses below those that cause skin inflammation or erythema. This might 
result from altering the function of immune and nonimmune cell types [449-450]. Monocytes 
(CD14+), dendritic cells (CD83+) and Langerhans’ cells as well as activated lymphocytes 
bearing the interleukin-2 (IL-2) receptor (CD25) and HLA-DR are selectively sensitized by  
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5-ALA [451], HpD57 and verteporfin [452], whereas non-activated cells remain relatively 
unchanged [452]. In superficial basal cell carcinoma biopsies taken after ALA-PDT, mast 
cells were shown to slightly increase up to 72 h while polymorphonuclear phagocytes 
significantly increased at 4 h but decreased at 24 h. On the contrary, lymphocytes and 
macrophages gradually increased starting at baseline [453]. Photosensitized cells may 
undergo functional changes in receptor expression and in the release of cytokines. PDT with 
ALA was shown to upregulate IL-1α and downregulate the angiogenic IL-8 in 
nasopharyngeal carcinoma cells [454]. An upregulation of IL-6 and a decrease in IL-10 
mRNA levels occurred in murine epidermal tumors treated with PDT and was accompanied 
by a dramatic increase in IL-10 expression in the skin [455]. It has been suggested that IL-6 
has a role in the localized inflammatory effect produced by PDT and may modulate 
antitumour immunity [455].  
PDT with ALA and other photosensitizers [456] of antigen presenting cells inhibit the 
immunologically mediated contact hypersensitivity response to topically applied haptens 
such as dinitrofluorobenzene. CHS response was also suppressed when the hapten was 
applied to a non-irradiated site, thereby suggesting a generalized suppression [457]. Finally, 
release of histamine, prostaglandin D2 and the platelet activating factor by mast cells, and 




2.3 CLINICAL APPLICATIONS OF PDT 
 
Once limited to the treatment of superficial skin dysplasias, PDT is now utilized in broader 
applications. Four photosensitizing drugs have been approved in the European Union, the 
USA, Canada and/or Australia for the treatment of various malignancies, including cervical 
cancer, bladder cancer and cancers of the head and neck. Endoscopic light delivery in 
hollow organes has allowed PDT of advanced and early lung cancer, superficial gastric 
cancer and esophageal cancer. PDT has also benefited from technological advances in fiber 
optics, which allows precise interstitial light delivery to almost any internal tumor site in the 
body including large buried tumors in solid organs that would normally require extensive 
surgery for treatment. Now, with the appropriate optical technology, the expanded utility of 
PDT as a viable, broad-application treatment option for multiple types of localized 
malignancies and pre-malignant diseases largely depends upon improvement of the 
biological properties of the photosensitizers employed. 
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In this context, we have published two review articles (Annex II and III) in which the medical 
applications of PDT are discussed along with general physical principles.  
 
2.3.1 APPROVED DERMATOLOGICAL APPLICATIONS 
 
ALA (Levulan®) and MAL (Metvix®) have been approved by the Food and Drug 
Administration (USA) and by the European Community, respectively, for the photodynamic 
treatment of precancerous lesions [actinic keratosis (AK), Bowen’s disease (BD)], superficial 
(sBCC) and nodular BCC (nBCC) in the skin. In accordance with international guidelines, the 
thickness of the tumour should not exceed 2 mm [100]. Topical PDT is particularly suitable 
for treatment of multiple skin lesions, extensive, often sun-exposed areas with multiple and 
recurring precancerous and cancerous lesions (field cancerization), areas where the 
cosmetic outcome is important, such as the face, neck and hands or where it is difficult to 
achieve a good cosmetic result using cryosurgery or excision surgery [459]. 
Their pharmacokinetic properties have been extensively studied and optimal treatment 
protocols have been defined. Levulan® (200 mg/g ALA) and Metvix® (160 mg/g MAL) are 
applied for 14-18 h and 3 h respectively, i.e. the time point of the highest ratio of porphyrin 
fluorescence depth to tumor depth, under an occlusive and light protecting dressing before 
irradiation with 75 J/cm2 of red light from a high-pressure filtered lamp or 37 J/cm2 of light 
from a diode lamp with an emission peak at 632 nm. Nevertheless, there are now 
publications reporting ALA efficacy when applied for 3 h, as with MAL [460]. 
 
Thin or moderately thick AK’s are treated once. If after 3 months the effect is insufficient, the 
treatment is repeated with a later 3 month follow-up [461]. Hyperkeratotic AK, AK with 
histopathological severe atypia and AK in patients with immunosuppression are treated twice 
with a treatment interval of 1 week [462]. Bowen’s disease and BCC are treated twice with a 
treatment interval of 1 week [459]. Photodynamic therapy can be repeated several times if 
required. Crusts and scales, if any, should be removed with keratolytic agents or curettage 
before applying ALA or MAL cream as the type of curettage may deeply influence results. 
 
2.3.1.1  ACTINIC KERATOSIS 
 
Actinic keratosis (AK) is a UV light–induced lesion of the skin that may progress to invasive 
squamous cell carcinoma. It is by far the most common skin lesion with malignant potential. 
The appropriate treatment of AK is generally chosen based on the number of lesions present 
and the efficacy of the treatment. Other variables to be consider include persistence of the 
lesions, age of the patient, previous history of skin cancer, and tolerability to the different 
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treatment modalities. Treatment consists in surgical destruction of the lesion or drug 
therapies, such as topical PDT, topical 5-fluorouracil (5-FU), 5% imiquimod cream and 
topical diclofenac gel. PDT has the advantage of allowing the treatment of large areas with 
many clinical and yet sub-clinical lesions. 
Several randomized studies described clearance rates of 69-86% and 87-91% following a 
single treatment with PDT or two treatments 7 days apart, respectively. No significant 
difference in efficacy was evident on randomized comparison ⁄control studies between PDT 
and 5-fluorouracil (5-FU) and cryotherapy. Significant superiority of cosmetic response was 
observed when comparing PDT with cryotherapy [463]. Thus, topical PDT is an effective 
therapy for thin and moderate thickness AK with a relatively poorer efficacy for acral lesions. 
A new stable nanoemulsion-based ALA formulation (BF-200 ALA) is currently in clinical 
development for PDT of AK. The efficacy and safety of PDT in the treatment of AK with  
BF-200 ALA have been evaluated indicating complete lesion clearance rates of 94,6% [146]. 
 
2.3.1.2  BOWEN’S DISEASE 
 
Bowen disease is a squamous cell carcinoma (SCC) in situ with the potential for significant 
lateral spread. Topical PDT clears, on average, 86–93% of lesions of BD following one or 
two treatments. Topical MAL-PDT has recently been compared with cryotherapy or 5-FU in a 
multicentre randomized controlled trial (MAL 3 h, 570–670 nm, 75 J/cm2, 70–200 mW/cm2) 
[464]. Three months after last treatment, clearance rates were similar following MAL-PDT 
(86%), cryotherapy (82%) and 5-FU (83%). PDT gave superior cosmetic results compared 
with cryotherapy and 5-FU. After 24 months of follow up, 68% of lesions remained clear 
following PDT, 60% after cryotherapy and 59% after 5-FU. Topical PDT has been reported to 
be of particular interest in the treatment of BD in unusual sites (nipple, subungual) [465-466] 
and where it arises in a setting of poor healing (lower leg, epidermolysis bullosa and radiation 
dermatitis) [467-469]. It has further been shown to offer therapeutic benefit in erythroplasia of 
Queyrat [470].  
In conclusion, topical PDT is an effective therapy for BD, with equivalence to cryotherapy and 
equivalence or superiority to topical 5-FU. Cosmetic outcome is superior to standard therapy. 
Topical PDT offers particular advantages for large ⁄multiple patch disease and for lesions at 
poor healing sites. Overall, the studies on the use of ALA and MAL-PDT for the treatment of 
Bowen’s disease have shown that PDT is at least as effective as cryotherapy and perhaps 
superior to 5-FU in overall clearance and response, with fewer side-effects and greater tissue 
sparing. 
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When primary cutaneous invasive SCC is considered, there is limited data on the efficacy of 
topical PDT. Clearance rates for superficial lesions of 54–100% have been observed 
following ALA and MAL-PDT but with recurrence rates ranging from 0% to 69% and reduced 
efficacy for the few nodular lesions treated [278]. The low efficacy of PDT on primary 
cutaneous invasive SCC is related to the limited depth of the therapeutic effect. In view of its 
metastatic potential, topical PDT cannot currently be recommended for the treatment of 
invasive SCC. 
 
2.3.1.3 BASAL CELL CARCINOMA 
 
Basal cell carcinoma (BCC) is the most common malignancy in humans. BCC is usually 
slowly growing, rarely metastasizes and has an excellent prognosis when properly treated. 
There are several clinical and histological subtypes, the two most frequent being the nodular 
and superficial BCC. Excisional surgery is conventionally regarded as the treatment of choice 
for BCC. Although effective, the cosmetic result following treatment is highly dependent on 
the anatomic site, lesion size, reconstruction method, and surgeon’s expertise. BCCs being 
partial to head and neck need a high degree of cosmetic outcome in the therapy chosen for 
it.  
Superficial BCCs have been reported to respond well to ALA-PDT with a clearance rate of 
87%, compared with 53% for nodular lesions [278]. For nodular BCC, prior debulking 
curettage achieved a clearance rate of 92% compared with 0% in the control groups 
(curettage or PDT alone) [471]. Further attempts to increase the response rate of BCC - 
particularly of nodular lesions - have been performed using the more lipophilic MAL. A 5-year 
randomized trial compared clearance rates and cosmetic outcomes between a single session 
of MAL-PDT (MAL 3 h, 570–670 nm, 75 J/cm2, 70–200 mW/cm2) and double freeze-thaw 
cryotherapy in sBCC. Patients with partial response at 3 months were given 2 further MAL-
PDT sessions or cryotherapy was repeated. Complete clinical response rates after 3 months’ 
follow-up were 97% and 95% for for MAL-PDT and cryotherapy, respectively. The difference 
between these two treatments was not statistically significant. After 5 years’ follow-up, 
clearance rates were similar for MAL-PDT (75%) and cryotherapy (74%). A superior 
cosmetic outcome was judged following PDT (87% vs. 49%) [472]. Recently, double MAL-
PDT treatment cycles for ‘difficult-to-treat’ sBCC (large-sized lesions and/or those occurring 
on the mid-face or ears) were also reported. A single cycle of MAL-PDT (MAL 3h, 75J/cm2, 
570-670nm, 50-200mW/cm2) involving 2 treatment sessions 1 week apart was performed. 
After a 3 months follow-up, a second cycle was performed for partially treated lesions. The 
complete clearance at 3 months was 85% for sBCC. After 2 years, the recurrence rate was 
22% for sBCC. Ninety-four percent of patients were assessed to have a good to excellent 
Chapter 2 Bibliographic Synthesis 
110 
cosmetic outcome [473]. Another study with the same protocol examined efficacy, safety, 
and cosmetic outcomes in BCCs that were ‘difficult-to-treat’ and at high risk for surgical 
complications. After 3 months’ follow-up, lesion complete response rate was 89% (93% 
sBCC and 82% nBCC). Fifteen percent of lesions had histologically confirmed recurrence 
within 2 years increasing to 20% within 4 years [474]. 
Other similar multicentre studies have focused on the PDT efficacy on nodular BCC 
treatment. Patients with nodular BCC received two sessions of either MAL-PDT or placebo 
cream plus light exposure in a randomized, double-blind controlled study. Before MAL 
application, lesions were surgically debulked. The overall complete response rates were 73% 
for MAL-PDT and 21% for placebo after 6 months [475]. MAL-PDT for nBCC was further 
compared with surgical excision. In patients with nBCC, two treatment sessions with MAL-
PDT a week apart or surgical excision had similar overall cure rates after 3 months (91% vs. 
98%). After 24 months, the recurrence rates were higher (10%) for MAL-PDT than for 
surgery (2%). The cosmetic outcome was good to excellent in 85% of the patients receiving 
MAL-PDT vs. 33% with surgery [473].  
Based on these reports the British Photodermatology Group has recently concluded that 
topical ALA and MAL-PDT is effective for sBCC. Topical MAL–PDT is effective in nodular 
BCC, although with a lower efficacy than excision surgery, It may thus be considered in 
situations where surgery may be suboptimal. Gorlin’s syndrome is a rare disease in which 
patients are prone to develop several lesions of BCC. Although the number of patients is 
small, PDT may be useful to treat patients with this disease as it leads to excellent healing 
and lack of scarring. 
 
2.3.2 OFF-LABEL APPLICATIONS OF PDT WITH ALA OR MAL 
 
The use of MAL or ALA in the photodynamic treatment of skin malignancies other than AK, 
BD and BCC, as well as for various infectious and inflammatory skin diseases, has been 
reported although they have not been approved by regulatory health authorities in Europe 
and USA. 
 
2.3.2.1  CUTANEOUS T-CELL LYMPHOMA 
 
Cutaneous T-cell lymphomas (CTCLs) are the largest group of cutaneous lymphomas, 
representing 65% of all cutaneous lymphomas. The goal of CTCL treatment is to induce 
remission, as there is currently no cure for this group of lymphomas. In the absence of 
remission, the goal is to reduce the tumor burden to some extent without compromising the 
already decreased immunity of the patient. Several palliative therapies have been used, with 
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variable efficacy rates. The choice of treatment depends on the stage of the disease, and the 
selected regimen must take into consideration toxicity, patient tolerance, and compliance, as 
well as potential benefits. 
Several case reports and case series utilizing topical ALA-PDT and MAL-PDT for early stage 
CTCL have been published with multiple treatments usually being required for clearance 
[278]. Shanler et al. treated patch/plaque-stage cutaneous T-cell lymphoma with promising 
results and showed that protoporphyrin IX accumulated within lymphocytic infiltrates. 
Boehncke et al. using an argon laser at 630 nm showed inhibition of proliferation of 
malignant transformed T cells in vitro and in vivo. Wolf et al. have demonstrated the efficacy 
of PDT (20% 5-ALA) using a broad-spectrum source (40 J/cm2 at 44 mW/cm2) in two patients 
with CTCL who cleared after four and five PDT treatments, respectively. Complete remission 
is reported of four patients with CTCL IA–IIB treated with one to seven topical ALA-PDT 
treatments using an incoherent light source (ALA 6 h, 600–730 nm, 72–144 J/cm2,  
60–120 mW/cm2) [476]. These patients had various histological types including two patients 
with CTCL, one CD30+ anaplastic large cell lymphoma and one CD8+ CTCL. Amman and 
Hunziker reported a poor response for an infiltrated plaque of CTCL to just one PDT 
treatment using an identical regimen suggesting that multiple treatments are required to 
obtain a complete histological response. Another report observed remission in four patients 
with unilesional CTCL and partial response in another following one to nine PDT treatments 
(MAL 3 h, 635 ± 18 nm, 37,5 J/cm2, 86 mW/cm2) [476]. Coors et al. showed a complete 
remission after PDT in patients with therapy-resistant lesions of CTCL. Therefore, PDT can 
have potential role in the treatment of localized CTCL, particularly as an additional treatment 
modality for patients with therapy-resistant lesions of CTCL. 
 
2.3.2.2  INTRAEPITHELIAL NEOPLASIA OF THE VULVA AND ANUS 
 
The use of topical PDT in the treatment of vulval intraepithelial neoplasia (VIN) indicates 
benefit with multiple treatments, with histological grade of VIN as a determinant of response. 
A retrospective review of different modalities for VIN observed a 48% relapse rate following 
PDT, comparable to rates of 42% following local excision and 40% after treatment by laser 
vaporization over 54 months [477]. Topical PDT has also been used to treat intraepithelial 
neoplasia of the anus with high recurrence rates in accordance with other tissue-preserving 
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2.3.2.3 EXTRAMAMMARY PAGET’S DISEASE 
 
The use of topical PDT as monotherapy for extramammary Paget’s disease (EMPD) is 
controversial as reports are mainly in combination with other therapies. However, clearance 
of EMPD lesions with ALA and MAL-PDT has been shown in several case reports [127]. In 
view of limited evidence and high recurrence rates, no recommendations are proposed 
concerning this indication. 
 
2.3.2.4 PHOTODYNAMIC THERAPY FOR INFECTIOUS AND INFLAMMATORY DERMATOSES 
 
The treatment of acne with PDT is based on the fact that Propionibacterium acnes contain 
endogenous porphyrins, in particular coproporphyrin III [479]. Therefore, visible as well as 
blue light phototherapy may be effective. Itoh et al. reported clinical benefit for several 
months after low-dose, single-course ALA-PDT [480]. A statistically significant reduction in 
inflammatory acne lesions after three courses of ALA-PDT performed within 3 weeks was 
also shown. However, no statistically significant reduction in P. acnes was observed. 
Therefore, it has been suggested alternative modes of action other than a mere bactericidal 
effect of ALA-PDT in acne [481]. 
 
Topical ALA and MAL-PDT has also been explored in nononcological indications other than 
acne. There is some limited evidence that inflammatory diseases such as psoriasis, 
sarcoidosis, localized scleroderma, as well as human papillomavirus dermatoses including 
condyloma acuminatum, epidermodysplasia verruciformis and verruca vulgaris may respond 
positively to topical PDT treatment. 
 
2.3.2.5 PHOTODYNAMIC THERAPY FOR SKIN CANCER PROPHYLAXIS AND SKIN REJUVENATION 
 
The use of PDT has also been associated with skin cancer prophylaxis and rejuvenation of 
the skin, namely changes in the signs of photodamage such as improvement in skin 
elasticity. Patients with AK who are also requesting a photorejuvenation process and organ 
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3.1 CHEMICALS AND BIOCHEMICAL REAGENTS 
 
Meso-Tetrasulfonatophenylporphyrin (TPPS4) was supplied by Porphyrin Products (Logan, 
UT). L-Histidine (His), meso-tetraphenylporphyrin (TPP), hematoporphyrin, PPIX, folin 
reagent, 1,1’,3,3’-tetraethoxypropane, thiobarbituric acid, butylated hydroxytoluene 
formaldehyde and protease inhibitor cocktail (P8340) were purchased from Sigma Chemical 
Co. (St Louis, MO). Reagents for cell culture, minimum essential medium with Earle's salts 
(EMEM), Hanks' balanced saline solution containing 20 mM Hepes (HBSS), Dulbecco's 
phosphate-buffered saline (DPBS), all without phenol red, fetal calf serum (FCS), trypsin, 
accutase and antibiotics were also provided by Sigma Chemical Co (St Louis, MO, USA). 1-
Butanol, absolute ethanol, trichloroacetic acid, phosphoric acid, EDTA, ammonium 
phosphate, calcium chloride and sodium dodecyl sulfate (SDS) Triton X100 (TX100), 
toluene, and dimethylsulfoxide (spectroscopic grade solvents) were supplied by Merck 
(Darmstadt, Germany). Neutral Red (NR) was a Fluka (Saint-Quentin Fallavier, France) 
product. LysoTracker Green was obtained from Molecular Probes (Eugene, OR, USA). 
Inhibitors of p38 (SB203580) and JNK (SP600125) were purchased from Calbiochem 
(Darmstadt, Germany). Annexin V-FITC and specific antibodies against caspase-3, caspase-
8, caspase-9 and p62/SQSTM1 were provided by Santa Cruz Biotechnology (Heidelberg, 
Germany) whereas those against total p38, phospho-p38, total JNK, phospho-JNK, total 
AKT, phospho-AKT, total ERK, phospho-ERK were purchased from Cell Signaling (Beverley, 
MA, USA). Mouse anti-cytochrome c antibody was purchased from BD Bioscience (Le Pont 
de Claix, France). Acetyl-Asp-Glu-Val-Asp-AMC (Ac- DEVD-AMC) for caspase-3, acetyl-Ile-
Glu-Thr-Asp-AMC (Ac-IETD-AMC) for caspase-8 and acetyl-Leu-Glu-His-Asp-AMC (Ac-
LEHD-AMC) for caspase-9 were purchased from AnaSpec, Inc (San Jose, CA, USA). All 
other chemicals used in this work were of the purest available grade and were used without 
further purification.  
 
3.2 PORPHYRIN SYNTHESIS 
 
Porphyrin conjugates (P-R) (Figure 1.1) have been synthesized by Professor Cavaleiro’s 
group at the University of Aveiro (Portugal), as described by Tomé et al. [482-483]. The  
500 µM stock solutions were prepared in water:DMSO (1:1 v/v) and stored at 0-4 °C. Since 
P-(Lys)n has no defined molecular weight (depending on the Lys chain polymerization and 
the degree of porphyrin linked) its concentration was determined assuming the same molar 
absorbance of the Soret band in 1% aqueous SDS for the parent porphyrin and the 
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conjugate P-(Lys)n. Taking into account the weighed material and the spectrophotometrically 
determined concentration it is found that the degree of polymerization n is about 35. 
 
3.3 BIOCHEMICAL AND PHYSICOCHEMICAL METHODS 
 
3.3.1 Spectroscopic Equipment 
 
UV/vis absorption measurements were performed with either a UVIKON 943 or a Shimadzu 
UV-2101PC spectrometer. Fluorescence spectra were recorded with an SLM Aminco-
Bowman (series 2) (Bioritech, Chamarande, France) equipped with software for emission 
spectra correction. Solutions for fluorescence measurements were prepared with an 
absorbance ≤0.05 at the excitation wavelength (usually 407 nm). Fluorescence quantum 
yields (ΦF) were determined using TPP as a reference (ΦF = 0.12 in toluene). Porphyrin 
fluorescence lifetimes were measured in solutions whose absorbance was ~0.5 using optical 
cells whose light path was 5 mm. Lifetimes were determined with a Horiba-Jobin Yvon 
NanoLed single photon counting system using 200 ps laser pulses excitation at 373 nm and 
monitoring emission at 654 nm. The IBH software library provided the emission decay 
analyses. 
 
3.3.2 Laser Flash Spectroscopy  
 
3.3.2.1  NANOSECOND LASER FLASH SPECTROSCOPY 
 
The nanosecond-laser flash spectroscopy equipment with photoelectric detection as built at 
the Institute of Technology of the Polytechnic University of Valence (Spain) is schematically 
shown on Figure 3.1.  
 
Figure 3.1 Scheme of the nanosecond laser flash set-up. 
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The analyzing light is constituted by a pulsed Lo255 Oriel xenon lamp emitting a quasi-
stationary light fluence over about one millisecond. After focusing, the beam passes through 
the optical quartz cell (1 cm light-path) containing the solution of the photosensitizer at right 
angle to the path of the exciting laser pulsed beam. The third harmonic of a pulsed Nd: YAG 
SL404G-10 Spectrum Laser Systems is used for excitation at 355 nm. The single pulses 
have a ~10 ns duration (the approximate detection limit for the timescale) and the energy is ~ 
10 mJ/pulse. The absorbance of the P-R samples was ~0.4 - 0.5 at the exciting laser 
wavelength. The short laser pulse results in the formation of transient species. At the output 
of the optical cell, the analyzing light is then focused on the entrance slit. The optical 
detection is achieved with an Oriel monochromator. The transmission of the sample before, 
during and after the laser pulse is thus measured by the photomultiplier which converts light 
into electrical signals which are acquired by a TDS-640A Tektronix oscilloscope. The output 
signal from the digital oscilloscope is transferred to a personal computer. Data are converted 
into absorbance and analyses are performed with the Kaleidagraph software. 
 
3.3.2.2 FEMTOSECOND LASER FLASH SPECTROSCOPY 
 
While nanosecond laser flash spectroscopy deals with the study of triplet states in the µs 
time scale, the study of the photophysics of upper excited singlet states in tenths of 
picoseconds when no significant triplet state formation has taken place requires special 
equipment. While the basic principles are the same as those of nanospectroscopy, lenses 
are replaced by semi-transparent mirrors allowing the fine tuning of optical paths. Thus, the 
time delay between excitation and analysis is defined by the time of flight of the photons 
(velocity: 3x 108 m/s) and geometry. We performed the femtosecond transient absorbance 
measurements at the Radiation Laboratory of the University of Notre Dame (Indiana, USA) 
using a Clark 6MXR 2010 laser system transient and an optical detection system provided by 
Ultrafast Systems (Helios). The source for the pump and probe pulses is the fundamental of 
the Clark laser system (775 nm, 1 mJ/pulse, FWHM = 130 fs, 1 kHz repetition rate). A 
second harmonic generator is introduced into the path of the laser beam to provide 387 nm 
(3.20 eV, 130 fs) laser pulses for the pump (excitation wavelength of the porphyrin solutions). 
5% of the fundamental is diverted through a sapphire crystal whose dielectric properties 
allow creating a white light continuum. Before creating the white light probe, the fundamental 
is fed through a delay providing the experimental time window of 1.6 ns with a maximum step 
resolution of 7fs. The energy of the pump beam (2 mm diameter) is 5 µJ/pulse on the sample 
cell (2 mm light path, absorbance of the porphyrin solution: 0.3) where it merged with the 
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analyzing white light with an angle < 10°. Thus in contrast to nanosecond laser flash 
spectroscopy, the analyzing and excitation beams are nearly co-linear. It should be noted 
that these experimental conditions ensure that no stimulated emission is produced (see 
supporting information in article of Chapter 4). After passing through the cell, the white light is 
focused on a 200 µm core fiber connected to a CCD spectrograph enabling time-resolved 
spectra recording in the range 425 - 800 nm. Usually, 5000 excitation pulses are averaged to 
obtain the transient spectrum at a set delay time. Kinetics at appropriate wavelengths are 
obtained from the time resolved spectra.The 3D data are analyzed with the surface Xplorer 
lite software [484]. 
 
3.3.3 Measurement of Histidine degradation photosensitized by porphyrins under 
steady state irradiation.  
 
The yield of singlet oxygen production by P-R under steady state irradiation was measured 
using histidine (His) as a specific type II photodynamic substrate [485]. Dioxygen-saturated 
10 mM phosphate buffer solutions (pH 7.0) containing 500 µM His and 5 µM TPPS4 (see 
below) or the porphyrin under study were irradiated with increasing light doses at 365 nm 
delivered by a filtered high-pressure mercury lamp [485]. Irradiations were performed in a 1 × 
1 cm cuvette (2.5 mL). Histidine destruction was monitored by HPLC using a Whatman 
Partisil 10/25 SCX cation exchange column and 15 mM NH4H2PO4 whose pH was adjusted 
to 2.3 by addition of phosphoric acid as a mobile phase. The TPPS4 was used as a 
reference photosensitizer producing singlet oxygen with a quantum yield of ~0.5. Chemical 
actinometry based on the photoreduction of ferrioxalate by the UV radiation was carried out 
according to Parker [486]. 
 
3.4 CELLULAR BIOLOGY METHODS 
 
3.4.1 Cell line 
 
We used in our study an immortalized NCTC 2544 human skin keratinocyte cell line 
purchased from ICN Flow (Fontenay sous Bois, France).  
 
3.4.2 Cell line maintenance 
 
The NCTC 2544 human skin keratinocytes are adherent cells which grow up to form 
monolayers after inoculation. A constant number of cells is reach at confluence as a result of 
contact cell cycle arrest. NCTC 2544 human skin keratinocytes are cultured, with passages 
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once a week (1:10 splitting ratio), at 37 ºC in a humidified sterile atmosphere with 95% air 
and 5% CO2, using EMEM supplemented with 10% FCS, 100 U/mL penicillin and 100 µg/mL 
streptomycin without other additives. Just before reaching confluence, cells are washed twice 
with 10 ml of DPBS. Then, two ml of a solution of 0.05% trypsin containing 0.02% EDTA are 
added to culture flasks for 5 minutes at 37 ºC to detach adherent cells. As soon as cells are 
in suspension, trypsin is inhibited by adding 2 ml of 10% FCS-supplemented EMEM. The cell 
suspension is then divided into 10 culture flasks containing culture medium. Culture flasks 
are finally placed with loosened caps in an incubator at 37 ºC with a humidified sterile 
atmosphere with 95% air and 5% CO2. NCTC 2544 human skin keratinocytes have a 
doubling time of about 1.5 days and there are approximately 1.5 x 107 cells per 75 cm2 
culture flask at the moment of culture division.  
Stock samples of NCTC 2544 human skin keratinocytes are kept frozen in EMEM with 10% 
DMSO. CryoTubes are filled with the cellular suspensions and placed in a cell Cryo Freezing 
Container slowly frozen to -80 ºC at a cooling rate of -1 ºC/min for successful cell 
cryopreservation. Frozen cells are rapidly transferred to a liquid nitrogen container  
(-196 ºC) and stored. To maximize recovery of the cells when thawing, the cells are warmed 
very quickly by placing the tube directly from the liquid nitrogen container into a 37°C water 
bath with moderate shaking. As soon as the last ice crystal melts, the cells are immediately 
diluted into prewarmed 10% FCS supplemented EMEM. 
 
3.4.3 Cell treatment 
 
With the exception of fluorescence microscopy experiments, cells from trypsinized confluent 
monolayers were seeded in 35 mm diameter plastic Petri dishes at a density of about 8,000 
cells/cm2 (2.5 mL at about 30,000 cells/mL in EMEM supplemented with FCS) and were 
grown for 4 days reaching 60-80% of confluency. For fluorescence microscopy, cells were 
seeded on 30 mm diameter and 0.15 mm thick coverglass at a density of about 1,700 
cells/cm2 (2.5 mL at about 5,000 cells/mL) and were grown for 4 days. 
 
The incubations were carried out with 1 ml of P-R at various concentrations and for various 
times in either HBSS or 10% FCS-supplemented EMEM, respectively for short (up to 3 h) or 
long incubations (up to 18h). In the case of endogenous PPIX synthesis, incubations were 
performed with 1ml of 0.2 to 0.8 mM ALA for 18 h in 10% FCS supplemented EMEM. After 








Cell monolayers were washed thoroughly with HBSS to remove any trace of photosensitizer. 
After washing, cells were covered with 1mL of HBSS without photosensitizer. Petri dishes 
were then irradiated with a broad band red light provided by a custom-built table consisting of 
two 300 watt tungsten- halogen lamps whose light was filtered with Balzers Y54 and Calflex 
3000 optical filters [487]. Petri dishes were placed on a 30 x 25 cm thermostated (37 °C) 
glass table above the lamps. The present system allows the simultaneous irradiation of 15 
Petri dishes (35 mm). During the irradiation period, control Petri dishes are kept in the dark 
under the same conditions as the irradiated cells. 
Under these conditions, most of the light originates from wavelengths in the range  
500 - 750 nm as determined with a CS 1000A Minolta spectroradiometer. The absolute 
calibration has been performed by chemical actinometry using the photodynamic degradation 
of 50 µM His by 20 µM hematoporphyrin in air saturated 50 mM phosphate buffer (pH 7.3). 
The quantum yield of His degradation is first measured under irradiation with 365 nm 
monochromatic light delivered by a filtered high-pressure mercury lamp as described above 
(section 3.3.3) [485]. Then, the His degradation is performed with red light. The relative 
absorbed light is equal to S∫(∫Iλ(1-10
-Absλ )dλ)dt, where S is the surface of the Petri dish, Absλ 
the optical density at the wavelength λ and Iλ the relative light intensity at the wavelength λ, 
obtained from the radiometer. It is thus possible to calculate the absolute spectral distribution 
assuming that the His degradation quantum yield in the red range is similar to that at 365 nm. 
Presently, the integration over the wavelength range yields a light intensity of  
5.0 × 1016 photon s−1 cm−2 corresponding to 15.2 mW cm−2.  
 
3.4.5 Cellular protein measurement 
 
The protein concentration of cell extracts has been determined using the Lowry protocol. The 
“Lowry assay: Protein by Folin Reaction” [488] has been used to estimate the amount of 
proteins in biological samples. Under alkaline conditions the divalent copper (Cu2+) ion forms 
a complex with peptide bonds in which it is reduced to a monovalent ion (Cu+). Cu+ and the 
radicals of tyrosine (Tyr), tryptophan (Trp), and cysteine (Cys) react with the Folin reagent, a 
phospho-molybdic-phosphotungstic reagent yielding a blue color. As a result, the total 
concentration of protein in the sample can be deduced from the concentration of Trp, Tyr and 
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Procedure: 
After irradiation or sham irradiation, supernatants are collected. Cells are washed twice with 
1ml of PBS, scrapped off in 400 µl of distilled water. Then, 60 µl of Tx100 (0.5%) are added. 
After homogenization, 150 µl of the homogenate is collected in which are added 100 µl of 
NaOH (0,1 N) and 2 ml of a reagent consisting of 100 mgl-1 of CuSO4.5H2O, 2 g.l
-1 of 
C4H4KNaO6.4H2O and 20 g.l
-1 of Na2CO3. After 15 minutes, 100 µl of Folin reagent is quickly 
added and vortex immediately. The absorbance is measured using a multiwell plate reader at 
750 nm after an incubation of 90 min at room temperature in the dark. Simultaneously, a 
standard curve is obtained using Human Serum Albumin. 
 
3.4.6 Neutral Red uptake assay 
 
The neutral red (NR) assay is based on the initial protocol described by Borenfreund and 
Puerner [489] that determines the active H+ pump-dependent accumulation of the neutral red 
dye in the lysosomes of viable cells [490]. The incorporated dye is then liberated from the 
cells in an acidified ethanol solution. An increase or decrease in the number of cells or their 
physiological state results in a concomitant change in the amount of dye incorporated by the 
cells in the culture. The assessment of photocytotoxicity by the NR uptake assay has been 
validated by the European Union for the testing of phototoxic chemicals and for the 
classification and labelling of hazardous chemical (EU Commission Directive 2000/33/EC).  
 
Procedure: 
A day before the experiments, a stock solution of NR (1.4 x 10-2 mol.l-1) is diluted to 1/80 in 
10% FCS supplemented EMEM. This solution is placed overnight at 37 ºC in the humidified 
sterile atmosphere. The day of the experiment, the RN solution is centrifuged at 3000 g 
during 20 minutes to eliminate microcrystals. Three hours after treatment and/or irradiation, 
the culture medium is discarded by suction. Cell monolayers are then washed twice with PBS 
and 0.5 ml of the RN solution are added to each Petri dish. After 3 hours at 37 ºC in a 
humidified sterile atmosphere with 95% air and 5% CO2 the medium is carefully removed. 
Cells are washed once with 1 ml of PBS and fixed with 0.5 ml of a solution of 0.4% 
formaldehyde and 10% CaCl2. The fixative solution is removed and the incorporated dye is 
then solubilized in 1 ml of elution solution (acetic acid 19% and ethanol 50% (v/v) followed by 
gentle shaking for 10 min so that complete cell dissolution is achieved. Aliquots of the 
resulting solutions are transferred to 96-well plates (330 µl per well) and absorbance at 550 
nm is recorded using a multiwell plate reader. The experiment is done in triplicate. Each test 
includes 3 blanks containing complete medium without cells to determine the background 
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absorbance. Results are analyzed and presented as percentage of control values. The 
average absorbance of untreated and un-irradiated cells is taken as 100% viability. The 
viability percentage after the various treatments is expressed taking this value as a 
reference.  
 
3.4.7 Thiobarbituric acid reactive substances (TBARS) assay 
 
The measurement of Thiobarbituric Acid Reactive Substances (TBARS) is a indirect method 
for screening and monitoring lipid peroxidation in vitro. Decomposition of the unstable 
peroxides derived from polyunsaturated fatty acids results in the formation of 
malondialdehyde (MDA), which can be quantified colorimetrically or fluorimetrically following 
its reaction with thiobarbituric acid under high temperature and acidic medium [491]. 
 
Procedure: 
Immediately after irradiation or sham irradiation, 900 µl of supernatants are collected. After 
adding 90 µL of butylated hydroxytoluene (2% w/w in ethanol), samples are kept at -20 ºC in 
the dark until the day of the TBARS assay. A negative control is prepared with 900 µl of 
HBSS which are treated in the same way as the cell samples. Cells are scrapped on the 
remaining 100  µl of supernatants and collected for protein determination. The day of the 
TBARS assay, samples are defrosted and, again, 90 µL of butylated hydroxytoluene (2% 
w/w in ethanol) are added. One ml of the TBA reagent (TBA 0.375% (w/v) and TCA 15% 
(w/v) in hydrochloric acid 0.25 N) is, then, added to each sample. After incubation at 80 ºC 
for 15 min, sample solutions are placed on ice. Then, one ml of 1-butanol is added and the 
mixture is vigorously vortexed. The upper butanol phase is collected and centrifuged at 
10000 rpm for 5 min. Finally, fluorescence intensity is measured (excitation = 515 nm, 
emission = 550 nm). TBARS are expressed as malondialdehyde equivalents using  
1,1,3,3-tetraethoxypropane, a precursor of MDA, as a reference counpound. Results 
normalized to the sample protein content (pmol of MDA/mg of protein) are means ±SD of 3 
experiments done in triplicate. 
 
3.4.8 Fluorescence microscopy equipment for study of photosensitizer localization 
 
Fluorescence microscopy is based on the phenomenon that certain cell components emit 
light of longer wavelengths upon irradiation with light of shorter wavelength. The cell 
fluorescence may arise from endogenous cell constituents (NAD(P)H, oxidized flavins, 
porphyrins....). Alternatively, the cell can become fluorescent after treatment with fluorescing 
chemicals. The basic task of the fluorescence microscope is to record the fluorescence 
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emission using a series of optical filters to make up the fluorescence image under excitation 
of cells with light of appropriate wavelength. 
 
Procedure: 
For fluorescence microscopy, sub-confluent cells (60-80% confluency) are cultured on  
30 mm diameter and 0.15 mm thick coverglass. After incubation with 1 ml of P-R for 3 h in 
10% FCS-supplemented EMEM cells are washed twice with 1 ml of PBS. Coverslips are 
incorporated into a custom-made open dish-type chamber that is compatible with 
fluorescence microscopy and cells are covered with 500 µl of PBS. Cell microfluorometry is 
then performed using an inverted fluorescence microscope (Nikon Eclipse TE 2000 DV) 
equipped with a CoolSNAPHQ™ detector cooled to – 30°C (Princeton Instruments; Division 
of Roper Scientific, Evry, France). This system is controlled by the Metaview/ Metamorph 
software, which is also used for image analyses. The fluorescence is recorded with a CCD 
camera (1392 × 1040 pixels, 8980 ×6700 µm) through a ×100 oil immersion Phaco 3 Nikon 
objective. A 2 × 2 binning is used to produce 696 × 520 images, corresponding to a field of 
about 110 × 80 µm. Fluorescence is collected through a filter block (UV2A Nikon) consisting 
of a dichroic mirror at 400 nm and an excitation filter in the range 330-380 nm. To record the 
porphyrin red fluorescence, the emission filter of the filter block is replaced by a 645AF75 
filter (~610-700 nm) from Omega Optical (Brattleboro, VT, USA). 
Double labeling experiments have been performed using LysoTracker, a fluorescent 
acidotropic probe for labeling and tracing acidic organelles, such as lysosomes in live cells. 
The LysoTracker dye stock solution is thawed at room temperature and protected from light. 
Dye solutions decompose rapidly if exposed to light. Thawed vials should not be refreezed 
as LysoTracker decomposes during freeze-thaw cycles. Because of the porphyrin red 
fluorescence, Lyso Tracker green is chosen to avoid fluorescence emission overlapping. 
After incubations with 1 ml of solution of 5 µM P-R for 3 h in 10% FCS-supplemented EMEM 
cells are washed twice with 1 ml of PBS. Coverslips are incorporated into a custom-made 
chamber and adherent living cells are covered with 500 µl of PBS. After LysoTracker green 
addition (final concentration of 125 µl), the chamber is immediately shaken to distribute the 
dye evenly and cells are incubated for 15 min at 37 ºC in the dark. A 535AF45 filter  
(~510-565 nm) from Omega Optical is used to record the LysoTracker green fluorescence. 
No porphyrin fluorescence is detected with the green emission filter while negligible 
fluorescence of the LysoTracker Green is recorded with the red emission filter. Background 
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3.4.9 Flow cytometry 
 
Flow cytometry is a means of measuring certain physical characteristics, such as cell shape, 
size, and internal complexity, as well as chemical characteristics of cells or particles as they 
pass in a fluid stream through the use of a beam of laser light. Light scattering or 
fluorescence emission (if the particle is labeled with a fluorochrome) provides information 
about the particle properties. Therefore, the rapid morphological alterations that characterize 
the progression of programmed cell death can be monitored by flow cytometry. Apoptotic and 
necrotic cell death can thus be detected by flow cytometry after annexin V-FITC and 
propidium iodide staining. 
 
Procedure:  
At various times after photosensitization with P-R, adherent cells are washed twice in ice 
cold DPBS and gently detached with 500 µl of accutase. Cells are transferred to 15 mL 
conical tubes and gently washed with 10% FCS supplemented medium by low speed 
centrifugation at 1500 rpm for 5 minutes. Cell pellets are washed once with DPBS and then 
re-suspended in assay buffer (0.1 M HEPES/NaOH, pH 7.4; 140 mM NaCl; 25mM CaCl2) at 
a concentration of 1x106 cells/mL. Annexin V-FITC binding has been assessed using the 
Santa Cruz Biotechnology Apoptosis Kit (Santa Cruz Biotechnology, Heidelberg, Germany) 
according to the manufacturer’s protocol as follows. An aliquot of the detached cell samples 
(100 µl) is transferred to a 5 ml culture tube. Annexin V-FITC (final concentration: 5 µg/mL) 
and propidium iodide (final concentration of 5 µg/mL) are then added. After 15 min of 
incubation in the dark at room temperature, 400 µl of assay buffer are added and cell 
fluorescence is measured in the spectral region 505-545 nm (FL1) for annexin V-FITC and 
610-650 nm (FL3) for propidium iodide with a Cytomics FC 500 flow cytometer (Beckam 
Coulter, Villepinte, France). Data analysis has been performed using the Cytomics Analysis 
software. Untreated cells are analyzed and results displayed on a two-parameter histogram 
(forward-scatter on x-axis versus side-scatter on y-axis). All the living cells are gated while 
dead cells, subcellular debris and clumps are excluded from analysis. These are 
distinguished from single living cells as they have lower forward scatter and higher side 
scatter. Fluorescence compensation is then defined using negative control readings, e.g. no 
annexin V-FITC, no propidium iodide, Annexin V-FITC alone and propidium iodide alone. For 
annexin-FITC and propidium iodide, the spillovers are 7.4% on FL3 and 2.2% on FL1, 
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3.4.10 DNA fragmentation assay 
 
DNA fragmentation has been assessed by determining cytoplasmic accumulation of histone 
associated DNA fragments using an enzyme-linked immunosorbent assay (Roche 
Diagnostics, Mannheim, Germany). This assay is based on the quantitative "sandwich 
enzyme immunoassay" principle using mouse monoclonal antibodies directed against DNA 
and histones. It provides specific determination of mono and oligonucleosomes in the 
cytoplasmic fraction of cell lysates. 
 
Procedure: 
Cells are incubated with P-R and irradiated as described above. Then, at different times after 
irradiation, the cell supernatant is removed and cells are washed twice with ice-cold DPBS. 
Both, adherent and floating cells are lysed with the kit buffer. After 30 min of incubation at 
room temperature, cell lysates are transferred to 2 ml Eppendorf tubes and centrifuged at 
20,000 g for 10 min. The supernatant and cytoplasmic fractions are carefully removed. The 
pellet containing high molecular weight unfragmented DNA is discarded. The protein 
concentration is determined on 5 µl of the cytoplasm fraction using the method of Bradford 
(Bio-Rad Laboratories, Marne-la-Coquette, France). Equal amounts of protein (100 µg) from 
the cytoplasmic fraction are then transferred separately into an anti-histone precoated 
microtiter plate. After 90 min of incubation at room temperature, wells are rinsed 3 times with 
300 µl of washing solution. After careful removal of the washing solution, 100 µl of conjugate 
solution (anti-DNA-peroxidase) are added to each well except for the blank. The conjugation 
solution is incubated for 90 min at room temperature after which each well is rinsed 3 times 
with the washing solution. The amount of peroxidase retained in the immunocomplex is 
determined with ABTS (2,2’-azino-di-[3-ethylbenzthiazoline sulfonate]) as a peroxidase 
substrate. Substrate solution is added and incubated on a plate shaker at 250 rpm until the 
color development is sufficient for photometric analysis (approximately 15 min). The content 
is homogenized by careful tapping of the plate and spectrophotometric determination is 
performed at 450 nm using a 96-microwell plate reader spectrophotometer. The substrate 
solution is used as a blank. Results are the average value of three independent experiments. 
 
3.4.11 Caspase assays 
 
The enzymatic activity of the caspase-3, -8 and -9 classes of proteases in P-R treated and 
irradiated cells has been determined by fluorometric reaction. Cells are first lysed to collect 
their intracellular content. The cell lysate can then be tested for protease activity by the 
addition of caspase-specific peptides that are conjugated to the fluorescent reporter molecule 
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aminomethylcoumarin (AMC). The cleavage of the peptide by caspases releases the 
fluorochrome that emits a fluorescence at 450 nm when excited with 350 nm light. The level 
of caspase enzymatic activity in the cell lysate is directly proportional to the fluorescence 
recorded with a fluorescent microplate reader. 
 
Procedure: 
Caspase activities are measured in cell lysates at various times after irradiation in the 
presence of P-R. To this end, adherent cells in 35mm Petri dishes are lysed in 50 µl of cold 
buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol and 1 mM 
phenylmethylsulfonyl fluoride, supplemented with 10 µg/mL pepstatin, aprotinin and 
leupeptin). After incubation for 10 min on ice, lysates are sonicated and centrifuged at 
14000g for 5 min at 4°C. Supernatants are saved as representative cytosol extracts and kept 
on ice. The protein content of the cell lysates is estimated using the Pierce BCA assay 
(Thermo Fisher Scientific, Cergy Pontoise, France). We have determined that the enzymatic 
reaction for caspase activity is best carried out in a 96 well flat bottom microplate that can be 
read with a microplate reader equipped with fluorescence detection. The specific substrates 
stock solutions are kept as aliquots at -20 ºC. They are thawed at room temperature and 
freshly prepared as a 1:200 dilution in lysis buffer. Aminomethylcoumarin (AMC)-conjugated 
caspase substrates at a final concentration of 20 µM are then added to 40 µg of total cytosol 
protein and incubated for 30 min at 37 °C. The fluorescence of the coumarin dyes is 
measured with a 96-microwell plate reader under excitation at 360 nm and emission at 460 
nm after incubation at 37°C for 90 min. The results are better expressed as the increase in 
caspase activity of apoptotic cells over that of non-induced cells. As the controls (substrate 
but no cell lysate and no substrate but cell lysate) give a substantial reading, these values 
are subtracted from the experimental results before calculating the increase in activity. The 
total reaction volume is kept constant and therefore distilled water is used to replace the 
volume normally occupied by either the cell lysate or the substrate reagent. The specific 
substrates used were: acetyl-Asp-Glu-Val-Asp-AMC (Ac- DEVD-AMC) for caspase-3, acetyl-
Ile-Glu-Thr-Asp-AMC (Ac-IETD-AMC) for caspase-8 and acetyl-Leu-Glu-His-Asp-AMC  
(Ac-LEHD-AMC) for caspase-9. 
 
3.4.12 Immunoblot analysis 
 
Protein blotting is an analytical method that involves the immobilization of proteins on 
membranes before detection using monoclonal antibodies. In immunoblotting, sample 
proteins are separated using SDS polyacrylamide gel electrophoresis (SDS-PAGE) prior to 
protein immobilization on the nitrocellulose membranes. It provides information about 
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Before lysis, cells are washed twice with ice-cold DPBS. Then, they are lysed during 15 min 
at 4°C with 50 µl of RIPA buffer supplemented with 1% of the Sigma P8340 protease inhibitor 
cocktail and sonicated. After centrifugation at 14,000g for 2 min, the supernatants are saved 
as cell lysates and kept on ice. The protein concentration of cell extracts is determined using 
the Pierce BCA assay (Thermo Fisher Scientific, Cergy Pontoise, France). Equal amounts of 
proteins (40 µg) of the cell lysates are separated by 12% SDS – PAGE on a 10 lane cassete. 
After migration, the gel is carefully removed from the electrophoresis apparatus by 
separating the glass plates using a spatula as a lever. The stacking gel including the wells is 
cut off with a scalpel and discarded. The remaining separation gel is placed in a container 
containing transfer buffer. Great care must be taken to fully immerse the gel in the buffer. 
Besides, a nitrocellulose membrane, 2 Scotch Brite pads, 4 paper filters are soaked in a 
container containing the transfer buffer. Paper filters and the nitrocellulose membrane must 
be thoroughly wet. The transfer cassette is opened with the black end placed on the table. 
From the black side (negative electrode) to the red end, the transfer cassette is assembled in 
the following way: Scotch Brite pad - paper filter (Whatman) - gel - nitrocellulose membrane - 
paper filter (Whatman) - Scotch Brite pad. Air bubbles are squeezed out by pouring buffer 
and rolling after each addition. Then, the cassette is closed and placed in the transfer 
apparatus. After filling the transfer chamber with the transfer buffer almost to top, an ice pack 
and a stir bar are added, while the transfer apparatus is placed on a stir plate. Proteins are 
transferred onto nitrocellulose membranes at 140 V during 1 h. The transfer buffer is re-used 
twice. 
After completion of the transfer, the membrane is removed and molecular weight bands 
marked using a ball-point pen. The entire membrane is submerged in Ponceau Red for 2 min 
until the membrane is completely red. The excess staining is then washed with deionized 
water long enough to detect bands. The efficiency of the migration/transfer is thus evaluated.  
After rinsing membranes with deionized water until the bands disappear, the nitrocellulose 
membranes are saturated with 5% skimmed milk in TTBS (25 mM Tris-HCl, pH 8.0,  
125 mm NaCl, 0.05% Tween 20) on a shaker for 1 h at room temperature or overnight at  
4 ºC. The skimmed milk solution is removed and the membranes washed 3 times with TTBS. 
Membranes are then immunoblotted in enough primary antibody solution (1:500 in in 5% 
skim milk in TTBS) to cover them and shaken for 1 h at 37 ºC. After washing 3 times with 
TTBS, primary antibodies are probed with their respective secondary antibody at the 
following dilutions: anti-goat-IgG-HRP (1:5000), anti-rabbit-IgG-HRP (1:5000) or antimouse 
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IgG-HRP (1:5000) for 1 h at room temperature. Secondary antibody solutions are made up in 
5% skimmed milk in TTBS. Membranes are rinsed 3 times with TTBS and immunoblots are 
visualized using an enhanced chemiluminescence detection kit from Amersham (Saclay, 
France). Western blots are scanned and quantified using the software ImageJ (National 
Institutes of Health). 
 
3.4.13 Cytochrome c immunofluorescent staining 
 
Immunofluorescent staining consists of labeling antibodies with a fluorescent dye, allowing 
the labeled antibodies to react with their specific antigen. Then, the reaction product is 
observed under the fluorescence microscope. Several reaction sequences can be 
performed. The direct immunofluorescent staining consists in directly applying solutions of 
antibody labeled with a fluorescent dye (often fluorescein) to preparations containing the 
antigen. The indirect staining is carried out by first treating the preparation containing the 
antigen with an unlabeled specific antiserum. Then, the resulting antigen-antibody complex is 
revealed by treatment with a fluorescent-labeled antibody to the specific antibody. 




Coverslips seeded with semi-confluent cell monolayers are incubated for 3 hours with 5 µM 
P-OGal or for 18 h with 0.8 mM ALA. After two washings with 1 ml of PBS, coverslips are 
irradiated during 15 min. Depending on the protocol, coverslips are processed immediately or 
after addition of 2.5 ml complete culture medium. The Petri dishes are placed at 37 ºC in a 
humidified sterile atmosphere with 95% air and 5% CO2. Then, cells are washed twice with 
DPBS, fixed for 30 min with 4% paraformaldehyde in DPBS (pH 7.4) and permeabilized with 
0.1% TX100. After DPBS washing, cells are incubated with mouse anti-cytochrome c 
antibody (1:200) in a humidified chamber at 37°C for 30 min and then, after another washing 
with DPBS, incubated with Cy3- conjugated mouse anti–mouse antibody (1:100) for 30 min 
at room temperature. After rinsing in blocking buffer, cell nuclei are stained for 5 min with 50 
µl of a 1 µg/ml solution of DAPI. The stained samples are rinsed and mounted in Mowiol 
(Calbiochem). All slides have been examined and photographed using a Nikon Eclipe 
TE2000-U fluorescence microscope equipped with a plan APO VC 60X / 1.40 objective 
under oil immersion. Images have been recorded with a Nikon DXM1200 CCD camera. For 
cytochrome c, the combination of a Nikon G-2A epifluorescence filter block and a Semrock 
Brightline® 617/73 emission filter has been employed, while for DAPI, a Nikon UV2A 
epifluorescence filter block and a Semrock Brightline® 457/50 emission filter has been used. 
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3.4.14 Cell transfection with GFP-LC3 
 
The introduction of nucleic acids into eukaryotic cells by non-viral methods is defined as 
transfection. Several methods obviate the issue of introducing negatively charged molecules 
(e.g., phosphate backbones of DNA and RNA) into cells with a negatively charged plasma 
membrane. Chemicals like cationic lipid-based reagents (e.g. Lipofectamine 2000) coat the 
transfecting DNA thereby neutralizing or even creating an overall positive charge on the 
complex. As a consequence, the DNA transfection reagent complex can cross the 
membrane. Transfection can be either transient or stable. In transient transfection, foreign 
DNA is introduced and later eliminated by the cell prior to or during mitosis. Much more 
rarely, foreign DNA is introduced and enters the cell nucleus, adding to or replacing a portion 
of the cell's native DNA. This type of transfection, called stable transfection, transforms the 
cell so that the modified DNA is duplicated during mitosis. Transfection allows the study of 
gene function and protein expression in cells. Transient cell transfection with the microtubule-
associated-protein-light-chain-3 (LC3) protein tagged at its N-terminus with green fluorescent 




The NCTC 2544 cells were grown on 18 mm coverslips and transiently transfected for 24 h 
with GFP-LC3 kindly provided by Drs. T. Yoshimori and N. Mizshima (Department of 
Bioregulation and Metabolism, The Tokyo Metropolitan Institute of Medical Science, Japan). 
Cells are transfected in the opti-MEM I medium supplemented with Glutamax, both agents 
provided by Gibco-Invitrogen (Cergy Pontoise, France), using Lipofectamine 2000 according 
to the supplier’s protocol (Invitrogen). After 6 h of incubation, the medium is replaced by 
complete medium containing 10% serum and antibiotics. After transfection, cells are 
incubated for 3 hours with 5 µM P-OGal or for 18 h with 0.8 mM ALA and irradiated for  
15 min. At various times after irradiation, cells are fixed with paraformaldehyde, rinsed and 
mounted on glass slides using Mowiol (Calbiochem). Cells are observed under the Nikon 
Eclipe TE2000-U fluorescence microscope equipped with a plan APO VC 60X / 1.40 
objective under oil immersion described above for cytochrome c immunofluorescent staining 
but a Nikon B-2A epifluorescence filter block and a Semrock Brightline® 536/40 emission 
filter are used. Cells with active autophagy are defined as those displaying 3 or more puncta 
of GFP-LC3. Results are given under each experimental condition as percentage of cells 
with more than 3 puncta of GFP-LC3 over 500 cells expressing GFP-LC3












STUDY OF THE PHOTOPHYSICAL AND 
PHOTOCHEMICAL PROPERTIES OF  
NEW TRI-CATIONIC PORPHYRIN DERIVATIVES 
 




Photodynamic therapy is inherently a dynamic process. At the most fundamental level the 
photodynamic process depends on the photosensitizer molecule itself. Notably, the behavior 
of the initial excited states of photosensitizers must be considered as a pre-requisite for a 
discussion on their photobiological activity. Thus, the first step of this study has consisted in 
the assessment of the photochemical and photophysical properties of the new tri-cationic 
porphyrin derivatives. 
As it has been widely discussed in Section 1.2, several photophysical parameters may assist 
in fully characterizing the photosensitizers and in understanding their photobiological 
activities. The most relevant parameters are the excited singlet and triplet transient 
absorbance spectra, the singlet state lifetime (τS), the triplet-state lifetime (τT), the 
fluorescence quantum yield (ΦF) and the triplet-state quantum yield (ΦT).  
 
4.2 OBJECTIVE 
Based on the above considerations, a thorough study of the photochemical and 
photophysical properties of five water-soluble tricationic porphyrin conjugates has been 
undertaken. Their properties have been compared to those of the parent compound. Their 
structure is given in the General Introduction and below in Fig. 1 of Article I. The 
microenvironmental-dependent interactions of the various conjugated chains with the 
porphyrin ring in the singlet and triplet excited states have been investigated in buffer, 
ethanol, and negatively charged or neutral micelles. The rationale for such a study is that 
these solvents conditions may mimic many of the microenvironments sensed by these 
porphyrins upon incorporation into living tissues. 












TRICATIONIC PORPHYRIN CONJUGATES: EVIDENCE 
FOR CHAIN-STRUCTURE-DEPENDENT RELAXATION OF 
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4.3 MAIN RESULTS AND DISCUSSION 
 
4.3.1   ABSORPTION SPECTRA AND EXTINCTION COEFFICIENTS 
The absorption spectrum of P-H is presented in Fig. 2A (Article I) and the characteristics for 
all compounds are given in Table 1 (Article I). Depending on solvent conditions (ethanol, 
buffer, TX100, SDS and PBS) the absorbance spectra of all derivatives exhibit the well know 
absorption spectra characteristic of porphyrins with a Soret band (strong UV absorbance 
band at ~420 nm) and 4 minor absorbance maxima at ~520, 550 and 630- 650 nm.  
Extinction coefficients are provided in Table 1 (Article I). As can be seen, no major 
differences are observed with solvents reproducing various microenvironmental conditions. 
As to the comparison between P-R, no major difference in their absorption properties is 
observed suggesting that all are potentially interesting photosensitizers in terms of ability to 
absorb light. When compared to the presently used PPIX in oncological dermatology, the 
absorbance of the photosensitizers better matches the therapeutic window beyond 650 nm, 
where light penetration is higher (see Section 2.1.8). 
 
4.3.2   FLUORESCENCE SPECTRA AND QUANTUM YIELDS 
Spectra are presented in Fig. 2B (Article I) and the characteristics for all compounds are 
given in Table 2 (Article I). All the compounds have rather similar fluorescence quantum 
yields with the exception of P-(Lys)n whose fluorescence quantum yield is slightly lower. The 
P-R fluorescence quantum yields are mostly independent of the solvent conditions except for 
SDS micellar solutions where they are significantly higher. Despite an excellent solubility in 
an aqueous medium, the formation of small-size oligomer-like or noncovalent dimer favoring 
nonradiative conversion processes is observed which result in the shortening of the 
fluorescence lifetime and a diminished fluorescence quantum yield of most conjugates. 
The existence of fluorescence is particularly interesting in the context of this work because 
the sensitivity of fluorescence measurements allows: 1/ quantitative measurements of P-R 
concentration in cell systems, and 2/ the study of the P-R intracellular localization. As noted 
above, all conjugates possess a good fluorescence quantum yield in micellar solutions 
allowing a possible detection in living tissues. 
Furthermore, in the event of a future clinical use of P-R, fluorescence is useful for the 
diagnosis/delineation of tumor tissue, the fluorescence-guided adjustment of the irradiation 
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area [492] and the assessment of the treatment success by checking the fluorescence 
quenching after PDT related to the porphyrin photobleaching in the irradiated area [493]. 
However, the use of P-R for this purpose may not be easy because of moderate 
fluorescence quantum yields. 
The modest P-R fluorescence quantum yields and the fluorescence lifetimes indicate that 
non-radiative pathways are involved in the deactivation of the 1S1 state of P-R with return to 
the 1S0 ground state. Thus internal conversion (heat exchange with the surrounding solvent 
molecules) and/or “intersystem crossing” with triplet state formation are likely to occur. 
 
4.3.3   FEMTOSECOND SPECTROSCOPY 
The femtosecond experiments were conducted at the Radiation laboratory of the University 
of Notre Dame (USA). The results are detailed in Fig. 3 and 4 of Article I published in the 
Journal of Physical Chemistry B. 
The laser flash photolysis in the femtosecond time scale allows to study the photophysical 
events taking place before the formation of the triplet state, namely the behavior of the 
excited singlet states (S1, S2, …, Sn). We have observed that in some cases the strong 
flexibility brought by the structure of the conjugated chain is responsible for the ultra-fast 
occurrence of an interaction between the side-chain and the porphyrin ring. Although these 
parameters are important in understanding the physical-chemical processes leading to the 
population of the 1S1 state of P-R, they do not give access to those characterizing their triplet 
state, the essential excited state regarding their photosensitizing ability.  
 
4.3.4   TRANSIENT ABSORBANCE SPECTRA AND PROPERTIES OF THE TRIPLET STATE  
Spectra are presented in Fig. 5 (Article I). The time dependence of the absorbance allows 
the measurement of triplet state lifetimes reported in Table 2 (Article I). All are in a time 
range extending from a few µs to 50 µs. They are longer in PBS than in the other solvents. 
The P-(Lys)n triplet has the longest lifetime. This may be due to the bulky conformation of the 
poly-lysine chains that may hinder fast collisionnal processes contributing to an increased 
rate of return from the 3T1 to the 
1S0 state. These long-lived triplet states make it possible to 
predict a photodynamic activity of P-R in aqueous environments. 
Another important parameter regarding the triplet state is its formation quantum yield. The 
triplet state quantum yield (φT) may be calculated from the absorption spectra of the triplet 
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state, provided we know its extinction coefficient (εT). Extinction coefficients are obtained by 
classical methods involving an energy transfer to β-carotene singlet ground state to produce 
the β-carotene triplet whose molar absorbance has been determined rather accurately. Such 
a transfer is very efficient because of the low-lying triplet state energy of β-carotene. As a 
consequence, the concentration of β-carotene triplets formed is assumed to be equal to that 
of the P-R triplets, thus allowing the calculation of the molar absorbance (εT) of the P-R 
triplets. The details of the calculation are mentioned in the supplemental data of Article I. The 
determination of the extinction coefficient of triplet state allows the determination of the P-R 
triplet concentration. 
Simultaneously, actinometry of the laser beam can be achieved with a molecule whose triplet 
state quantum yield and extinction coefficient are well known. Here meso-
tetraphenylporphyrin (TPP) has been used as an actinometer. Thus, the unknown triplet 
state quantum yield (φT) can be calculated by comparing the triplet concentrations of P-R and 
TPP obtained with solutions of P-R and TPP having the same absorbance at 355 nm, the 
exciting laser wavelength (see Chapter 3) [494]. 
A summary of all these properties appears in Table 4 (Article I) which also reports the 
calculated rate constants for the non-radiative (internal conversion and intersystem 
conversion) and radiative (fluorescence) deactivation processes characterizing the P-R. The 
triplet state quantum yield of P-R but P-(Lys)n is rather high (0,5 – 0,6) whatever the solvent. 
This suggests that P-R may be efficient photosensitizers in most environments.  
 
4.3.5   SINGLET OXYGEN FORMATION 
The above data strongly suggest that singlet oxygen can be produced with an efficient 
quantum yield. Singlet oxygen formation can be probed by measurement of the histidine 
(His) oxidation which only occurs through a type II photodynamic process. The quantum yield 
of singlet oxygen mediated-His oxidation is reported for all the P-R in Table 5 (Article I). 
Quantum yields of about 0.08 are obtained with all P-R but P-(Lys)n for which the quantum 
yield is about 0.02 consistent with its lower φT. As expected, no His oxidation occurs in the 
absence of O2. The formation of 
1O2 is supported by adding N3
- which inhibits His oxidation 
by reducing the 1O2 lifetime. On the other hand, replacing H2O by D2O, which enhances 
1O2 
lifetime, leads to an increase in the rate of His consumption definitely demonstrating singlet 
oxygen formation.  
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Using meso-tetrasulfonatophenylporphyrin (TPPS4) whose singlet oxygen formation quantum 
yield is known [495], we are able to calculate the quantum yield of singlet oxygen formation 
via the photodynamic action of P-R. These values are close to 0.8 for P-H, P-Me, P-DCC,  
P-OGal and P-Gal, and close to 0.2 for P-Lys. The values obtained here are slightly higher 
than the triplet state quantum yield values mostly because of uncertainty in the comparative 
standard we used. Nevertheless, these results demonstrate that the transfer from P-R triplet 
state to molecular O2 is very efficient in generating 
1O2 in aqueous media. 
 
4.4 CONCLUSIONS 
This work was undertaken to establish the photophysical properties underlying the 
effectiveness of P-R as cell photosensitizers. Considering the results described above we 
can conclude that: 
1- All compounds are potentially interesting considering their efficacy in singlet oxygen 
formation. The poly-S-lysine conjugate might be considered a priori as the less 
interesting, due to its lower quantum yield of singlet oxygen production. However, it 
will be shown in the next chapter that its photocytotoxic activity in cells cannot be 
solely inferred from the photophysical study. 
2- The fluorescence properties of all compounds permit their use for further fluorescence 
studies in cell systems in vitro and, possibly, for the clinical diagnosis of tumor tissue. 
3- The present work suggests that the eventual differences in the photocytotoxic activity 
of all compounds, other than the poly-S-lysine conjugate, could not be explained in 
terms of different photodynamic efficiencies. Other factors might be implicated such 
as modulation of cellular uptake and of intracellular localization/partition within 
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5.1 INTRODUCTION  
 
In Chapter 4, we have demonstrated that the excited triplet state of the tricationic conjugates 
is highly populated. We have further established that all the conjugates under study are 
effective type II photodynamic agents producing singlet oxygen - a cytotoxin - at comparable 
and high yields except P-(Lys)n. 
 
The photobiological properties of a photosensitizer depend on its structural features (nature 
of peripheral groups, coordinated metal ion and accompanying axial ligands), which 
determine the electronic charge, the hydrophobic character, the aggregation state, and 
ultimately, the affinity for binding sites [38, 496]. As reported in Section 2.1.3.5 and section 
2.1.6, these structural features determine several key factors for the outcome of 
photodynamic therapy, such as cellular uptake and subcellular localization of the 
photosensitizer [174]. This is of particular interest in this study, as it has been previously 
showed that all photosensitizers have similar intrinsic 1O2 production capacity. As a 
hypothesis, the cell photosensitization effectiveness of P-R may primarily depend on 
photosensitizer uptake and localization and, thus, may be chain-dependent.  
 
When studying new photosensitizers, their photocytotoxicity effectiveness and their capacity 
to induce an oxidative stress must be determined. Most PDT sensitizers may also trigger a 
variety of responses ranging from antioxidant response to programmed cell death. There is 
considerable interest in elucidating the signaling pathways leading to these responses in 
order to better understand how PDT operates at the cellular and molecular levels. These 
include the modulation of the cell survival and cell death pathways and activation of signal 
transduction pathways [173].  
 
 
5.2 OBJECTIVE  
This chapter can be divided in two complementary parts with the following objectives: 
 
Objective of Part I. 
The first part concerns the assessment of the uptake kinetics and subcellular localization, as 
well as the mechanisms of the photocytotoxicity of five new tri-cationic porphyrin derivatives 
in a proliferating human skin keratinocytic cell line (NCTC-2544). Such a study allows a 
comparison of the different biological effects of molecules belonging to the same class of 
compounds but endowed with different chemical and physical properties reported in chapter 
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4. Their photobiological properties will be compared to those of the parent compound. The 
rationale for such a study is that the different substituents of the tri-cationic porphyrin 
derivatives may affect their cell uptake and intracellular distribution pattern. As a result, some 
structure-photocytotoxic activity relationship for these new tri-cationic porphyrin derivatives 
can be established. Furthermore, it is a pre-requisite for further study on their mechanism of 
action and the prevailing form of cell death they induce.  
 
Objective of Part II. 
The second part is devoted to the study of these prevailing forms of cell death and the 
involved signaling pathways. The elucidation of the signaling pathways leading to these 
responses is of interest since it provides clues to better understand how PDT operates at the 
cellular and molecular levels.  
As deduced from Part I, it turns out that the P-OGal conjugate is the most photocytotoxic tri-
cationic porphyrin conjugate. As a result, we have more extensively investigated the 
oxidative signaling events associated with the cell killing induced by the P-OGal-PDT. There 
are only a few studies regarding the MAPKs involvement in the PDT stress, especially those 
concerning cationic porphyrins. We have thus examined the role of MAPK’s. We provide 
evidence for the modulation of p38, JNK, ERK and AKT expression during the PDT mediated 
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5.3 MAIN RESULTS AND DISCUSSION 
 
5.3.1 CELLULAR UPTAKE OF P-R DERIVATIVES 
The P-R uptake as a function of incubation time is presented in Fig. 2A (Article II) for P-(Lys)n 
and in Fig. 2A (Article III) for P-H, P-Me, P-DDC, P-Gal and P-OGal. The uptake of P-H,  
P-Me, P-DDC, P-Gal and P-OGal is extremely rapid and reaches a plateau within less than a 
hour after the beginning of the incubation. In the case of P-(Lys)n it takes longer (3 hours) to 
reach this plateau. The five conjugates are more efficiently taken up by cells than P-H. The 
uptake of all derivatives increases almost linearly as a function of the incubation 
concentration. The P-R incubation has also been performed in serum-free HBSS to 
determine whether serum proteins play any peculiar role in the uptake process. Only P-(Lys)n 
slightly interacts with serum proteins (see Fig. 7 (Article II)). 
 
5.3.2 PHOTOCYTOTOXICITY OF P-R DERIVATIVES 
The photocytotoxicity efficiency of the P-R derivatives has been estimated by the Neutral 
Red assay. The following relative order of PDT efficiency -- P-OGal > P-DDC = P-Me > P-
(Lys)n  >> P-Gal > P-H -- has been established (Fig. 2C and 2D and Table 1 in Article III)). A 
clear relationship between photocytotoxicity effectiveness and structure is evidenced as P-H, 
P-Me, P-DDC, P-Gal and P-OGal have a similar intrinsic 1O2 production capacity and absorb 
similar light doses. On the other hand, P-(Lys)n has a lower intrinsic 
1O2 production capacity 
than P-H and P-Gal but it is a stronger photocytotoxic agent (see Fig. 3 in Article II and Table 
1 in Article III). Therefore, other factors than the intrinsic 1O2 production capacity must be 
invoked to explain this superior photosensitizing effect on cells. These are the modulation of 
the cellular uptake and the intracellular localization/partition within cytosolic sites and cell 
membranes. It is important to note that P-OGal, P-DDC and P-Me favorably compare with 
endogenous PPIX induced by treating cells with ALA (see Fig. 3B in Article III). Since the 
amounts of light absorbed by intracellular P-R and PPIX are rather identical, P-OGal, P-DDC 
and P-Me are as powerful photosensitizers as PPIX in our cellular model. 
 
5.3.3 PHOTO-OXIDATIVE STRESS INDUCED BY P-R DERIVATES 
Singlet oxygen is the main cytotoxin involved in PDT [25]. The photophysical studies 
presented in Chapter 4 revealed no major difference in the singlet oxygen quantum yields of 
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P-H, P-Me, P-DDC, P-OGal and P-Gal whereas P-Lys was found to be about 4 times less 
effective. As presented in Table 1 (Article III) cell photosensitization is inhibited by N3
- ions,  
which are specific 1O2 quenchers, further demonstrating the role of singlet oxygen in the 
photo-oxidative stress induced by these tricationic porphyrins.  
Lipid peroxidation was chosen as an overall index of the “intensity” of the photo-oxidative 
stress. Lipid peroxidation was assayed by measuring TBARS formation [497]. Measurements 
of TBARS formation induced by P-R are reported in Fig. 4 (Article II) and in Fig. 3A (Article 
III). The TBARS production is shown to increase nearly linearly with the irradiation time. The 
most effective TBARS producers are P-OGal, P-DDC, P-Me. As a matter of fact, the greater 
photocytotoxic efficiency of P-OGal, P-DDC, P-Me and P-(Lys)n compared to that of P-H and 
P-Gal also applies to the lipid peroxidation initiation. It thus suggests a correlation between 
photocytotoxicity of the studied derivatives and their overall ability to produce an oxidative 
stress. 
It is also demonstrated that oxidative membrane damages are more pronounced with PPIX 
than with P-Me, P-DDC and P-OGal (see Fig. 3C (Article III)). This is in agreement with the 
highest hydrophobicity of PPIX, which favours its intracellular localization in lipophilic 
environments. 
 
5.3.4 FLUORESCENCE MICROSCOPY OF P-R DERIVATIVES TREATED CELLS 
Phase contrast and fluorescence images obtained with cells exposed to P-R exposed are 
illustrated in Fig 5 (Article II) and Fig 4 (Article III). A sensitive fluorescence microscopy 
system has been used to avoid the interference of photobleaching, photodamage and dye 
relocalization during image acquisition. Intracellular fluorescence experiments have 
confirmed that P-H and P-Gal are less taken up by NCTC 2544 keratinocytes than P-Me, P-
DDC and P-OGal. Moreover, the fluorescence of P-Me, P-DDC, P-OGal and P-(Lys)n is more 
specifically localized in spots that may correspond to endo- or pinocytotic vesicles. The 
rather diffuse fluorescence observed in cells treated with P-H and P-Gal suggests a main 
cytoplasmic and plasma membrane localization. It should be noted that the mitochondria and 
the nucleus are not primary sites of P-R localization. These observations demonstrate that  
the methyl (P-Me), the Di-O-isopropylidene-α-D-galactopyranosyl (P-OGal) and the  
N,N´-dicyclohexylureidooxycarbonyl (P-DDC) groups on the conjugated side chain are more 
critical than the electric charge of the porphyrin ring in controlling their uptake and 
localization site and, as a consequence, their greater photosensitizing efficiency. 
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5.3.5 MECHANISMS OF THE PDT-INDUCED DEATH IN NCTC 2544 CELLS 
After describing the chain structure dependence of the photocytotoxic potential by tri-cationic 
porphyrin conjugates, we have established the nature of the programmed cell death 
mechanisms induced by P-R and their relative importance. As P-Me, P-OGal and P-DDC 
exhibit similar intracellular localization, P-OGal -- the most effective photosensitizer -- was 
chosen as representative P-R for this study. 
 
a) Role of apoptosis 
It has been established by Oleinick’s group that PDT was a strong inducer of apoptosis [498], 
as previously discussed in Section 2.2. The translocation of phosphatidylserine from the 
inner layer to the outer layer of the plasma membrane is an early marker of apoptosis. 
Apoptosis was thus assayed by simultaneous cytometric analysis of annexin V binding and 
propidium iodide uptake. As presented in Fig 5A (Article III) no significant change in the 
percentage of annexin V positive cells is observed up to 9 h after irradiation. Similar results 
were obtained with different P-OGal concentrations, P-OGal incubation durations and light 
doses. Another well established marker of apoptosis is the nuclear DNA breakdown into 
oligonucleosomal units. As shown in Fig. 5B (Article III), no significant increase in 
cytoplasmic histone-associated DNA fragments is found up to 24 h after P-OGal PDT as 
assayed by an enzyme-linked immunosorbent assay. Furthermore, no caspase-3, caspase-8 
and caspase-9 activities and no procaspase-3, procaspase-8 and procaspase-9 cleavage 
have been observed up to 12 h after P-OGal-PDT. These results and those showing the 
absence of cytochrome c leakage in photosensitized cells are presented in Fig. S1 (Article 
III). All these data support the lack of apoptosis induction by P-OGal PDT in NCTC 2544 
cells. 
These results raise the following question: Are NCTC 2544 cells capable of entering 
apoptosis or are they apoptosis deficient cells? To answer these questions, we have used 
two positive controls (5-methoxypsoralen+UVA and campothecin). Apoptosis induction has 
been observed as soon as 9 h after campothecin treatment whereas extensive activation of 
caspase-3 (6-fold increase in activity) has been measured 24h after  
5-methoxypsoralen+UVA. 
Therefore, our observations are in sharp contrast with most of the published reports that 
attribute cell death after photodynamic therapy to apoptosis [384]. The absence of internally 
triggered apoptosis is consistent with the non-mitochondrial localization of the photocytotoxic 
P-R. 
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b) Role of autophagy 
As apoptosis plays no significant role in the photocytotoxicity induced by P-R, we look for an 
alternative cell death pathway, namely autophagy. Although autophagy was originally 
described as a cell survival response, it has also been implicated as a death pathway in 
numerous studies [353, 499-500]. 
As for apoptosis, we have used multiple criteria to score the development of autophagy after 
P-OGal-PDT. First, autophagic activity has been studied using a fluorescent marker  
(GFP-LC3) consisting in a fusion microtubule-associated protein light-chain 3 (LC3) tagged 
with a green fluorescent protein (GFP). The proteolysis process and recruitment to 
autophagosomal membranes of LC3, a marker of autophagy, has been followed by 
fluorescence microscopy and is presented in Fig. 6A (Article III). After P-OGal-PDT, the 
development of multiple cytosolic vacuoles labeled with a punctated pattern of GFP-LC3 is 
observed associated to a time-dependent increase in the number of cells showing the 
characteristic vacuolar pattern of GFP-LC3 (Fig. 6B in Article III). Another accepted marker of 
autophagy is the p62/SQSTM1 degradation. The western blotting analysis presented in  
Fig. 6D (Article III) reveals that after irradiation the amount of p62/SQSTM1 decreases 
(~60%) in the P-OGal-treated cells. To confirm these data, ALA-induced phototoxicity was 
used as a negative control. By contrast, none of the above autophagy markers is modified in 
the photocytotoxicity induced by equitoxic ALA in NCTC 2544 cells.  
Autophagy induction in P-OGal-induced cell death is further confirmed in our work by 
treatment of cells with 3-methyladenine (3-MA), a well-characterized autophagy inhibitor. Cell 
pre-incubation with 3-MA suppresses, as expected, the GFP-LC3 puntacted pattern (Fig. 6C 
(Article III)) and the p62 degradation (Fig. 7D (Article III)).  
To assess the contribution of autophagy in cell death induced by P-R, cytometric analysis of 
annexin V binding and propidium iodide uptake by dead cells was undertaken. As presented 
in Fig. 5C (Article III), P-OGal-induced cell death is inhibited by about 40% after incubation 
with 3-MA. Furthermore, no evidence of apoptosis induction is observed after autophagy 
inhibition by 3-MA. These experiments suggest that: 1) autophagy plays a pro-death role in 
our system; 2) autophagy occurs independently of apoptosis but in association with necrosis.   
There are a few recent reports on the induction of autophagic cell death by photodynamic 
therapy and most were performed with apoptosis deficient cells. Moreover, in several 
studies, autophagy was only observed after inhibition of caspase activity [364, 501-502]. It is 
of utmost importance to note that we used an apoptosis competent cell model in which the 
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tri-cationic porphyrin conjugates induced predominantly autophagic cell death in the absence 
of any apoptosis inhibitor. The incorporation of P-R in lysosomes or pre-lysosomes in the 
vicinity of the Endoplasmic Reticulum and the Golgi apparatus and non-mitochondrial 
localization might be responsible for this conjunction of non-apoptotic events although its 
relationship with autophagy has to be elucidated. We may attribute the autophagy induced by 
P-OGal photodynamic therapy to an attempt to remove photo-oxidized organelles or to 
degrade large cross-linked protein aggregates which cannot be removed by the ubiquitin-
proteasome system. Depending on the degree of cellular damage, persistence of autophagy 
may conduct cells to a metabolic collapse and, ultimately, to autophagic cell death. In 
addition, autophagy may be initiated by several signaling molecules whose expression is 
modulated during photodynamic therapy in response to oxidative stress. This modulation 
may switch this process from a survival to a lethal pathway. 
 
5.3.6 MAPK PARTICIPATION IN DEATH OF NCTC 2544 CELLS AFTER PDT WITH P-R 
DERIVATIVES 
The above presented results strongly suggest that autophagy is implicated is cell death 
induced by P-R. As a consequence, one may raise the following question: Do 
photosensitizers activate/inactivate any specific molecular pathway that modulates the 
autophagic process?  We thus probed oxidative signaling events associated with the 
photodynamic induced cell killing, particularly those mediated by the MAPKs JNK and p38 
(typically associated with apoptosis/autophagy) and ERK1/2 and AKT (typically associated 
with cell survival and proliferation). 
Immunoblot assays performed to assess JNK, p38, ERK1/2 and AKT phosphorylation are 
presented in Fig 7A (Article III). A rapid, albeit transient, appearance of activated p38 and 
JNK is observed in photodynamically stressed NCTC cells. By contrast, a striking decrease 
in the content of p-ERK and p-AKT is observed, the former showing a large decrease to 
almost undetectable levels despite its high pre-existing level. The role of MAPKs is further 
evidenced by adding JNK (SP600125) and p38 (SB203580) inhibitors. After confirming the 
inhibitor specificity by submitting the NCTC 2544 to an osmotic stress, cytometric analysis of 
their effect on the annexin V binding and propidium iodide uptake has been performed. 
SP600125, but not SB203580, increases the photo-induced cell death as reported in Fig 7B 
(Article III). This cytotoxic effect is not due to the direct toxic effect of SP600125 as the 
viability of control cells treated with P-OGal and pre-incubated with SB203580 and 
SP600125 but left in the dark is unchanged. Furthermore, no significant effect on the 
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percentage of annexin V positive cells is observed after P-OGal -PDT of cells pre-incubated 
with p38 and JNK inhibitors 
To better understand how SP600125 increases the photo-induced cell death, the 
fluorescence detection of GFP-LC3-puncta and the p62 immunoblot assays have been 
performed. As presented in Fig.7C (Article III), GFP-LC3 is increased in cells treated with  
P-OGal and SP600125 while SP600125 has no effect on the basal level of GFP-LC3-puncta. 
As expected, SP600125 but not SB203580 increases the p62 degradation after PDT. 
Altogether these results confirm that JNK exerts a negative regulator effect on P-OGal PDT-
induced autophagy and PDT-dependent programmed cell death. 
These results corroborate several studies performed with different cell lines and 
photosensitizers, that demonstrate the MAPKs participation in the oxidative signalling events 
induced by PDT [442]. However, the precise role of p38 and JNK MAPK in cell viability after 
PDT is still unclear, as previously discussed in Section 2.2.3. Taken together the results 
suggest that the degree of p38 and JNK phosphorylation as well as their effect on the cell 
death regulation after PDT may depend on the cell type, the photosensitizer used and the 
light dose administered [396, 406]. In contrast to the PDT-induced apoptosis, relatively little 
is known about the PDT-induced autophagy signalling in terms of MAPK activation and 
possible cross-talk among different pathways.  
The role of JNK in cell death has long been controversial as it exhibits a pro-survival effect or 
triggers cell killing depending on the physiological or pathological condition studied [503]. 
This paradoxical effect is partially due to different modes of JNK activation [504]. Apparently, 
an early transient phase of JNK activation determines cell survival, whereas sustained JNK 
activation can induce cell death signals. As an example, sustained activation of JNK has 
been implicated in reactive oxygen species-induced necrosis [505] and etoposide- and 
staurosporine-induced autophagy in Bax/Bak DKO cells [506]. Our results are in accordance 
with the previous data as we observed a rapid and transient activation of JNK after P-OGal 
PDT associated with a negative regulatory effect on cell mortality and autophagy. We may 
speculate that this effect might be partially explained by the JNK1 mediated Bcl-2 
phosphorylation. Bcl-2 phosphorylation was shown to inhibit the binding of Bcl-2 to Beclin 1 
leading to autophagy activation [507].  
Conflicting data also exist regarding the role of p38 in apoptosis and autophagy. Several 
reports support the role of p38 as inhibitor of autophagy [508-509] while others suggest that it 
is an inducer of autophagy [510]. Although we observed an activation of p38 after  
P-OGal PDT, our data suggest that p38 is not directly implicated in cell death induction in our 
system. 
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A downstream event in the mitogenic pathway is the activation of ERK. The activation of the 
Ras/Raf-1/ERK1/2 pathway is able to promote opposite pro-survival or antiproliferative 
cellular responses, such as apoptosis and autophagy. This wide variety of processes 
triggered by the activation of a single pathway has been shown to depend on the timing, 
duration and strength of this activation, as well as on specific subcellular localization and on 
the presence of reactive oxygen species [511]. As presented in Section 2.2.3, available 
evidence suggests that PDT may modulate ERK activity. Depending on the photosensitizer 
and cellular lines, ERK has been found to variably respond to the PDT-induced oxidative 
stress by irreversible inhibition [403], moderate attenuation [512], no significant modulation 
[406] or even a transient activation of ERK1/2 [407]. We found a decrease in the content of 
p-ERK after P-R conjugates PDT to almost undetectable levels 3 h after PDT despite high 
pre-existing expression (Fig. 7A). The role of the indicated trend of ERK1/2 in cell death 
mechanisms observed in our PDT model is to be clarified in further studies.  
Activation of the PI3-K/AKT is another important signaling pathway known to inhibit apoptosis 
and promote cell survival. AKT acts on a variety of ways including activation of mTOR, 
phosphorylation of Bad, phosphorylation of IκB kinase and inhibition of caspase-9 [513]. Data 
about the PDT effect on AKT phosphorylation are somewhat conflicting varying from 
dephosphorylation and subsequent activation of caspase-assisted death [514] to stimulation 
of AKT phosphorylation [411]. Our results show a time dependent decrease in the content of 
p-AKT after PDT treatment with P-R conjugates. A recent study showed that transcription 
factor FoXO3 functions downstream of AKT/PKB and increases the expression of many 
autophagy related genes. The transcription factor FoXO3 is inhibited by AKT in a TOR 
independent pathway [515]. We may thus speculate that AKT inhibition by P-OGal PDT 
would ultimately augment FoXO3 activity and would contribute to autophagy induction.  
Noteworthy, several studies have shown that ERK and PI3-K/AKT signaling pathways may 
be aberrant in various human cancers [516-517]. As tricationic porphyrin conjugates inhibit 
ERK1/2 and PI3-K/AKT signaling pathways, we might suggest their potential beneficial role 
in cancer treatment.  
 
5.4 CONCLUSIONS 
This work was undertaken to study the photocytotoxicity effectiveness of tricationic porphyrin 
conjugates and the related mechanisms of cell death. Considering the results described 
above we can conclude that: 
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1- All compounds are potentially interesting considering their photocytotoxic efficacy in 
cultured proliferating human skin keratinocytes. In particular, P-OGal, P-DDC, P-Me 
favorably compared with endogenous PPIX produced by ALA treatment. The 
following relative PDT efficiency has been estimated: P-OGal > P-DDC = P-Me > P-
(Lys)n  >> P-Gal > P-H.  
2- The cell uptake and intracellular localization contribute to the different photocytotoxic 
responses. It is suggested that the nature of the conjugated side chain is more critical 
than the electric charge of the porphyrin ring in controlling the uptake and site of 
localization of P-R, and consequently the photocytotoxic efficacy. 
3- In our apoptosis-competent cell system, autophagy plays a major role in the cell 
death photo-induced by tricationic porphyrin conjugates. Apoptosis is not activated 
probably because of the non-mitochondrial localization of P-R. 
4- MAPK JNK exerts a negative regulator effect on P-OGal PDT-induced autophagy. A 
close relationship between tricationic porphyrin conjugates PDT and MAPK pathway 
impairment is also suggested through activation of p38 and inhibition of the AKT and 
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CONCLUSIONS AND PERSPECTIVES 
 
The objective of this work was to unravel the photobiological/biochemical characteristics of 
five tri-cationic porphyrin conjugates - new photoactive substances which may be suitable for 
therapeutic applications in dermatology.  
 
In the first part of our work, we have conducted a rather thorough study of their photophysical 
and photochemical properties with emphasis on the influence of the structure of the 
conjugated chain on their excited singlet and triplet state properties.  
 
Regarding the first excited singlet state, absorbance spectra, extinction coefficients, 
fluorescence spectra and fluorescence quantum yields of the tri-cationic porphyrin 
conjugates have been determined in solvents of different polarity mimicking the numerous 
microenvironmental conditions that prevail in living cells. Using ultrafast spectroscopy, we 
demonstrated that the presence of galactosyl moieties or of a polylysine chain linked to the 
porphyrin macrocycle allows molecular interactions between the conjugated chain and the 
aromatic ring within a few tenths of picoseconds. It may therefore be anticipated that, once 
incorporated into cells, such flexibility may favor the interaction of the conjugate with 
appropriate complex biological assemblies. Furthermore, we found that their fluorescence 
quantum yield and lifetime of all compounds is compatible with their further use for 
fluorescence studies in cultured cells and, possibly, for the detection of tumor tissues in 
clinical practice. 
 
The rather long lifetime (up to ~60 µs) and the high quantum yield of formation (~0.5) of their 
first excited triplet state lead to effective production of singlet oxygen, the cytotoxin involved 
in PDT. From the analysis of these results it is suggested that all compounds are potentially 
interesting although the poly-S-lysine conjugate which produces less singlet oxygen seems a 
priori less relevant. 
At this stage of the work, it was clear that with the exception of the polylysine conjugate, the 
possible difference in the photocytotoxic activity of the conjugates could not be explained by 
a higher intrinsic photodynamic efficiency. Other factors could be implicated such as a 
difference in their cellular uptake and/or in their intracellular localization/partition within 
cytosolic sites and cell membranes. 
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As a consequence, the second part of our work was dedicated to the study of the 
photocytotoxic effectiveness of the tri-cationic porphyrin derivatives towards cultured 
proliferating human skin keratinocytes. Their photosensitizing capacity was examined as a 
function of their physicochemical characteristics, cellular uptake and intracellular localization.  
 
We found that all the studied compounds were photocytotoxic towards cultured proliferating 
human skin keratinocytes. However, the following relative order of PDT efficiency could be 
established: P-OGal > P-DDC = P-Me > P-(Lys)n  >> P-Gal > P-H. In particular, P-OGal,  
P-DDC, P-Me favorably compared with endogenous PPIX produced by ALA treatment, the 
“gold standard” of topical PDT in Dermatology. As previously hypothesized, the cell uptake 
and intracellular localization contributed to the different photocytotoxic responses. It was 
observed that the nature of the conjugated side chain is more critical than the electric charge 
of the porphyrin ring in controlling the uptake and site of localization of P-R and, 
consequently, the photocytotoxic efficacy. 
 
A particular attention was paid to the assessment of cell death pathways and molecular 
mechanisms involved in the photocytotoxicity induced by tri-cationic porphyrin derivatives. 
We found that autophagy along with necrosis play a major role in the cell death photo-
induced by tricationic porphyrin conjugates. This observation disagrees with the majority of 
the published reports that attribute the PDT-induced cell death to apoptosis. In fact, 
apoptosis was not observed - even after autophagy inhibition - probably because of the non-
mitochondrial localization of P-R. 
 
To shed light on the molecular mechanisms involved, we studied the role of MAPK in the 
photocytotoxicity induced by P-OGal, the most effective tri-cationic porphyrin derivative. We 
showed that JNK exerts a negative regulatory effect on P-OGal PDT-induced autophagy. We 
found a close relationship between PDT with tricationic porphyrin conjugates and MAPK 
pathway impairment through activation of p38 and inhibition of the AKT and EGFR-ERK 
signaling pathways. The induction of a specific death mode and the inhibition of the AKT and 
EGFR-ERK signaling pathways may be susceptible to result in a therapeutic advantage. 
 
The conclusion that can be drawn after completion of this work is that the potential interest of 
P-OGal as a PDT photosensitizer in dermatology warrants further in vitro and in vivo studies. 
Here are some interesting issues. 
 
1- It will be interesting to study the role of autophagy in PDT-induced cell death by the 
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most effective tri-cationic porphyrin conjugates. The clarification of the role of MAPK’s 
modulation in photocytotoxicity and associated autophagy is of major interest. In this 
regard, the use of the siRNA technology would be of definite interest to understand 
the role played by the JUNK pathway in the photo-induced death mechanism.  
2- It will also be valuable to assess tri-cationic porphyrin conjugates photobiological 
activity towards squamous cell and basal cell carcinoma cell lines. As topical PDT is 
indicated for these diseases, these studies may raise up a definitive therapeutic 
interest. 
3- This work shows that P-OGal, P-DDC, P-Me and P-(Lys)n are potentially interesting 
considering their photocytotoxic efficacy in proliferating human skin keratinocytes in 
culture. These tri-cationic porphyrin conjugates should thus be assayed in in vivo 
murine models of skin tumors allowing assessment of their acute toxicity, 
pharmacokinetics, selectivity and efficacy. These will be followed by the study of the 
relationship between cellular uptake, intracellular/intratumoral localization, 
photocytotoxicity, cell death mechanisms and signaling pathways induced by PDT in 
vivo.  
4- Finally, should these further studies on animal tumor models be successful then 
photopatch tests on human volunteers could be performed as a prerequisite for - and 
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